Tender Ref. No.: PMBI/DRUG/RC-222/2025 **Dated: 30.04.2025**

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

(Under the Department of Pharmaceuticals, Govt. of India)

B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029

Telephone: **011- 49431800/49431874/49431829/49431854/49431811**

Website: janaushadhi.gov.in

e- TENDER FOR SUPPLY OF DRUGS

TO

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI) FOR TWO YEARS

RATE CONTRACT

LAST DATE FOR ONLINE SUBMISSION OF TENDER: 22.05.2025 (Thursday)

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office & Working Office: B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, Delhi -110029

Telephone: 011-49431800/49431874/49431829/49431854/49431811

Website: janaushadhi.gov.in

e-TENDER FOR TWO YEARS RATE CONTRACT

FOR SUPPLY OF DRUGS TO PMBI

Critical Dates:

Tender Reference No.	**PMBI/DRUG/RC-222/2025**
Tender Website	https://eprocure.gov.in
Date of availability of tender documents on website	**01.05.2025 (Thursday)**
Doubts and queries regarding Tender document should be sent by e-mail-to-e-mail ids., "proc6@janaushadhi.gov.in, proc9@janaushadhi.gov.in, proc10@janaushadhi.gov.in, by the likely bidders latest by	**Till 09.05.2025 (Friday) up to 17.00 Hours.** ***Note: Bidders must raise the queries on or before the time and date scheduled.***
Time and date and place of pre-bid meeting	**On 13.05.2025 (Tuesday) at 15:00 Hours** Pharmaceuticals & Medical Devices Bureau of India, B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi - 110029
Last date and time for submission of Online Bid i.e., Bid Submission End Date and time	On **22.05.2025** (**Thursday**) up to 17.00 Hours
Last Date and time for submission of Earnest Money Deposit (EMD) ***and Original Required Documents as per ANNEXURE I (Check List), in physical Form*** **in office of** Pharmaceuticals & Medical Devices Bureau of India, B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi - 110029	**On 26.05.2025 (Monday) at 14:00 hours**
Time and date of opening of Technical Bid	**On 26.05.2025 (Monday) by 15:00 hours**
Place of opening of tender	**Pharmaceuticals & Medical Devices Bureau of India (PMBI),** B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi - 110029
Opening of Tender Online	On https://eprocure.gov.in

Address for Communication		**Pharmaceuticals & Medical Devices Bureau of India (PMBI),** B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi - 110029
Cost of the Tender Document		**Free of cost**
Contact Person for clarification if any		1. Mr. Gaurav Kaushik J.O (Procurement) Phone: - 011-49431874 Email: - proc10@janaushadhi.gov.in
		2. Mr. Prasant Kumar Thakur Assistant Manager (Procurement) Phone: - 011-49431829 Email: - proc6@janaushadhi.gov.in
		3. Mr. Manik Bera, Manager (Procurement) Phone: - 011-49431854 Email: - proc9@janaushadhi.gov.in

The tender document can be downloaded free of cost from the CPPP e-Procurement Portal https://eprocure.gov.in and from the website of PMBI: janaushadhi.gov.in.

Note: ***The bidders shall be solely responsible for checking these websites at least 3 days prior to closing date of submission of tender for any addendum/amendment issued subsequently to the bid document and take into consideration the same while preparing and submitting the bids. Bidders must avoid last minute submission of the tender on CPP Portal.***

TABLE OF CONTENTS

……

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

e-TENDER FOR RATE CONTRACT FOR THE SUPPLY OF DRUGS

TO

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

PRADHAN MANTRI BHARTIYA JANAUSHADHI PARIYOJANA (PMBJP) is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called PRADHAN MANTRI BHARTRIYA JANAUSHADHI KENDRA (PMBJK). PMBI was established in December 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for PMBJP.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April 2010.

At present, more than ***15700 stores*** are functional. It is proposed to channelize efforts to popularize PMBJP and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – C.E.O, Pharmaceuticals & Medical Devices Bureau of India, B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi - 110029 (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Pharmaceuticals & Medical Devices Bureau of India (hereinafter referred as **PMBI** unless the context otherwise requires).

Tender Inviting Authority Invites **Tender for the supply of Drugs to PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI) for Two Years.**

PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI) was formerly known as BUREAU OF PHARMA PSUs OF INDIA (BPPI).

1.TENDERING SYSTEM:

The Bids are to be submitted in two Parts i.e.

i. Technical Bid **(Cover "A")**
ii. Financial Bid / Price Bid **(Cover "B")**

i. The **TECHNICAL BID** shall contain the complete technical details of the firm and the documents to provide the eligibility and competency of the bidder and shall be submitted online only in the manner prescribed in Bid document.

The documents like Tender Document and **Earnest Money Deposit (EMD)** shall be submitted before the specified schedule at the office of PMBI super scribed, **"Tender Documents & Earnest Money Deposit (EMD) for Tender Reference No.-PMBI/DRUG/RC-222/2025 dated 30.04.2025 for the procurement of Drugs for the year 2025-2027".** However complete hard copy of uploaded tender shall be provided by the bidder firm along-with the mandatory required documents as per clause 3 of Bid and Earnest Money Deposit for evaluation purpose only. This hard copy shall under no case substitute/modify the provisions of e-tender system.

ii. The **Financial Bid/Price Bid** shall be valid for a period of 150 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, PMBI reserves the right to place purchase orders at the quoted rate till such period.

a) The **Tenderer shall fill in the rate per unit size**, % age rate of GST in respective column of BOQ for the items quoted.
b) In determining the lowest evaluated price, the rate quoted per unit size exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration.
c) Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE-XII** and Packing Type etc. of drugs should be as per **ANNEXURE XIII** (attached). Any variation, if found, will result in rejection of the tender.
d) Rates (inclusive of customs duty, packing & forwarding charges, transportation, insurance, and any incidental charges, but exclusive **GST** should be quoted for each of the required drugs, medicines etc., on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.
e) *The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer*.

In case any tenderer quotes higher than the DPCO controlled price, competent authority shall be informed for appropriate action.

2. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDER:

i. (a) Online Bids [in two separate Cover {Technical bid (Cover "A") and price bid (Cover "B")}] shall be submitted till **17:00 Hours Up to 22.05.2025** (**Thursday**) on CPP portal i.e., https://eprocure.gov.in.

(b) Hard copy of complete required documents as Per Clause 3. Eligibility Criteria of Bid and Earnest Money Deposit (EMD) shall be submitted as before the specified schedule at the below mentioned address of PMBI with super scribed, **"Tender Document & Earnest Money Deposit (EMD) for Tender Reference No.-PMBI/DRUG/RC-222/2025 dated 30.04.2025 for the procurement of Drugs for the year 2025-2027"**

"To,

The Chief Executive Officer
Pharmaceuticals & Medical Devices Bureau of India, (PMBI)
B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029

ii. **Late Tender:** -There is NO PROVISION of uploading late tender beyond stipulated date & time in the e-tendering system.

3. ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"):

Minimum Eligibility criteria along with list of documents to be submitted in Cover 'A'. Bidders should meet the following criteria to be eligible for bidding and relevant papers/documents must be submitted by them in their technical bid (Cover- 'A') in support of their eligibility for the tender.

A) **Earnest Money Deposit (EMD)**: EMD of **Rs. 10,00,000.00/-** (Rupees Ten Lakh only as specified in Clause 6 of the Tender document in the form of **Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque or Demand Draft from Nationalized/Scheduled Bank** favoring "**PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA** "payable at Delhi, **which is to be submitted in original to PMBI, New Delhi on or before the date and time stipulated in tender document**. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMD instrument must be uploaded **(ANNEXURE III)** to the e-Procurement portal.
EMD in any other form like ***Cheque/cash/postal order*** etc. **will not be accepted. The Bid without EMD shall be summarily rejected.**

Account Details for National Electronic Fund Transfer (NEFT):

Bank Name: Bank of Baroda, Account No. 05860200001696, IFSC Code: BARB0PARLIA.

B) Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.

C) Power of Attorney (on Non-judicial stamp paper / stamp duty paid) or Resolution of the Board (duly sealed and signed on Company letterhead) by which the authorized signatory has been authorized by the bidding firm to sign the documents should be submitted. The appointed Authorised Signatory should hold a position of General Manager or higher within the firm.

D) Bidders must have: -

a) Minimum three years old valid Manufacturing License of the quoted product.
b) Approved product list issued along with **the latest license renewal certificate** for quoted drugs.
c) Manufacturing license along with approved product list must be valid till the last date of the submission of tender.
d) In case of those drugs which are notified first time in IP Addendum 2022 the Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.
e) Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted ***for the latest three (3) consecutive years*** (Certificate should be enclosed with list of items) except for the drugs falling under the category of **'New Drug'** as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46/CT-23 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.
f) In case of drug where patent has recently been released (in 2021-2024) submission of market Standing Certificate may be exempted. However, if the patent is expired before FY 2021-22, bid of such drugs may be accepted with two-year Market Standing Certificate.
g) FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.

Note: *(i) If Manufacturing License for the quoted product is issued under "for export only" category will not be accepted.*

(ii) Bidders shall submit duly attested copies of required manufacturing license and approved product list in support of above-mentioned condition, and they are required to specify the quoted product in their approved product list by highlighting it.

E) Bidder must have Market Standing Certificate (in India) of ***latest three (3) consecutive years*** of quoted product issued by the concerned Licensing Authority from Drugs Control Department. Self-attested copies are to be submitted.

F) Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority of the state certifying that the firm/company has not been convicted in last three years should be submitted. **It should not be more than 12 months old**. Self-attested copies are to be submitted.

G) WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- 'M' of the manufacturing unit and **Certificate of Pharmaceutical Product (CoPP) product wise** issued by the Drug Licensing Authority/ Drugs Control Department. **The WHO-GMP certificate and CoPP must be valid as on the last date of submission of tender.** Self-attested copies are to be submitted.

H) Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted.

I) Copies of the Audited Balance Sheet, Profit and Loss statement showing details of their annual average turnover for three consecutive years of the last four financial years not less than Rs. **50 Crores (Fifty crore).** In case of loan licensee average annual turnover of manufacturing unit/ Host Company for three consecutive years of the last four financial years not less than Rs. **50 Crores (Fifty crore).** Details shall be provided in **Annexure IV**. Self-attested copies are to be submitted.

J) Declaration on **Non-Judicial Stamp Paper Duly Notarized** for eligibility in participating the tender for quoted drugs in prescribed format as per **Annexure-II**

K) Tenderers shall furnish Company's bank details as per **Annexure V (Part – A)** with cancelled cheque. Further, Details of company official shall be furnished in **Annexure V (Part – B)** for official communications on company letter head.

L) Tenderers are required to submit **Annexure-VI** indicating details of manufacturing License and three years Market Standing Certificate (MSC), Certificate of Pharmaceutical Products (CoPP), Batch Manufacturing Record (BMR) and Stability Study Data as mentioned therein.

M) Tenderers are required to submit declaration duly signed to supply the drugs as per the design in Enclosure 1 and Enclosure 2 in Annexure VII as well as other instructions given in this regard.

N) Duly attested Checklist as per (**ANNEXURE- I**) shall be submitted.

O) Copy of PAN Card of the bidder company should be submitted (self-attested).

P) Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).

Q) Copy of Income Tax Return (ITR) for three consecutive years of last four Assessment years which should be in line with declaration under Annexure IV. The self-attested copies of the same shall be submitted.

R) Duly attested Copy of valid GS-1 registration certificate from GS1 India.

S) **Bidder shall declare the %age of local content used in the manufacturing of quoted item in accordance with the calculations for local content as per point no. 6 of Order issued by Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals vide no. 31026/4/2018-Policy dated 01.01.2019 in <u>ANNEXURE-X on non-judicial stamp paper duly notarized.</u>**

The category of supplier against each quoted drug shall be mentioned in Annexure X in accordance with Order issued by Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals vide no. *order no. 31026/65/2020-MD dated 30.12.2020* and as per table mentioned under Clause 5.B.(d).

T) If the procurement value is more than Rs. 10 crores, the Class-I Local Supplier/Class-II Local Supplier shall be required to provide a certificate from the statutory auditor or cost auditor of the company (in the case of companies) or from a practicing cost accountant or practicing chartered accountant (in respect of suppliers other than companies) giving the percentage of local content as per pt. no. 9.b of DPIIT order no. P-45021/2/2017-PP(BE-II) dated 16.09.2020 in Annexure X duly notarized on Non-judicial stamp paper at the time of award of contract.

U) A set of Batch Manufacturing Record (BMR) of any of the latest marketed batch in last three year shall be uploaded/submitted with the Cover-A i.e., technical bid against each quoted drug code.

<u>Note: -</u>

(i) The certificates/ reports/annexure submitted with the bid document should be self-attested by the authorized signatory of the firm with official seal.

ii) Technical evaluation of the Bid will be done on the basis of the above-mentioned criteria and documents mentioned in Clause no. 3 (TECHNICAL BID- COVER 'A') are Mandatory Documents and shall be submitted online only at CPPP portal: https://eprocure.gov.in failing which the bid will not be considered for technical evaluation.

iii) Hard copy of required documents uploaded shall be submitted along with Earnest Money Deposit (EMD) and other required documents on or before the last day of submission of tender for purely evaluation purposes. However, the submission of hard copy of uploaded tender document submitted shall not substitute/modify the provisions of e-tendering system.

iv) The technical evaluation shall be done only on the basis of documents/papers submitted by the bidder on https://eprocure.gov.in.

v) **Clear copy of valid drug license and approval list highlighting the quoted drugs with PMBI drug code should be uploaded.** In case scanned copy of license uploaded is not visible or tempered or quoted drugs are not highlighted, PMBI shall not considered the license for such drug.

vi) In case, if renewal application for Manufacturing License has been filled by the bidder or joint inspection has been carried out by the concerned Licensing Authority for the renewal of WHO-GMP

certification (as per official pharmacopoeia reference for such drug), scanned copy of same duly receipted by Drug Authorities must be uploaded along with the validity certificate from State Licensing Authority (SLA). It shall be issued before the last date of submission of tender by the Licensing Authority.

vii) In case if bidder has quoted from their Loan License unit, they shall submit Valid WHO-GMP certificate, Product Permission (minimum three-year-old), Non-conviction Certificate (NCC), Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority, Turnover Certificate issued by CA/CS and balance sheet of manufacturing/host unit shall be submitted with the technical bid (Cover-A) as per tender provision mentioned in this document

3.1 ELIGIBILITY OF BIDDERS FROM SPECIFIED COUNTRIES:

Compliance under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 and ORDER NO: F. No. 6/18/2019-PPD DATED 23/07/2020 & 24/07/2020 issued by Department of Expenditure (MoF) restricting procurement from bidders from certain countries that share a land border with India shall apply to this procurement.

I. GoI vide Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020 & 24 Jul 2020 has imposed Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 on bidders from a country which shares a land border with India.

II. "Bidder" for the purpose of this Order (Public Procurement No.1, 2 & 3) (including the term 'tenderer', 'consultant' 'vendor' or 'service provider' in certain contexts) means any person or firm or company, including any member of a consortium or joint venture (that is an association of several persons, or firms orcompanies), every artificial juridical person not falling in any of the descriptions of bidders stated hereinbefore, including any agency, branch or office controlled by such person, participating in a procurement process.

III. "Bidder from a country which shares a land border with India" for the purpose of this Order (Public Procurement No.1, 2 & 3) means.

a. An entity incorporated, established, or registered in such a country; or
b. A subsidiary of an entity incorporated, established, or registered in such a country; or
c. An entity substantially controlled through entities incorporated, established, or registered in such acountry; or
d. An entity whose beneficial owner is situated in such a country; or
e. An Indian (or other) agent of such an entity; or
f. A natural person who is a citizen of such a country; or
g. A consortium or joint venture where any member of the consortium or joint venture falls under any ofthe above

Note: "Beneficial owner" for the purpose of above paragraph (3) will be as under:

i. In case of a company or Limited Liability Partnership, the beneficial owner is the natural person(s), who, whether acting alone or together, or through one or more juridical person(s), has a controlling ownership interest or who exercises control through other means.

Explanation:

a) "Controlling ownership interest" means ownership of, or entitlement to, more than twenty-fiveper cent of shares or capital or profits of the company.

b) "Control" shall include the right to appoint most of the directors or to control the management or policy decisions, including by virtue of their shareholding or management rights or shareholder's agreements or voting agreements.

ii. In case of a partnership firm, the beneficial owner is the natural person(s) who, whether acting alone or together, or through one or more juridical person, has ownership of entitlement to more than fifteen percent of capital or profits of the partnership.

iii. In case of an unincorporated association or body of individuals, the beneficial owner is the natural person(s), who, whether acting alone or together, or through one or more juridical person, has ownership of or entitlement to more than fifteen percent of the property or capital or profits of such

association or body of individuals.

iv. Where no natural person is identified under (i) or (ii) or (iii) above, the beneficial owner is the relevant natural person who holds the position of senior managing official.

v. In case of a trust, the identification of beneficial owner(s) shall include identification of the author of the trust, the trustee, the beneficiaries with fifteen percent or more interest in the trust and any other natural person exercising ultimate effective control over the trust through a chain of control or ownership.

vi. "Agent" for the purpose of this Order (Public Procurement No.1, 2 & 3) dated 23rd July, 2020 & 24th July, 2020 isa person employed to do any act for another, or to represent another in dealings with third persons.

Rule: Following shall be complied by the Bidders of the said countries while submitting bids.

A. Any bidder from a country who shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the Competent Authority. The Competent Authority for the purpose of registration under this Order shall be the Registration Committee constituted by the **Department for Promotion of Industry and Internal Trade (DPIIT).** However, Order will not apply to bidders from those countries (even if sharing a land border with India) to which the Government of India has extended linesof credit or in which the Government of India is engaged in development projects. Lists of countries to which lines of credit have been extended or in which development projects are undertaken are given in the website of the Ministry of External Affairs.

B. The Bidder shall have to submit declaration / certificate as per the attached Format towards compliance of Public Order on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017. B). Further as per above the format of declaration is added as Annexure XV. It shall be furnished by the bidder(s) on duly notarized Non-Judicial Paper.

4. GENERAL CONDITIONS:

A) Tender is invited directly from Manufacturers in India falling only under category described as Class-I Local Supplier and Class-II Local Supplier in the tender. **Non-local supplier whose local content is less than or equal to 50% shall not be eligible for participating in tender process.** Loan licensee is also eligible. **Distributors/agents/contract manufacturers/Importers are not eligible to participate in the tender.**

B) Manufacturer shall comply with Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period.

C) Bidders are advised to quote only for such drugs which meets the drug specification as mentioned in Annexure XII. Do not quote if it differs with regard to any parameter.

D) **The quantities specified in the tender is for the tender purpose only and it represents the basis of unit for ease of pricing. The actual quantity may vary from zero to the maximum required quantity during the contract.** The quantity will be drawn from successful tenderers as and when required from time to time during the contract period.

E) Standard Testing Procedure (STP) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

F) Stability Study data against each quoted products shall be uploaded/submitted along with Technical Bid.

G) The manufacturer shall declare the Active Pharmaceutical Ingredients (API) polymorphic form used in formulation for all quoted drugs and declare that it is internationally accepted active polymorph when ask by PMBI. Bidder shall submit the source of API and Certificate of Analysis (CoA) of last purchase of all API (Batch no. declared under Annexure XVI) against quoted drug codes with the online bid and

self-attested hard copy in sealed envelope. ***Certificate of Analysis (CoA) of excipients used in manufacturing of awarded drugs must be submitted with all other documents against each supply***.

H) The **Tenderer should have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government/ PMBI/Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/PMBI during last two years. If any tenderer has been blacklisted/debarred/de-registered/banned due to quality failure, such tenderer or their Partner/Director/Owner shall not be permitted to participate in the tender.**

I) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government/ Central Government/ PMBI/ Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to PMBI along with relevant authentic document by the tenderer firm/ company within one month.

J) During tender or Rate Contract period, **if L1 bidder is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, PMBI may purchase the drugs from other bidders at L1 rate or may go for fresh tender as per discretion of PMBI.**

K) The PMBI reserves the right to purchase any drugs from PSUs as per discretion of PMBI. In case of emergencies, PMBI may go to PSUs and price will be as per negotiation and at the discretion of PMBI.

L) The Tenderer should confirm that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

M) **Validity of Rate Contract: -**The rate contract will be applicable for 2(two) year from the date of issuance of LOA. **The validity of contract may be extended with mutual consent for some specified period to the maximum of 1(one) year by PMBI, if necessary.**

N) **If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be uploaded as a separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.**

O) Only authorized employee of the Company/Tenderer will be allowed to transact the business with the Tender Inviting Authority.

P) Authorized Signatory should be in a position of General Manager or higher within the firm.

Q) Labelling as per Section 96 in the Drugs and Cosmetics Rules 1945 should be strictly followed by the awardee.

5. PRICE BID – "COVER-B" (Financial Bid/BOQ)

A) Cover "B" (Financial Bid/BOQ) contains the Price Bid of the Tenderer. The Tenderer shall fill in the rate per unit size, % age rate of GST in respective column of BOQ for the items quoted.

B) **Determination of L1 Bidder:**

a) In determining the lowest evaluated price, the rate quoted per unit size for the given specification, exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration. **The rates quoted should be in rupees and paisa up to 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE-XII.**

b) **GST (Goods and Services Tax)-The Tenderers must indicate the rate of GST applicable and payable by them. In case no information is given, it shall be presumed that rate is inclusive of GST and no GST shall be charged by them under any circumstances.**

c) **The bidder is required to indicate rate of GST (%) as digit only in column 9 of BOQ without suffixing the % sign and not to indicate amount of GST in Rs. at particular cell of excel sheet of BOQ.**

d) *Purchase preference shall be given to bidder(s) based on their declaration of the percentage (%) of minimum local content used in the manufacturing of quoted product as per* ***Public Procurement (Preference to make in India), Order 2017*** *notification issued by GoI, Ministry of Commerce and Industry, Department of Industrial Policy and Promotion (DIPP) vide* ***order no. P-45021/2/2017-PP (BE-II) dated 16.09.2020*** *and* ***order no. 31026/65/2020-MD dated 30.12.2020*** *issued by Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals and accordingly bidder(s) shall be categorized as Class-I Local Supplier / Class-II Local Supplier based* ***on Percentage (%) of minimum local content declared.***

The assessment of Class-I Local Supplier, Class-II Local Supplier or Non-Local Supplier shall be done as per below mentioned table*:* -

S. No.	Type of Class	Percentage (%) of minimum local content
1	Class-I Local Supplier	Local content equal to more than 80%
2	Class-II Local Supplier	Local content more than 50% but less than 80%
3	Non-Local Supplier	Local content less than or equal to 50%

(i) **Purchase preference:** *The 'margin of Purchase preference' means the maximum extent to which the price quoted by the "Class-I local supplier" above the L1 (landed cost).*

*(ii) "**Local Content**" means the amount of value added in India which shall be the total value of the item procured (excluding net domestic indirect taxes) minus the value of imported content in the item (including all customs duties) as a proportion of the total value, in percent.*

6. EARNEST MONEY DEPOSIT (EMD):

A) The Earnest Money Deposit referred to under Clause 3.A, shall be **Rs. 10,00,000.00 (Ten lakhs). The Earnest Money Deposit shall be paid in the form of Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque/ Demand Draft in favor of Pharmaceuticals & Medical Devices Bureau of India, payable at Delhi. EMD in form of Bank Guarantee, Irrevocable Bank Guarantee** in favor of Pharmaceuticals & Medical Devices Bureau of India, from any Nationalized/scheduled Bank should be valid for a period of 12 months **from the date of tender opening**. The format of Bank Guarantee is at **ANNEXURE-X.** PMBI will not pay interest on any deposit held in the form of **Bankers Cheque or Demand Draft or Electronic Fund Transfer.**

Account Details for National Electronic Fund Transfer (NEFT):

Bank Name: Bank of Baroda, Account No. 05860200001696, IFSC Code: BARB0PARLIA

PSUs are exempted from the submission of Earnest Money Deposit (EMD).

B) The tender submitted without Earnest Money Deposit (EMD) in the prescribed proforma **(Annexure-III)** will be summarily rejected.

C) The Earnest Money Deposit will be refunded to the successful bidders after successful completion of first supply. EMD of unsuccessful bidders will be released after finalization of the tender.

D) **The bid of the Tender will be suspended/disqualified without further notice if:**

a) If the tenderer withdraws his bid any time after opening of price bid.

b) On refusal to supply medicine after the award of contract/Letter of Acceptance (LOA).
c) In case of the lowest bidder (L1 bidder), fails to execute the contract or fails to complete the first supply successfully within the stipulated time.
d) If the undertaking as Annexure II is not found correct at any stage during the contract period.

7. GUIDELINES FOR THE PREPARATION OF TENDER:

A) The bidder shall bear all costs associated with the preparation and submission of its bid and Tender Inviting Authority will in no case be responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.

B) **Language of Bid: -** The Bid prepared by the bidder and all correspondence and documents relating to the bid exchanged by the bidder and the Tender Inviting Authority, shall be in English language, Supporting documents furnished by the bidder may be in other languages provided they are accompanied by an authenticated (by the authority concerned) accurate translation of the relevant passages in the English language in which case, for purposes of interpretation of the Bid, the English translation shall alone govern. Failure to submit authentic translation of documents would result in rejection of bids. No bid can be partly in one language and partly in another language.

C) Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.

8. PERIOD OF VALIDITY OF TENDER:

a) The tender must remain valid for minimum 150 days from the date of opening of Technical Bid. (As mentioned in Clause 1.ii)

b) Prior to the expiration of the bid validity the Tender Inviting Authority may extend the bid validity for further period with mutual consent of the bidder.

c) The bidder who has extended the bid validity is not required or permitted to modify its bid.

d) The bidder cannot withdraw the bid within validity of Tender.

9. AMENDMENT OF TENDER DOCUMENTS:

At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by uploading an amendment on PMBI website: www.janaushadhi.gov.in and on CPP portal i.e., https://eprocure.gov.in will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

A) Bidders are advised to check the *website of PMBI:* www.janaushadhi.gov.in and CPP Portal i.e., https://eprocure.gov.in regularly at least 3 days prior to closing date of submission of tender for any corrigendum or amendment to the tender document.

B) PMBI will not issue separate communication for any corrigendum or amendment.

10. METHOD OF SUBMISSION OF TENDER:

A) The tender document shall be downloaded from the website www.janaushadhi.gov.in and CPP portal i.e., https://eprocure.gov.in. Tender Document is free of cost. No tender cost is to be deposited.

B) Bids shall be submitted online only at CPP Portal i.e., https://eprocure.gov.in. Manual bids shall not be accepted except for the original documents/instruments as mentioned in Clause 3 of tender document.

C) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e- Procurement Portal https://eprocure.gov.in.

D) If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.

E) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited, and bidder is liable to be banned from doing business with PMBI.

F) Interested eligible Tenderer may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

G) Once the bid has been uploaded on the CPP Portal https://eprocure.gov.in the bidder has to make sure that he has uploaded the files in the correct format and the bidder must download the uploaded files from their own end and has to check whether the files uploaded is in proper format or not, no corrupted files have to be uploaded.

11. MODIFICATION AND WITHDRAWAL OF BIDS:

A) The bidder may modify or withdraw its bid after the bid submission before last time and date of submission of online Technical Bid.

B) No bid will be allowed to be withdrawn after the last date & time of submission of online Technical Bids.

Note: Any reason *(whatsoever it may be except the Force Majeure events / condition as defined in the tender document or by the Government)* for withdrawal of bid / modification in bid / any request pertaining to have quoted wrong rates for any unit size instead of the desired unit size in tender document / BOQ shall not be considered. Bidder who are making such withdrawal request shall be penalized for alternate purchase of such drugs by PMBI besides blacklisting for a duration of not less than three (3) years as per clause no. 27 of the tender document.

12. OPENING OF TENDER:

A) The opening of the Technical Bid and the Price Bid will be done online as specified. The date of technical bid opening is published in advance. The date of opening of price bid will be announced only after the opening and evaluation of technical bid. The bidder who are found eligible and on satisfying the criteria for technical evaluation/based on undertakings & declaration, will only be informed the time and date of opening of Price Bid - Cover "B" of the tender.

B) Only authorized employee of tenderer is entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

C) In case, the date for opening of technical bid is declared holiday, the technical bid shall be opened on next working day at 11.30 A.M.

D) The original/attested hard copies (as mentioned in Clause no. 3, eligibility criteria) must reach the PMBI Head office on or before stipulated time, failing which the bid shall be summarily rejected.

13. EVALUATION OF TENDER:

A) Technical evaluation of the Bid will be done on the basis of criteria and documents mentioned in S.N. 3 (TECHNICAL BID-COVER A) & Annexure I (Check List) which are present on the CPP Portal i.e., https://eprocure.gov.in.

B) Bids of firms who have furnished all the required documents for each of the product quoted will be considered.

C) If at any stage, it is found that the contract has been successfully obtained by the bidder by submitting forged/fabricated certificates/documents/licenses and/or by concealing the fact about blacklisting/debarring/de-registration of the firm by Govt. of India/Suspension/Cancellation/non-

renewal of the manufacturing license of the bidder firm, the tender bid/rate contract may be rejected/terminated and suitable punitive action may be taken against the firm.

D) **In event of financial bid opening, due to provisions/compulsion of e-tendering system if complete quoted product list of financial bids of a bidder is opened then only those financial bids of quoted product shall be considered of whose technical bid has been found eligible by the Technical Evaluation Committee**.

E) **After evaluation of technical bid of tenderer/bidder, PMBI may ask the objection/clarification from tenderer/ bidder**.

14. INSPECTION OF MANUFACTURING FACILITIES:

A) PMBI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections. Copy of one full set of the documents submitted for the bid should be made available at the time of inspection.

B) Originals of all the documents uploaded/submitted in the Technical Bids should be produced for verification during Site inspection and Physical Verification. Inspection team will be authorized to collect all relevant evidences like photos, videos etc.

15. ACCEPTANCE /REJECTION OF BIDS:

A) PMBI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

B) Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done based on rate per unit size exclusive of GST as mentioned in column 7 of **BOQ.** PMBI shall have the right to call other eligible bidders those are willing to match L1 rates. If such firms are found, then the order quantity may be dispersed in ratio of: -

"Minimum 50% of the tender quantity may be awarded to the qualified bidder(s) falling under Class I local supplier category, if qualified for award of contract and/or subject to the matching of L1 price for quoted drugs at the discretion of PMBI. PMBI would follow the guidelines and respective clauses of DPIIT order no. P-45021/2/2017-PP(BE-II) dated 16.09.2020." For Category of Class-I Local supplier & Local content refer clause no. 5.B.d.

The following possible cases may be considered for the award of contract:

Case-I: If bidders up to L3 bidder are falling under Margin of Purchase Preference, the quantity shall be distributed among L1:L2:L3 bidders in the ratio of 50:30:20.

Case-II: If only two bidders up to L2 bidders are falling under Margin of Purchase Preference, the quantity shall be distributed among L1:L2 bidders in the ratio of 60:40.

C) However, in case the price quoted by the lowest responsive tenderer (L1) is not reasonable and un-acceptable, the price may be negotiated with L1 only as per CVC guidelines and, if it reduces the price to the desirable level, rate contract may be concluded with L1. To meet the demand, PMBI shall conclude parallel rate contract by counter offering the L1 rate to higher eligible bidders as per above provision.

D) Negotiation if required will be done strictly as per Central Vigilance Commission guidelines.

E) Letter of acceptance of tenders for Rate Contract will be communicated to the Tenderers in writing as per **ANNEXURE XI.**

F) Purchase preference: The margin of Purchase preference shall be 30%.

16. AWARD OF CONTRACT:

A) The contract will be awarded to the lowest evaluated responsive bidder qualifying to the final round after Technical and Price Bid evaluation as per the clause 5. B) Determination of L1 bidder and clause 16. B. Acceptance /Rejection of BID, subject to the reservations and preferences to PMBI.

"Minimum 50% of the tender quantity may be awarded to the qualified bidder(s) falling under Class I local supplier category, if qualified for award of contract and/or subject to the matching of L1 price for quoted drugs at the discretion of PMBI. PMBI would follow the guidelines and respective clauses of DPIIT order no. P-45021/2/2017-PP(BE-II) dated 16.09.2020" **as mentioned in clause 15 (B).**

B) **Letter of Acceptance (LoA):**

The Tender Inviting Authority shall issue Letter of Acceptance (LoA) as per Annexure-XI to the lowest responsive bidder in respect of the drugs selected. Communication by e-mail / fax / letter will be deemed as valid communication.

C) *The successful bidder, upon receipt of the Letter of Acceptance (LoA), shall communicate the acceptance / acknowledgement of the same to the PMBI and shall furnish the documents, asked if any*.

D) The bidder shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons whatsoever. Such practices will be deemed as fraudulent practices and also as breach of terms of contract and shall invite punitive action.

E) The bidder shall execute an agreement on a non-judicial stamp paper of value of Rs. 100/- (to be paid by tenderer) within 15 days from the date of intimation from PMBI informing that their tender has been accepted/ the issuance of the LoA. The specimen form of agreement is available as Annexure-XVII.

Note: i) The place of signing of agreement will be PMBI Head Office, New Delhi.

ii) A copy of Power of Attorney, Authorisation letter and company ID Card shall be brought at the time of agreement signing.

17. PERFORMANCE SECURITY DEPOSIT:

A) On being informed about the acceptance of the tender for Rate Contract, the Performance Security Deposit @ 3% will be deducted from each running bills and accumulated security deposit will be refunded without any interest by PMBI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf-life obligation.

B) The Security deposit of supplier will be returned by PMBI only after the supplier has given undertaking to replace such medicines and indemnify PMBI against any losses on account of quality parameters duly notarized.

18. METHODOLOGY FOR PLACING ORDERS:

A) For the above purpose the following procedures will be adopted:

After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.

B) **PMBI reserves right to issue purchase order for any drug on any one rate contract holder or more than one rate contract holder for same drugs**.

C) If two or more than two tenderer(s) are declared as lowest suppliers for the same item(s), such tenderers are eligible for Rate Contract and the placement of Purchase Orders for such item(s) for which they are declared as lowest.

D) The supplier shall start supply of the Drugs/Medicines to any or all the Warehouse (Address/Location) **as mentioned in clause 19 (A)** or any other place decided by PMBI and supply shall confirm to the conditions mentioned in the provision of tender documents, viz, logo, nomenclature, specification etc. within the stipulated period.

E) The supplier shall supply the Drugs/Medicines at any of the PMBI Warehouse **as mentioned in purchase order** (or any other place decided by PMBI) along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

F) A purchase order is placed on supplier for supply of definite quantity in terms of Rate Contract during validity period of Rate Contract that purchase order is valid and binding contract.

G) No Minimum drawl is in the Rate Contract. The actual quantity may vary from nil to maximum required quantity during validity of Rate Contract.

H) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. PMBI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

I) The purchaser reserves the right to conclude one or more than one rate contract for the same item.

J) The purchaser has the option to renegotiate the price with the rate contract holders. In case of emergency, the purchaser may purchase the same item through Ad hoc contract with a new supplier.

K) Purchase orders, incorporating definite quantity of drugs/products to be supplied along with all other required conditions following the rate contract terms, shall be issued for obtaining supplies through the rate contract.

L) The purchaser is entitled to place purchase orders up to the last day of the validity of the rate contract and, though supplies against such purchase orders will be affected beyond the validity period of the rate contract, all such supplies will be guided by the terms & conditions of the rate contract.

M) The details of the required drugs, medicines, etc. are shown in ANNEXURE -XII. ***The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** **by the PMBI, at its discretion, depending on it is actual need**. Though the tentative quantity is indicated in the Rate Contract, the PMBI, will confirm the actual requirement through purchase order/orders from time to time. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of Rate contract period by the PMBI. Any supply without a valid purchase order will not be acceptable by PMBI and the PMBI shall not be responsible for any loss on this account.

N) However, once the purchase order/orders is/are issued by the PMBI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the acceptance of tender for Rate Contract.

O) The rates quoted shall not be varied with the Purchase order quantity during the full contract period.

P) The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. However, Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.

Q) No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

R) Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

S) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to PMBI for payment. Also, the supplier shall ensure the quantity relevant to the

Batch Number of the Drugs/Medicines is mentioned in the invoice. Drugs to be supplied of any batch shall not be accepted with different MRP.

T) "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

U) The Rate Contract (RC) awarded under the present tender enquiry will be in the nature of standing offer. Purchase Order (PO) may be placed from time to time against Rate Contract (RC).

V) **FALL CLAUSE:**

If at any time during the execution of the contract, the controlled price becomes lower or the supplier reduces the sale price or sells or offers to sell such stores, as are covered under the contract, to any person / organization including the purchaser or any department of Central government/state Govt. or its procurement agencies at a price lower than the price chargeable under the contract, he shall forthwith notify such reduction or sale or offer of sale to the purchaser and the price payable under the contract for the stores supplied after the date of coming into force of such reduction or sale or offer of sale shall stand correspondingly reduced

W) Subject to the conditions mentioned in the Purchase Order, Tender Document, Price Agreement/letter of Acceptance and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 60 days from the date of receipt of payment, failing which PMBI will not entertain any claim thereafter

NOTE: PMBI don't give any guarantee of minimum purchase under this Rate Contract.

19. SUPPLY CONDITIONS:

A) Purchase orders will be issued to the Tenderer(s) at the discretion of the PMBI as per actual requirements. All the supplies shall be received at any or all of the following warehouse of PMBI or any other place decided by PMBI:

i) Central Warehouse Gurugram [Pharmaceuticals & Medical Devices Bureau of India (PMBI)]
Sugal Logistic Park, Warehouse No.1, Opp. GITM College, Bilaspur-Tauru Road
Village Bilaspur and Khasra No. 60//14/2, 17,24,6,15, 16, 25, 7/1, 14/1, 61//9, 10, 11,62//3/2, 4,10//17, 24, 19//3, 8/2, 9/1/1, 12/2/2/2 min 13/1/1 min.
Pin Code – 122413
Phone No. – 011-49431800

ii) Regional Warehouse Guwahati [Pharmaceuticals & Medical Devices Bureau of India (PMBI)]
DAG No. 884 of K P PATTA No. 04, Mughuapara, Pamohi Village, Dist. Kamrup (M) Guwahati, Assam India 781035.
Phone No. – 011-49431800

iii) Regional Warehouse Chennai [Pharmaceuticals & Medical Devices Bureau of India (PMBI)]
79, KIZHMUTHALAMPEDU, PANAPAKKAM,
City Tiruvallur, State Tamil Nadu
Pin Code – 601201
Phone No. – 011-49431800

iv) Regional Warehouse, Surat, [Pharmaceuticals & Medical Devices Bureau of India (PMBI)].
Plot no. A-23/2 & A -24/1,
Ichhapore – Bhatpore GIDC, Ichhapore
Surat, Gujarat – 394510

v) "**Regional Warehouse, Bengaluru, [Pharmaceuticals & Medical Devices Bureau of India (PMBI)]**
Plot No 162 163,
KIADB Industrial Area,
Hi Tech Defence Aerospace Park, Devanahalli,
Bengaluru Rural -562110"

B) Within 3 days from the receipt of purchase orders the Tenderer should inform PMBI through PMBI vendor portal/mail about the confirmation for the receipt of the purchase order or queries (if any).

C) The Tenderer should also fill the details of supply/delivery schedule to PMBI through **PMBI vendor portal** within 7 days from the receipt of the purchase order with expected dispatch/supply date.

i. The bidder shall have to fill Advance supply notice (ASN) on PMBI vendor portal with all other details i.e., invoice copy, Certificate of Analysis (COA) of finished product along with CoA of excipients, CoA of Primary and secondary packaging material, Batch no. Quantity, Date of Manufacturing (DOM) Date of Expiry (DOE), no. of shipper boxes etc.

ii. Once the ASN is accepted by the PMBI, the bidder will be provided the date to execute the supplies at PMBI warehouse as mentioned in purchase order.

Note:

- In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received through **PMBI vendor portal** within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and PMBI shall purchase the drugs from alternative sources.
- In case of newly awarded bidder, bidder must share their permanent email ID and phone number for **PMBI vendor portal registration** to it1@janaushadhi.gov.in and customercare1@janaushadhi.gov.in. The supplier must supply the ordered quantity by abiding to the following delivery schedule or as mentioned on purchase orders:

Sl. No.	Nature of Product	Delivery Schedule (Days)
1	Delivery Schedule against first P.O. for injectable/Infusion/Vials (Products required sterility testing)	60 days
2	Delivery Schedule against subsequent P.O. for Injectable/Infusion/Vials (Products required sterility testing)	45 days
3	Delivery Schedule against first P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	45 days
4	Delivery Schedule against subsequent P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	45 days
5	For biological products	60 days
6	Vaccines and Blood products	120 Days

D) If the delivery date happened to be a holiday for PMBI, the supply should be completed by 5.00 PM on the next working day.

E) In case of non-execution of the order, PMBI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

F) If a supplier fails to execute supply as per Purchase Order, the 5% of value of unexecuted quantity of Purchase Order shall be recovered from pending bill/Bank Guarantee/Performance security deposit and their bad performance shall be kept in record of PMBI for future dealing as considered appropriate by PMBI.

G) If the Tenderer fails to execute the supply within the stipulated time, the PMBI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the PMBI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 25.

H) The liquidated damages as specified in clause 25. (B) of the tender conditions will be levied on the quantity supplied after the schedule as mentions in "Clause 19. (D) from the date of issue of

purchase order. However, no supplies will be accepted after 30 days of the expiry of delivery date i.e., completion of specified liquidated damages period as per clause 25 (B), the purchase order shall be cancelled at the risk and cost of the supplier. **However, the supplier must take prior approval from PMBI for supply of drugs beyond stipulated delivery period in Purchase order.**

I) Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders. Further, supplies against a purchase order are to be made in minimum numbers of batches as far as possible and same batch should not be supplied in repeated consignment.

J) Bidder must comply to the shelf life of each quoted drugs in accordance with Schedule P of Drugs and Cosmetics Rules, 1945. **In case drug/medicine not covered in Schedule P of Drugs and Cosmetics Rules, 1945, the bidder must supply the drug/medicine with minimum 24 months shelf life. Bidders must declare the required shelf-life detail in Para VI of Annexure II**.

K) The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned to the suppliers, and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with IP/BP/USP and the specifications, stipulations and conditions specified in the tender.

L) Tenderer should supply the product as follow:

(i) Within 2 months excluding month of manufacture of products having shelf life up to 2 years,

(ii) Within 3 months excluding month of manufacture of products having shelf life more than 2 years & up to 3 years and

(iii) Within 4 months excluding month of manufacture of products having shelf life more than 3 years

(iv) Within 3.5 months excluding month of manufacture of products for drug code 574 HUMAN RABIES VACCINE INJECTION 2.5 IU.

Products supplied beyond the above-mentioned period from the date of manufacturing shall levied a LD as Per Clause 25. (E) of tender documents. For example, product having manufacturing of November 2024 must be supplied by 31st January 2025 in case shelf life up to 2 Years.

M) If at any time the Tenderer has, in the opinion of the PMBI delayed the supply of drugs due to one or more reasons related to **Force Majeure events** such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the PMBI at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The supplier shall not be liable to pay LD and forfeiture of Security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

N) The exceptional events do not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

O) Suppliers are required to supply the drugs within the delivery period mentioned in the purchase order. In this regard it is informed to the bidders that their performance shall be considered unsatisfactory in case of delayed supply (beyond delivery period) or non-supply of products. PMBI may reject their bid in future tenders considering their unsatisfactory performance of supplies.

P) Leaked, soiled, broken containers with damaged labels shall not be accepted.

Q) If PMBI observes any physical defects (like empty blisters, improper labelling etc.) of the supplies during sampling, the batch shall be rejected. If supplier wants to take back the batch for rectification, they can take back at their cost, rectify and send back to PMBI within 15 days

otherwise same batch shall not be accepted. Due to rectification, if its shelf-life condition as per tender provision does not meet, it shall be discretion of PMBI depending upon requirement to accept the goods with penalty.

R) Tenderers shall not supply the drugs declared banned by Government of India, even if Purchase Order is placed.

20. LOGOGRAM:

Logogram means, wherever the context occurs, the design as specified in **Enclosure 1 & 2 of ANNEXURE-VII. The name of the drug shall be mentioned in English and Hindi** as per pharmacopoeia and its strength.

A) Tenders should supply for Drugs etc., as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/Lamitubes etc. as per the design enclosed as per **Enclosure 1 to ANNEXURE –VII** and **Enclosure 2 to ANNEXURE –VII.**

B) All dosage form has to be supplied in packing as specified in product list (**ANNEXURE XIII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned at supplier's cost.

C) Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed PMBJP logogram of proportionate size.

D) Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of Rate Contract / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier and levied a LD as per clause 25 (D) of tender documents.

E) Drugs without GS-1 Standard Barcoding on Primary, Secondary and Tertiary Packaging will not be accepted.

21. PACKING:

A) The drugs shall be supplied in the package specified in **ANNEXURE -VIII, ANNEXURE -XII and ANNEXURE-XIII** and the package shall carry the logograms of proportionate size specified in 1 to **ANNEXURE –VII & 2 to ANNEXURE –VII** and shall also conform to Schedule P1 of the Drug & Cosmetic Act & Rules 1945, whether it applicable.

Non-affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 25 (D) of tender documents.

B) The drugs in any dosage form to be supplied by the supplier should not be embossed indicating any code no./logo or name of the company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25. (D)

C) The packing in each carton shall be strictly as per the specification mentioned in **Annexure-VIII**. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated and embossed** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**). **The material to be used for carton should be from virgin chemical pulp.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25 (D). Storage conditions must be indicated on outer label.

D) The cap shall be provided with PMBI logogram as per provided design under clause 3. (h) of Enclosure- 2 to Annexure– VII, Ref. Clause No. 3(M) & 20. The cap/packing of bottle /preparations should not carry the name/logo/other details of the supplier.

E) The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

F) It should be ensured that only virgin packaging material of uniform size, including bottle and vial etc., is used for packing. Drugs / Medicines meant for external uses or external preparations shall not be packed in pet bottle. Awarded bidder / supplier shall supply them in specified bottle as per market standard.

G) All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

H) Packing should be able to prevent damage or deterioration during transit.

I) The packings/labels of two different products of a same supplier should be clearly distinct from each other.

J) In the event of items of drug supplied found to be **not as per specifications in respect of their packing and logogram**, the PMBI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the PMBI has every right to recover the cost and impose penalty as mentioned in Clause 25 & 26.

K) Designs of packaging with the logograms shall be subject to approval by PMBI within 3 days of receipt of purchase order or within 30 days of release of letter of acceptance. Text matter of all type of label must be checked and responsibility shall be of manufacturer.

In case of failure of PMBI to do so, the supplier may go ahead with the design as per the specification in Enclosure-1 to ANNEXURE VII and Enclosure-2 to ANNEXURE VII.

STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

L) The color of the strength must be different from the colour of the generic name of the drug on primary and secondary packaging and the approval for the same should be taken from the quality/regulatory department while taking artwork approval. The printing ink used should be of good quality (clarity, brightness, contrast) which is easily readable.

M) WHO-GMP certified, Therapeutic/Drug code & NABL lab tested shall be indicated on the primary and secondary packaging and shall be incorporated as per the approval from the quality/regulatory department while taking artwork approval. PMBI Drug Code must be indicated on front side of the pack or as directed by PMBI during artwork approval.

N) Barcodes as per GS-1 standards are required to be printed on products at various packaging levels (Primary, Secondary and Tertiary) as per Annexure-IX.

O) Certificate of Analysis (CoA) of Primary and secondary packaging material shall be submitted at the time of supply.

P) Wherever any category of medicine requires insert in the final packaging as per the Drugs & Cosmetics Rules, 1945, the bidder shall supply the medicine with insert containing proper information.

22. QUALITY TESTING & QUALITY CONTROL:

A. All the batches of the drugs supplied shall be supported by test/ analysis reports furnished by independent NABL Accredited Drugs Testing Laboratory/Central Drug Testing Laboratory/In House Quality Control Laboratory. The Tender Inviting Authority has the right to get the drugs tested at the laboratories of his choice for further verifications, from PMBI empanelled laboratories.

B. Random samples of each supplied batch will be chosen at the point of supply or distribution/storage points for testing. The samples will be sent to different PMBI empanelled

laboratories including Government Drugs Testing Laboratory/NIPER/PSU labs for testing. Handling and testing charges will be deducted by PMBI for the above purpose, as specified in Clause 24.

C. **STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance by mail to Quality and Regulatory officer of PMBI with artwork approval for design of packaging with the logogram as per Clause 21.K.**

D. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf-life period of the drug. The samples will be drawn periodically throughout the shelf-life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also, action will be initiated for blacklisting as per clause 26 & 27 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

E. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the PMBI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the PMBI has every right to recover the cost and impose penalty as mentioned in Clause 26(I).

F. If the product / sample fails in quality test, every failed batch shall be taken back by the supplier at their own cost and PMBI shall not be responsible for any damage during this period.

G. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the PMBI. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. **For New drugs, complete stability data of 6 months' period shall be acceptable.**

H. **The** products should conform to the standards of IP/BP/USP/EP/JP as the case may be. **However, the drugs notified in the IP (amended up to date) shall be accepted only if supplied conforming to the standards outlined in the IP.** In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.

I. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 26. If such lapses happen more than twice in a tender period such cases will be treated as "Misbranded Drugs".

23. PAYMENT PROVISION:

A) No advance payments towards costs of drugs will be made to the supplier.

B) Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original **ANNEXURE -V (Part – A)** with cancelled cheque to make the payment through RTGS/Core Banking/NEFT.

C) All bills/Invoices should be raised in triplicate and the bills should be drawn as per GST Rules **in the name of Pharmaceuticals & Medical Devices Bureau of India (PMBI)**. B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029 or in the name of any other authority as may be designated.

D) (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of PMBI.

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within delivery period stipulated in purchase order from the issue of such purchase order.

b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk, and cost etc., as per the tender conditions.

E) If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the PMBI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

F) In case of any increase of decrease in the Taxes/GST after the date of submission of tenders and during the tender period, such variation in the taxes/GST will be to the account of the PMBI. For claiming the additional cost on account of the increase in taxes/GST, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to PMBI from the concerned authorities and also must claim the same in the invoice separately. However, the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly, if there is any reduction in the taxes/GST and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/GST/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender. Any increase or decrease in taxes/GST and statutory levies will be considered based on the notification issued by the Government.

G) However, if the firm supplies after originally stipulated Delivery period, increase in taxes/GST due to statutory variation in taxes/GST shall be borne by the supplier. In case of decrease in taxes/GST due to statutory variation in taxes/GST, the same shall be passed on by the supplier to the PMBI.

24. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

25. LIQIDATED DAMAGES & OTHER PENALTIES:

A) All supply should be made within the stipulated time as per the clause 19.D of the Delivery Schedule and quantity as mentioned in the Purchase Order.

B) If the supply reaches the Drug Warehouses beyond the stipulated time as mentioned in PO/Bid document, liquidated damages will be levied at the rates 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the PMBI has suffered any damage/loss or not, on account of delay in effecting supply.

C) If the supply is received in damaged condition, it shall not be accepted. The supplier shall have to replace the goods with damage and the penalty equal to the penalty for unexecuted supplies will be levied for the damaged goods and payments will be withheld till proper replacement.

D) All the Tenderers are required to supply the product(s) with printed MRP as per purchase order and logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to

blacklist the product, and/or a separate damage will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.19.F, 19.H and 21.J.

E) If supplier supplied the drug time beyond the manufacturing date as mentioned in clause 19. (M) of supply conditions, a liquidation damage will be levied for shelf-life losses @ 5% per month subject to maximum 30% (Up to 6 months).

F) In all the above conditions, the decision of the Tender Inviting Authority shall be final and binding.

26. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

A) If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the PMBI. Such stock shall be taken back at the expense of the Tenderer. Further, actual handling and testing charges shall be paid to PMBI by the supplier otherwise these charges shall be recovered from their pending bill/Performance Security Deposit.

B) The PMBI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The PMBI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice and shall also collect handling charges (in case the product is sent back to supplier on freight to pay basis)/ demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

C) If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description (Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words, the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

D) For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to PMBI. PMBI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company.

If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of PMBI for supply of Drugs for a period of 5 years from the date of blacklisting.

In case of supply of NOT OF STANDARD QUALITY drug(s) to PMBI, the product shall be blacklisted by PMBI, and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of PMBI for supply of such Drugs for a period of 2 years from the date of blacklisting.

In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Performance Security Deposit will also be forfeited without any intimation.

E) The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the PMBI. The PMBI reserves the right to cancel the purchase orders if the source of supply is not furnished.

F) The decision of the PMBI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the PMBI will be at liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Performance Security Deposit.

G) For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the PMBI, and the Tenderer shall be liable to pay for all losses sustained by the PMBI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Performance Security Deposit.

H) Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years/ Blacklisting the tenderer.

I) In the event of making Alternative Purchase, as specified in Clause 19.H, Clause 21.J and in Clause 22.E penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the PMBI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

J) In all the above conditions, the decision of the PMBI shall be final and binding.

27. BLACKLISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE:

A) BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

a) If the Tenderer fails to perform the obligations under the tender conditions / commits default in the performance of the contract/LOA, such Tenderers will be blacklisted for a period of **2 years** by PMBI from the date of intimation besides forfeiture of Performance security deposit.

b) **The Tenderers who have withdrawn after participating in the tender after the last date and time of submission of online bid, either fully or partially, the entire firm/company will be blacklisted for a period of 3 years from the date of intimation by PMBI apart from forfeiture of the Security Deposit.**

B) BLACKLISTING FOR QUALITY FAILURE/QUALITY TEST BY THE EMPANELLED LABORATORIES OF PMBI.

a) Each and every batch of drugs/medicines supplied by the supplier shall be subjected to quality test by the Empaneled laboratories as per the procedure adopted by PMBI.
PMBI shall also draw the samples of products supplied in the marketplace and get the same tested, to make sure the products are conforming to quality requirements till Self life.

b) If the sample of any batch fails in quality test and report is received stating "Not of standard quality "in any test the report along with the chromatograms etc. such batch of drugs shall be rejected & no further procurement of that drug from the supplier will be taken for two years from the date of sample being declared not of standard quality.

(i) If the supplier challenges the Certificate of Analysis (CoA) and request for retesting, the controlled sample from PMBI warehouse shall be tested at any two empaneled NABL laboratories of PMBI and if the CoA at both the laboratory declares the sample as standard quality, the sample will be considered pass else it may be sent to government testing laboratory or reputed govt. institute like NIPER. In that case the CoA of the govt. lab or NIPER will be final and will be binding to the supplier.

(ii) The cost of such Re-testing shall be recovered from the supplier.

(ii) If 2 batches of item/drug supplied by the same supplier is reported to **NOT OF STANDARD QUALITY** in specification, then the firm shall be blacklisted for 2 years after observing procedure laid down in Para 27(D) besides forfeiture of Performance Security Deposit.

(iii) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded by the Government Authorities during the shelf life of the product supplied irrespective of tender period, the company/firm shall be blacklisted for a period of **2 years from the date of intimation & forfeiture of security deposit.**

C) Quality Test by Statutory Authorities:

(i) If any drug is declared "NOT OF STANDARD QUALITY", by any government agencies or drug licensing authority, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/JAS will be retrieved.

(ii) If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period or during quality check within shelf-life period, the company/firm shall be blacklisted for a period of **2 years from the date of blacklisting** after observing procedure laid down in Para 27. D

D) Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/MISBRANDED" (**As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, PMBI may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Performance Security Deposit.

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for such item floated by the PMBI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the PMBI until the period of blacklisting is over.

E) BLACKLISTING FOR NON-SUPPLY:

Due to non-supply of item against any purchase order, 5% value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase.

In case of repeated circumstances of non-supply of items i.e., 2 times, the supplier may be blacklisted for 2 years in addition of forfeiture of Performance Security Deposit and other penal action.

28. SAVING CLAUSE:

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

29. RESOLUTION OF DISPUTES

The PMBI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract.

A) ARBITRATION AND JURISDICTION.

Normally, there should not be any scope of dispute between the PMBI and the supplier after entering a mutually agreed valid contract/ Rate Contract.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/ Rate Contract leading to disagreement PMBI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the PMBI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the CEO of PMBI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties. The second party shall consent on the following conditions while signing the Agreement/ contract:

i. The second party shall consent that the arbitrator appointed by CEO, PMBI shall be paid fees for each hearing/proceeding of arbitration.

ii. The fees of the arbitrator shall be such as decided by PMBI.

iii. The fees of the arbitrator for each hearing/proceeding shall be borne by both the parties in equal-half-proportion

B) In case of a complaint received from any local supplier indicating a need for review / verification of Local content of successful vendor / awarded vendor, for accepting a complaint from such complainant (w.r.t the false declaration given by the successful vendor on the local content), a complaint fee of Rs.2 Lakhs or 1% of the locally manufactured items being procured (subject to a maximum Rs.5 Lakhs), whichever was higher, to be paid by demand draft by the complainant. In case, the complaint is found to be incorrect, the complaint fee shall be forfeited. In case, the complaint is upheld and found to be substantially correct, deposited fee of the complainant would be refunded without any interest.

30. CONTACTING THE PURCHASER (PMBI) BY THE BIDDER:

A) No bidder shall contact the PMBI on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

B) Any effort by a bidder to influence the PMBI in the Purchaser's bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

C) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

D) Notwithstanding anything contained in clause (C) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

31. FRAUDULENT AND CORRUPT PRACTICES:

A) For Bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser.

a) Defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving, or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party ("another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context,

"public official" includes staff and employees of other organizations taking or reviewing procurement decisions.

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party ["parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non-competitive level].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (a "party" refers to a participant in the procurement process or contract execution).

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

b) Will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices in competing for the contract in question.

c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub-contractors engaged in corrupt, fraudulent, collusive, or coercive practices

d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

B) For Suppliers:

If the PMBI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the PMBI may, after giving 7 days' notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Performance Security Deposit apart from other penal actions.

a) For the purposes of this Sub-Clause:

(i) "Corrupt practice" is the offering, giving, receiving, or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party.

(ii) "Fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation.

(iii) "Collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party.

(iv) "Coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party.

(v) "obstructive practice" is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

32. JURISDICTION:

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

…….

ANNEXURE-I

Ref. Clause 3 (N)

CHECK-LIST (Whether uploaded the documents)

COVER – A

S.N.	Check List	YES/ No	Page No.	Remarks
1	Check list – ANNEXURE – I **as per clause 3. N.**			
2	ANNEXURE –II (Declaration on **non-judicial Stamp Paper** for eligibility in participating the tender) **original Annexure II delivered to PMBI as per clause 3. J.**			
3	EMD Rs. 10,00,000/- (ten lakhs) in the form of Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque or Demand Draft or BG as per ANNEXURE-III (Clause 3. A & 6. A).			
4	Copies of documentary evidence for the constitutions of the company / Firm/ Proprietorship such as Memorandum and Article of Association, Partnership deed with complete address as per Clause 3. B.			
5	Power of Attorney (on Non-judicial stamp paper / stamp duty paid) or Resolution of the Board (duly sealed and signed on Company letterhead) by which the authorized signatory has been authorized by the Tenderer to sign the tender documents as per clause 3. C.			
6	Copy of Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate as per Clause 3. D.			
7	Copy of Market Standing Certificate issued by the Licensing Authority from Drug Controller Administration of the State of quoted product for last 3 Years as per Clause no. 3. E.			
8	Copy of Non-Conviction Certificate issued by the concerned Licensing Authority from Drug Controller Administration of the State, not older than 12 months as per Clause no. 3. F.			
9	Copies of **WHO-GMP** (WHO-Good Manufacturing Practice) certificate as per revised Schedule- 'M' of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA. The WHO-GMP certificate must be valid as on the last date of submission of tender as per Clause 3. G.			
10	Copies of valid CoPP certificate as per WHO format of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA. The CoPP certificate must be valid as on the last date of submission of tender as per Clause 3. G.			
11	Copy of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drug Control Department/FDA highlighting the quoted product section as per Clause no. 3.H			
12	ANNEXURE IV {certificate from the C.A. (Chartered Accountant) or Company Secretary. **Original Annexure IV delivered to PMBI as per clause 3.I.**			
13	Copy of Audited Annual Balance sheet and Profit and loss statement showing details of their annual turnover not less than **50 Crores (Fifty Crore)** for three consecutive years of the last four financial years as per Clause 3. I.			
14	ANNEXURE-V **(Mandate form)** PART – A & PART – B with cancelled cheque to furnish company bank details as per clause 3 (K) & 23(B)			
15	ANNEXURE-VI indicating manufacturing License, validity of license and market standing certificate details as per clause 3. L.			

16	ANNEXURE-VII (Declaration to supply the drugs as per the design in enclosure 1 and enclosure 2 in Annexure VII) as per clause 3(M), 20 & 21.			
17	Self-attested copy of PAN Card of the Bidder Company. As per Clause 3(O).			
18	Self-attested copy of Certificate of valid GST registration of the bidder company. As per Clause 3(P).			
19	Self-attested copy of Income Tax Return (ITR) for any three of last four consecutive Assessment years. As per Clause 3(Q).			
20	Copy of valid GS-1 registration certificate for bar coding as per Clause 3. R.			
21	ANNEXURE-X (Declaration of Local Content as per clause no. 3(S) & 5(B)(d)			
22	Copies of Batch Manufacturing Record (BMR) of any of the latest marketed batch in last three year of each quoted drug code as per Clause 3.U.			
23	Stability Study data against each quoted products as per tender clause 4.F.			
24	Annexure XV (Clause No. 3. (1) Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020& 24 Jul 2020 under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 on Non-Judicial Paper duly notarized.			
25	Annexure XVI Declaration of source of Active Pharmaceutical Ingredient (API) as per Clause No. 4. G.			
26	Authorization letter nominating an employee of the tenderer to transact the business with the Tender Inviting Authority as per clause 4(O).			
27	Certificate of Analysis (CoA) of last purchase of API against quoted drug codes.			

NOTE:- (i) ANNEXURE-II, ANNEXURE-III; Earnest Money Deposit (EMD), ANNEXURE-IV, ANNEXURE-V, ANNEXURE-VI, ANNEXURE-X (Declaration of Local Content) and Annexure XV are to be delivered in original to PMBI, rest of the document duly authorized should be submitted on or before stipulated date as mentioned in the tender document "technical cover A".

(ii) In case a bidder has quoted from their Loan License unit, they shall submit Valid WHO-GMP certificate, Product Permission (minimum three-year-old), Non-conviction Certificate (NCC), Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority, Turnover Certificate issued by CA/CS and balance sheet shall be submitted with the technical bid (Cover-A) as per tender provision mentioned in this document.

Name of authorized signatory: ……..

Signature of authorized signatory with date: …….

Company seal:

ANNEXURE –II
(On nonjudicial Stamp Paper)
Ref. Clause No. 3. (J)

DECLARATION

I/We M/s. ……..represented by its **Proprietor/Managing Partner /Managing Director/Authorized Signatory** having its registered office at …….....and its factory premises at…….……..……do hereby declare as under: -

(I) that I/we have carefully read all the terms and conditions of tender in ref. no**. PMBI/DRUG/RC-222/2025 dated 30.04.2025 including** Amendment(s) to Tender document (if any) issued by Pharmaceuticals & Medical Devices Bureau of India (PMBI), New Delhi, 110029 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

(II) A. that I/We are holding and have uploaded (a) valid drug license along with product permission for quoted drugs (b) valid WHO-GMP certificate, (c) valid CoPP certificate for each quoted drug code (d) valid Batch Manufacturing Record (BMR) for each quoted drug code (e) Valid stability study data for each quoted drug codes (f) minimum three (3) years market standing certificate for quoted products issued by licensing authority, (g) valid non conviction certificate not older than 12 months, (h) declaration of the active API polymorphic form used in formulation for quoted drugs and declare that it is internationally accepted active polymorph **(if any)** and (i) the copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document.

B. that I/We shall submit the complete stability data (long term stability studies and accelerated stability studies) for all awarded drugs within 15 days from the date of issue Letter of Acceptance. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor shall be submitted along with licensing agreement).

C. **that I/we shall supply the drugs as per the specification, composition, pack size given in ANNEXURE-XII, design, logo as given in ANNEXURE-VII & VIII and Color, Packing Type, etc. of drugs as given in ANNEXURE-XIII.**

On the basis of above undertaking/declaration, the price bid shall be opened subsequently after opening of technical bid. However, any document uploaded with technical bid is not complying as per undertaking, the contract/ Rate Contract shall be cancelled with forfeiture Performance Security Deposit/Bank guarantee (if any) against tender no. **PMBI/DRUG/RC-222/2025 dated 30.04.2025** along with other action including suspension/disqualification of contract**.**

(III) A. I/We declare that we possess the valid drug manufacturing license for PMBI's tendered items as per details below:

Sr. No.	Drug Code	Description of Drug as per PMBI Tender	Unit Size	Drug Lic. No.	Date of Issue	Validity of Drug Lic.	Address of Manufacturing Unit

B. I/We declare that we possess the valid WHO-GMP (World Health Organization-Good Manufacturing Practices) Certificate and CoPP certificate issued by competent authority and complies and continue to comply with the condition lied in schedule M of Drug & Cosmetic Act, 1940 the rules there under 1945.

C. I/We declare that the information of local content provided in Annexure X is correct.

I am / We are aware of the Tender inviting Authority's right to forfeit the Performance Security Deposit/impose penalty and suspending/disqualifying/blacklist me/us/our firm for a period of five (5) years if, any information furnished by us proved to be false at the time of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

(IV) I do hereby declare that I have uploaded valid GS1 registration certificate for bar coding and will supply the drug with bar code as per ANNEXURE IX and as per the design as per enclosures to ANNEXURE XII enclosed with tender document as well as other instruction given in this regard.

(V) that in pursuant to the conditions in Clause No. 6. (A) of the tender, the bids can be suspended/disqualified by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

(VI) that our company/applied items have not been blacklisted/debarred/de-registered/banned **due to quality failure for the quoted product /firm by any State Government / Central Government/ PMBI/ Central or State Government's Drug procurement agencies** for the following products quoted in the tender at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/PMBI during last two years. We are eligible to participate in the tender ref. No. **PMBI/DRUG/RC-222/2025 dated 30.04.2025 for** the following quoted products with mentioned shelf life as per clause 19.J: -

(1)	(2)	(3)	(4)	(5)
S. No.	**Drug Code**	**Description of Drug as per PMBI Tender**	**Unit Size**	**Shelf life complying the Schedule-P" of the Drugs and Cosmetics Rule, 1945.**

(VII) that I/we have quoted the rates in BOQ for above mentioned drug codes (table under para VI) in my/our full consciousness abiding by the terms and condition laid down in the tender document considering unit size, secondary pack, shelf life, packaging type etc. and declare it to be invariable.

Signed:…….

Name: ……..

Designation…….

(Company Seal)

Witness: -

(1) Signed: …….

Name:……

Designation: …….

(2) Signed: …….

Name: .....

Designation: …….

(To be attested by the Notary)

ANNEXURE-III

(Ref: -Clause **3(A),** 6.A)

DETAILS OF EMD SUBMITTED

(UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER/BANK GURANTEE/NEFT RECEIPT)

MODEL BANK GUARANTEE (BG) FORMAT FOR FURNISHING EMD (if bidder intends to submit BG)

Whereas……(hereinafter called the "tenderer") has submitted their offer dated…… for the supply of Items (hereinafter called the "tender") against the purchaser's tender enquiry No. PMBI/DRUG/RC-222/2025 know all men by these presents that we…….. of……..……..……having our registered office at..…… …… are bound into Pharmaceuticals and Medical Devices Bureau of India (PMBI) of India New Delhi (hereinafter called the "Purchaser) in the sum of Rs. 10,00,000.00 (Ten lakh) only for which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this…… day of ……..202...

The conditions of this obligation are:

(1) If the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of this tender.

(2) If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity: -

(a) Fails or refuses to accept/execute the contract.

We undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to 12 months from the due date of tender i.e., ...and any demand in respect thereof should reach the Bank not later than the above date.

(Signature of the authorized officer of the Bank) …….

Name of the officer……

Designation of the officer……..

Seal, name & address of the Bank and address of the Branch……...

ANNEXURE-IV

Ref. Clause No. 3. (I)
(on *CA/CS* letter head)

{Format for a certificate from the C.A. (Chartered Accountant) or Company Secretary}

(I) It is certified that M/s……..…….……is a Private Limited/Limited/Proprietorship/Partnership company/firm and they have PAN no…….and GST registration no……..……..They have filed Income tax returned and GST returned up to date. The authorized signatory of the company/firm is Shri……and ***whose signature is attested as under:……..***

(II) The annual Turnover of M/s. ..... for three consecutive years of the last four financial years for manufacturing of drugs are given below and certified that the statement is true and correct.

Sl. No.	Financial Year	Turnover in Rupees (₹) in Crore (Rs.)	Turnover in Rupees in Crore (in words)
1.	2021-22	₹	
2.	2022-23	₹	
3.	2023-24	₹	
4.	2024-25	₹	
Total Turnover		Rs (₹)…….. Crore	Rs (in words)……
Average Turnover per annual		Rs (₹)…….. Crore	Rs (in words)……

It is certified that M/S …….(Name of company and address) having factory at…… (address of factory) have required plant/plants, machinery/machineries, building/buildings & other infrastructure to manufacture the tendered drugs. It is also certified that the statement is true and correct.

(III) It is certified that M/s……..…….has Production & financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

(V)They have manufactured & marketed at least two (2) or more commercial batches of each quoted items in last three years.

Date:

Name: ……

Signature: ……..

Stamp: ……

Registration No.:……

Note: Turnover certificate (Annexure-IV) shall be submitted in original on CA/CS letter head.

ANNEXURE-V (Part A)

Ref. clause 3 (K) & 23. (B)

MANDATE FORM FOR BANK DETAILS

Sl. No.	Details Required	Information to be filled for correspondence
1.	**Company Name:**	
2.	Postal Address of the Company	
	GST No.	
	PAN Card No.	
	Telephone No.	
	Fax No.	
	E-mail ID (Registered)	
	Email ID (on Company Website)	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No.	
	E-mail ID	
	Permanent E-mail ID	
	Permanent Mobile No.	
4.	**Bank Details**	
	Name of the Bank	
	Branch Name & address	
	Branch Code No.	
	Branch Manager Mobile No.	
	Branch Telephone no	
	Branch E-mail ID	
	9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	IFSC Code of the Branch	
	Type of Account (Current / Savings)	
	Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold **Pharmaceuticals & Medical Devices Bureau of India (PMBI)** responsible. I have read the conditions of the tender / Rate contract entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Signature :

Name :

Designation:

Place: Company Seal (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

Note: Without bank seal and signature document shall not be accepted.

ANNEXURE-V (Part -B)

Ref. clause 3 (K) & 23. (B)

MANDATE FORM FOR COMPANY DETAILS

(On company letter head duly signed by Authorized signatory)

Sl. No.	Details Required	Information to be filled for correspondence
1.	**Company Name:**	
2.	Postal Address of the Company	
	GST No.	
	Telephone No.	
	Fax No.	
	E-mail ID (Registered)	
	Email ID (on Company Website)	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name:
		Designation:
	Mobile No.	
	E-mail ID	
5.	Name and Designation of the company official Authorised for communication in respect of technical documents.	Name:
		Designation:
	Mobile No.	
	E-mail ID	
6	Name and Designation of the company official Authorised for communication in respect of status of Purchase Orders/artwork.	Name:
		Designation:
	Mobile No.	
	E-mail ID	
7	Name and Designation of the company official working in manufacturing premises (Plant Head/Production Manager/Quality Manger)	Name:
		Designation:
	Mobile No.	
	E-mail ID	
8.	**For Vendor Portal Registration**	
	Permanent E-mail ID	
	Permanent Mobile No.	

Date: Signature :

Name:
Designation:

Place: Company Seal (Name of the person signing & designation)

Annexure-VI

Ref. Clause No. 3 (L)

Date:

Sl. No.	Drug Code (Only Quoted Drugs as mentioned in Annexure II)	Drug Specification (As per Tender Specification)	Unit Size	Drug Manufacturing License *(Bidder must highlight the indicated drug codes with highlighter on reference page no.)*					Marketing standing Certificate (MSC) *(For latest three years)*			Batch Manufacturing Record (BMR)			Certificate of Pharmaceutical Product (CoPP)		
				Drug Manufacturing License No.	License Issue date (first approval)	License Renewal Date (latest)	License Validity Date	Page no. of Document in uploaded Scan Copy (Do not put page nos. in range)	Market Standing Certificate Issue Date	Period of Marketing as per Marketing standing Certificate (MSC)	Page no. of Document in uploaded technical bid (Do not put page nos. in range)	BMR document no. as per official record	BMR finalization date	Page no. of Document in uploaded technical bid (Pages in range)	CoPP document no.	CoPP Issue and validity date	Page no. of Document in uploaded technical bid (Do not put page nos. in range)

Note:

(i) In case any details as desired above is missing/not submitted against quoted drug, the bid for such drug are liable to be rejected

(ii) It is directed to not put page nos. in range and should indicate the page nos. one by one for all respective quoted drug codes.

Signed.....

Name: ……..

Designation…….

(Company Seal)

ANNEXURE -VII

Ref. Clause no. 20 & 21
(on letter head)

DECLARATION

I/We do hereby declare that I/we will supply the drug as per the design in Enclosure 1 to Annexure VII & Enclosure 2 to Annexure VII as well as other instruction given in this regard.

Signature of the Tenderer

Name: ……

Designation: ……...

(Company Seal)

Enclosure–1 to ANNEXURE - VII

Ref. Clause No. 3(M) & 20

DESIGN FOR: Foil / blister of Tablet and capsule

1. **Text Matter Printing on** Foil /Blister should be in minimum two colour i.e., Black & red. **However, colour and design of PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) logogram in standard colour format & PMBI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply should be as given below.**

2. PMBJP Logogram should be placed along with the address as given below.
3. PMBI helpline number 1800 180 8080 should be printed.

4. Font type should in CALIBIRI format for any type of title name of generic medicines.

5. Title name of generic medicine should be **bold** in minimum 12 font size & the strength corresponding to it must be **bold** in minimum 14 font sizes and it may increase respectively according to size of label & the rest text matter should be in minimum 8 font size.
6. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.

7. "Pharmaceuticals & Medical Devices Bureau of India" should be running text only and should not be prominent.

1. Pradhan Mantri Bharitya Janaushadhi Priyojana should be printed in Hindi at side of strips.

Enclosure – 2 to ANNEXURE – VII
Ref. Clause No. 3(M) & 20

1. **Design for injection for primary packing**

a) Vial (5ml or more) should be supplied with the following PMBJP logogram & PMBI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply as under:
b) PMBI helpline number 1800 180 8080 should be printed
c) Font type should in CALIBIRI format for any type of title name of generic medicines
d) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.
e) "Pharmaceuticals & Medical Devices Bureau of India" should be running text only and should not be prominent.

Manufactured for:

प्रधानमंत्री भारतीय जन औषधि परियोजना

Pharmaceuticals & Medical Devices Bureau of India
B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029
PMBI helpline number 1800 180 8080 PMBI DRUG CODE—XXXX

2. Ampoules or Vials less than 5 ml for primary packing

a. Injection in ampoule or vial (less than 5 ml) should be supplied with PMBJP logogram **& PMBI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply**.
b. PMBI helpline number 1800 180 8080 should be printed.
c. Font type should in CALIBIRI format for any type of title name of generic medicines.
b) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.
c) "Pharmaceuticals & Medical Devices Bureau of India" should be running text only and should not be prominent.

Manufactured for:

प्रधानमंत्री भारतीय जन औषधि परियोजना

Pharmaceuticals & Medical Devices Bureau of India
B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029
PMBI helpline number 1800 180 8080 PMBI DRUG CODE—XXXX

3. LIQUID:

d) Liquid preparation should be supply with pilfer proof ROPP cap.
e) Bottle cap should not bear the manufacturer's logogram.
f) Bottle label should bear PMBJP logogram & PMBI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply as below:
g) PMBI helpline number 1800 180 8080 should be printed.
h) "Pharmaceuticals & Medical Devices Bureau of India" should be running text only and should not be prominent.
i) Font type should in CALIBIRI format for any type of title name of generic medicines

j) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

Manufactured for:

Pharmaceuticals & Medical Devices Bureau of India
B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029
PMBI helpline number 1800 180 8080 PMBI DRUG CODE--XXXX

k) Cap on bottle/jar type of packing shall contain printed logogram as per below design provided the direction to unscrew the seal.



4.. OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear PMBJP logogram **& PMBI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply** as below:

Manufactured for:

Pharmaceuticals & Medical Devices Bureau of India
B – 500, Tower – B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi – 110029
PMBI helpline number 1800 180 8080 PMBI DRUG CODE-XXXX

b) PMBI helpline number 1800 180 8080 should be printed
c) Ointment / cream Lamitube should be packed in mono carton (secondary packing) with PMBJP logogram **& PMBI Drug code-XXXX as given in PO as per approval at the time of Artwork approval before supply** as given below.
d**)** "Pharmaceuticals & Medical Devices Bureau of India" should be running text only and should not be prominent
e) Font type should in CALIBIRI format for any type of title name of generic medicines
f) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

Note: The awarded bidder shall highlight the PMBI Drug Code with a font size of minimum 14 on front side or as directed by PMBI while developing artwork design so as to promote clear visibility of the drug code to all stake holders(s) of PMBI.

ANNEXURE-VIII

Ref. Clause No. 21

SCHEDULE FOR PACKAGING OF DRUGS

GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be 0.07 mm thickness and grammage of foil minimum 80 g/m^2, LDPE minimum 35 g/m^2 and total GSM not less than 110 g/m^2.
2. Aluminum foils back material for blisters should be minimum 0.025 mm thickness, grammage of foil minimum 75 g/m^2 and tensile strength minimum 400 Kg/cm^2.
3. The rigid PVC used in blister packing should be of not less than 250 microns (thickness) and grammage minimum 350 g/m^2.
4. ALU-ALU blisters, total grammage minimum 250 g/m^2, total minimum thickness 130 microns, and bursting strength minimum 15 Kg/cm^2.
5. Pin hole should be nil, and toxicity should be complied as per USP in all foil and PVC.
6. All glass bottles should be new neutral glass, Type-1, free from visual defects.
7. PET bottles used for syrups/solution should be clean, standard for market and so accepted as per drug laws stipulation.
8. Ointments should be packed in lacquer zed Aluminum tubes or Lamitubes and properly sealed.
9. Small Tablets packed in blisters should be packed to facilitate easy removal of the Tablet without breaking / crushing.
10. Specification of outer cartons should be as per given in their Schedule.
11. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
12. All plastic containers should be made of virgin grade plastics
13. Injection in vials should have a flip-off seals.
14. Container used for infusions should be as per market standard and must not leak during use.
15. The strips shall be aluminum strip / blisters with aluminum foil back.
16. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**). **The material to be used for carton should be from virgin chemical pulp.**
17. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle in a mono carton. In case of Pediatric Preparation, all liquid oral has to be provided with a measuring plastic cup, dropper fitted over the cap of the bottle in a mono carton.
18. All primary/secondary/tertiary packaging should have PMBJP logo and PMBI drug code mentioned as per purchase order.

19. Two Horizontal/vertical/standing lines in two different colour will be there on Primary and secondary packaging, to differentiate therapy groups. The colors of lines will be intimated during Artwork approval.

Shipper size or corrugated box specification with weights

S. No.	Particulars	Weight	Ply	Grammage	Bursting strength
1	Tablets	Not more than 12.0 Kg	7	Outer box should be 150 GSM and inside partition/ lining should be 120 GSM.	Not less than 10 Kg/cm^2.
2	Capsules (Hard gel and soft gel)	Not more than 12.0 Kg	7		
3	Syrups	Not more than 12.0 to 14.0 Kg	7		
4	Ointment/gel/cream	Not more than 12.0 Kg	7		
5	Injection (vial, respules and ampules)	Not more than 8-12.0 Kg	7		
6	IV fluids	Not more than 12.0 Kg	7		
7	Bottles/Jars	Not more than 12.0 Kg	7		

NOTE:

a) In the case of 10 ml Ampoules, 20 or 25 ampoules may be packed in a mono carton. Multiples of mono carton boxes should be packed in CB.
b) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.
c) In case of ampoules less than 10 ml, every 10 or 5 ampules should be inside the tray with printed white board box.
d) Vials of eye, ear drops, and nasal drops should be packed in an individual mono carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed as per approved artwork and market standard.
e) Bidders shall strictly follow the Packaging guideline to ensure its easy handling and stability of packaging as per tender guideline and Schedule P of the Drugs & Cosmetics Act 1940 and Rules there under 1945.

ANNEXURE IX
(BARCODE REQUIREMENTS}
Reference clause 3(R)

GS1 barcode requirements on Drugs procured by Pharmaceuticals & Medical Devices Bureau of India (PMBI)

These requirements cover medicines/drugs procured by **Pharmaceuticals & Medical Devices Bureau of India (PMBI)**, New Delhi meant for supply and distribution through PMBI regulated distribution channel.

Barcode based on GS1 identification standards are provided below at various levels of product packaging which includes primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to PMBI.

GS1 India is unique identification & barcoding standards body setup by Ministry of Commerce & Industry, Govt. of India along with APEDA, BIS, Spices board, IIP and apex industry chambers like CII, FICCI, ASSOCHAM to assist India industry and govt. bodies on adoption of global standards.

Suppliers are also required to provide GS1 subscription validity certificate at the time of supply of medicines/drugs issued by GS1 India. For validity certificate suppliers can contact GS1 India at 011-42890-846.

Barcodes based on GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

For barcode generation on primary, secondary and tertiary level bidders may also approach M/s Dash Technologies & Levels Pvt. Ltd. besides the active services from GS1 India. GTIN No. shall remain continued with GS1 India only. Bidders may see the circular no. PMBI/PROC./BARCODE/2024 dated 02.02.2024 on PMBI website.

Tertiary Level Pack:

Is defined as a level of packaging that shall contain one or more secondary/primary levels of packaging and is also considered as the final logistics unit like shippers/pallets.

The Tertiary label will carry two barcodes in GS1-128 format

First Barcode

a) Unique product identification code (GTIN - Global Trade Identification Number)
b) Manufacturing Date
c) Expiry date
d) Batch no.
e) Quantity

Second Barcode

f) Serial Shipping Container Code (SSCC) –

Note-

1) *While encoding Manufacturing and expiry date in the barcode, if a specific Manufacturing or expiry date is not printed on the finished pack/drug then Supplier should select first day of the month as the Manufacturing date and Last day of the month as expiry date.*

   Example- If Shelf life is 24 months, April 2020 manufacturing date should be encoded as 200401 and March 2022 expiry date as 220331.

2) *SSCC number of the Tertiary pack should never be reused on another Tertiary pack irrespective the Item, Batch or expiry is different.*

3) *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*Unique Product Number-GTIN-14*	*14*	*Fixed*	*Numeric*
(11)	*Application Identifier to indicate Manufacturing date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
180101	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*
(17)	*Application Identifier to indicate Expiry date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
220131	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*

(10)	*Application identifier to indicate Lot/batch number Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*20*	*Variable*	*Alphanumeric*
(37)	*Application identifier to indicate Quantity in Outer Carton*	*2*	*Fixed*	*Numeric*
500	No of Primary packs like number of strips/Bottles in the tertiary.	*Upto 8*	*Variable*	*Numeric*
(00)	*Application identifier to indicate the SSCC Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 000000000 6	*Unique number of the tertiary pack. It should never be reused.*	*18*	*Fixed*	*Numeric*
Recommended Barcode – GS-128				

Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode

GTIN-14- Unique product code with first digit being the packaging indicator	**Description**	**Length**	**Nature**	**Data Type**
Application identifier to indicate Lot/batch Brackets not encoded in the barcode		*2*	*Fixed*	*Numeric*
Batch No / Lot No		*14*	*Fixed*	*Numeric*
Application Identifier to indicate serial number Brackets not encoded in the barcode		*2*	*Fixed*	*Numeric*
Quantity/Units in Secondary pack		*Upto 20*	*Variable*	*Alphanumeric*
(37)		*2*	*Fixed*	*Numeric*
5		*Upto 8*	*Variable*	*Alphanumeric*

Recommended Barcode depending upon the space available – GS1 Data matrix *Or* *GS1-128*	 (02) 0 8901072 00255 3 (10) BATCH123 (37) 5 *or*  (02) 0 8901072 00255 3 (10) BATCH123 (37) 5

Primary Level Pack:

Is defined as the first level of packaging in direct contact with the product like Strip, Vial, Bottle etc

<u>Scenario-I</u> Primary pack with a Mono-carton/Carton/Secondary level pack

For primary packaging packed in a Mono-carton/Secondary pack carton

Unique product identification code (GTIN)

Note-

10) For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14 with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
Recommended Barcode – GS1 Datamatrix,	 (01) 0 8901072 00255 3			

<u>Scenario-II</u> Primary pack without Mono-carton/Secondary level pack

For Primary packaging going directly into Tertiary pack without a Carton/Mono-carton/Secondary pack

- *Unique product identification code (GTIN)*
- *Batch No.*

Note-

- *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

(01)08901072002533
(10) BATCH123

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(10)	*Application identifier to indicate Lot/batch Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*Up to 20*	*Variable*	*Alphanumeric*

Mapping of Manufacturer GTIN with PMBI Drug code-

- GS1 has facilitated an online application to link Manufacturer GTIN code with PMBI Drug code. The manufacturer must update the same before sending the physical consignment to PMBI.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg for the same at 011-42890846/42890818 or write email at <u>ankit@gs1india.org</u> or <u>amrit@gs1india.org</u>

Barcode Design and Printing-

- For PMBI suppliers, GS1 India and M/s. Dash Technologies & Levels Pvt. Ltd. have facilitated an online application to generate the barcode designs for each level of packaging.
- Using the same, the supplier will be able to generate Primary, secondary and Tertiary barcodes as per PMBI format.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg or Ms. Neha Sawakhande for the same at 011-42890846/42890818 or write email at <u>ankit@gs1india.org</u> or <u>amrit@gs1india.org</u> or <u>implwest@gs1india.org</u>

Please contact GS1 India office for any further assistance –

GS1 India
(Under Min. of Commerce, Govt. of India)
330, 2nd Floor, 'C' Wing, August Kranti Bhawan,
Bhikaji Cama Place, New Delhi - 110066
T +91-11-42890890, (D) +91-11-42890846
F +91-11-26168730

E ankit@gs1india.org
W http://www.gs1india.org

- Kindly contact following from M/s. Dash Technologies & Levels Ovt. Ltd. for any further assistance:
  1) Mr. Dashmesh Singh
     For New Registration
     E.mail : dashmesh@dashtechlabels.com
     Contact No: 9599597056
  2) Mr. A. K. Garg
     For Technical Support
     E.mail : info@asarindia.org
     Contact No: 9873937280

ANNEXURE-X

(On nonjudicial Stamp Paper)

(Refer Clause no. 3.S)

(To be submitted on Non-judicial Stam paper duly notarized)

DECLARATION OF LOCAL CONTENT

I……S/o, D/o, W/o……Resident at …….…….. in the capacity of Proprietor/Managing Partner /Managing Director/Authorized Signatory in M/s……having its registered office at…….……and factory premises at…….…….…….…….…….…….…….……do hereby solemnly affirms and declare the local content for the quoted item(s) as under:

S. No.	Item code	Item Name	Details of Location(s) at which value addition is made	Percentage (%) of Local content	Category
1					
2					
3					

That I……..abide by the terms and conditions laid down in guidelines issued by Department of Pharmaceuticals, Ministry of Chemicals & fertilizers, Government of India vide F. No. 31026/65/2020-MD policy dated 30.12.2020 and DPIIT order no. P-45021/2/2017-PP(BE-II) dated 16.09.2020 for the implementation of provisions of Public Procurement (Preference to Make in India) Order (PPO) 2017 related to procurement of Goods and Services on behalf of M/s……

Further, the calculations of local content used in manufacturing of quoted drugs/medicines are done in accordance with the guidelines laid down in Para 6 of Department of Pharmaceuticals order vide F. No. 31026/4/2018- policy dated 01.01.2019 and that I found our firm under Class …… local supplier for the quoted drugs/medicines.

That the information furnished hereinafter is correct to the best of my knowledge and belief and on behalf of M/s…… I hereby undertake to produce relevant records before the procuring entity, or any authority so nominated by the Tender inviting Authority/ Department/ Any assigned by the Tender inviting Authority for the purpose of assessing the local content and verification.

Signature.....

Name: ……..

Designation…….

(Company Seal/Stamp)

(To be furnished by person in capacity as per para 1)

Note: The category of supplier against each quoted drug shall be mentioned in accordance with Order issued by Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals vide no. *order no. 31026/65/2020-MD dated 30.12.2020* and as per table mentioned under Clause 5.B.(d).

ANNEXURE-XI

Ref. clause no. 15.E

Letter of acceptance (LoA) of tender for Rate Contract

Speed post/e-mail

Ref. No. PMBI/DRUG/RC-222/2025 **Date: …….**

To,
M/S_____
_____

Sub: Tender for the Supply of Drugs and Medicines to PMBI for two years: Acceptance tender for Rate Contract.
Ref: Your quotation against PMBI e-Tender No. PMBI/DRUG/RC-222/2025 dated: 30.04.2025 opened on ……. (Technical Bid) & on …… (Price bid).

Please refer to your quotation i.e., technical and price bid (BOQ) along with enclosures/Annexure against subject tender read with your subsequent clarification/confirmation for the supply of Drugs to PMBI, the rate offered/accepted by your firm has been approved for Rate Contract for two years from the date of issue of this letter.

S. N.	Drug Code	Drug Name	Unit Size	Rates in Rs. Per unit exclusive of GST	Rate of GST (%)	Rates in Rs. Per unit inclusive of GST

2. The contract will be with financial limit and PMBI can place the Purchase Order with unlimited variation in quantities indicated in the tender.
3. The estimated value of the contract awarded to you is Rs.....(in word).
4. Performance Security Deposit @ 3% will be deducted from each bill and accumulated security deposit will be refunded by PMBI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf-life obligation.
5. Approval for Artwork should be obtained from our Quality Control department by you within 30 days of release of this letter. (e-mail id: procure12@janaushadhi.gov.in; procure13@janaushadhi.gov.in, quality4@janaushadhi.gov.in, quality14@janaushadhi.gov.in & quality5@janaushadhi.gov.in).
6. STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit to Quality Control department (e-mail id: procure12@janaushadhi.gov.in; procure13@janaushadhi.gov.in, quality4@janaushadhi.gov.in, quality14@janaushadhi.gov.in & quality5@janaushadhi.gov.in) within 15 days from the date of Letter of Acceptance.
7. As per clause 4.M of Tender document, the Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.
8. The terms and conditions of Rate Contract shall be applicable as mentioned in tender document. By issue of this acceptance letter, the Rate Contract is hereby concluded.
9. The Letter of Acceptance shall be acknowledged on the company letter head duly signed by Authorized Signatory within 7 days of receipt of the same and signing of the contract shall be completed as per format under Annexure-XVII within 15 days/ till ……. from the issuance of this LoA or as scheduled to be convened by PMBI/ Competent Authority.

Authorized Signatory,
For and on behalf of PMBI

Annexure -XII
Clause 18 (M)

Pharmaceuticals & Medical Devices Bureau of India, New Delhi
Tender for supply of drugs (Tender No. PMBI/DRUG/RC-222/2025 dated-30.04.2025)

Sr. No.	Drug Code	Generic Name of Drug	Detailed Specification	Unit Size	Pack Size	Indicative requirement in Unit Size
1	9	Diclofenac Sodium Prolonged Release Tablets IP 100 mg	Each Prolonged Release film-coated tablet contains: Diclofenac Sodium IP 100 mg	10's	10's X 10	1600000
2	10	Diclofenac Sodium Injection IP 25mg per ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml Ampoule	1's X 10	2500000
3	15	Ibuprofen Tablets IP 200 mg	Each film coated tablet contains: Ibuprofen IP 200 mg	10's	10's X 10	500000
4	26	Tramadol Hydrochloride Injection 100 mg per 2 ml	Each ml contains: Tramadol Hcl 50 mg	2 ml Vial	2ml X 10	600000
5	31	Amikacin Injection IP 250 mg per 2 ml	Each ml contains: Amikacin sulphate IP equivalent to Amikacin 125 mg	2 ml Vial	2ml X 10	200000
6	35	Amoxycillin 1g and Potassium Clavulanate 200mg Injection IP	Each vial contains: Amoxycillin Sodium IP (Sterile) eq. to Amoxycillin1g Potassium Clavulanate Diluted IP (Sterile) eq. to Clavulanic Acid 200mg	Vial with Wfi	1's x 10	250000
7	42	Amoxycillin Trihydrate Dispersible Tablets IP 125 mg	Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 125mg	10's	10's X 10	200000
8	45	Amoxycillin Capsules IP 500mg	Each hard gelatin capsule contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 500mg	10's	10's X 10	3000000
9	55	Cefixime Tablets IP 200 mg	Each film coated tablet contains: Cefixime Trihydrate IP eq. to Cefixime Anhydrous 200mg	10's	10's X 10	4400000
10	67	Ceftazidime Injection IP 1g	Each vial contains: Ceftazidime Pentahydrate IP eq. to Anhydrous Ceftazidime 1g (As a sterile mixture of sterile Ceftazidime Pentahydrate and Sodium Carbonate IP)	Vial with Wfi	1's x 10	150000
11	68	Ceftazidime Injection IP 250mg	Each vial contains : Sterile Mixture of Ceftazidime Pentahydrate IP eq. to Ceftazidime 250 mg	Vial with Wfi	1's x 10	150000
12	69	Ceftazidime Injection IP 500mg	Each vial contains : Sterile Mixture of Ceftazidime Pentahydrate IP eq. to Ceftazidime 500 mg	Vial with Wfi	1's x 10	150000
13	70	Ceftriaxone 1g and	Each vial contains:	Vial with	1's x 10	900000

		Sulbactam 500mg Injection	Ceftriaxone Sodium IP eq. to Ceftriaxone 1g Sulbactum Sodium IP eq. to Sulbactum 500mg	Wfi		
14	77	Ceftriaxone injection IP 500 mg	Each vial contains: Ceftriaxone Sodium IP (sterile)equivalent to anhydrous Ceftriaxone 500 mg	Vial with Wfi	1's x 10	150000
15	83	Ciprofloxacin 250mg and Tinidazole 300mg Tablets	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Tinidazole IP 300mg	10's	10's X 10	300000
16	102	Ofloxacin Tablets IP 400mg	Each film coated Tablet contains: Ofloxacin IP 400mg	10's	10's X 10	350000
17	112	Beclomethasone Dipropionate 0.025%w/w, Clotrimazole 1%w/w and Gentamicin Sulphate 0.1%w/w Cream	Contains : Beclomethasone Dipropionate IP 0.025% w/w Clotrimazole 1% w/w Gentamycin Sulphate 0.1% w/w	15g tubes	1's X 20	3500000
18	126	Povidone-Iodine Solution IP 10 % w/v	Composition: Povidone-Iodine IP 10 % w/v	500 ml	1's X 6	150000
19	133	Glibenclamide Tablets IP 2.5 mg	Each uncoated tablet contains: Glibenclamide IP 2.5 mg	10's	10's X 10	250000
20	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	10's X 10	15000000
21	145	Metformin Hydrochloride Tablets IP 500mg	Each uncoated tablet contains: Metformin Hydrochloride IP 500mg	10's	10's X 10	27500000
22	150	Pioglitazone 15mg and Metformin 500mg Sustained Release Tablets	Each uncoated bilayer tablet contains: Metformin Hydrochloride IP 500mg (As sustained release form) Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg	10's	10's X 10	3600000
23	153	Cisplatin Injection IP 10 mg per10ml	Each ml contains: Cisplatin IP 1 mg	Vial	1's x 10	150000
24	158	Etoposide Injection IP 100 mg per 5 ml	Each ml contains: Etoposide IP 20 mg	Vial	1's x 10	200000
25	163	Tamoxifen Citrate Tablets IP 10 mg	Each uncoated tablet contains: Tamoxifen Citrate I.P equivalent to Tamoxifen 10 mg	10's	10's X 10	200000
26	164	Tamoxifen Citrate Tablets IP 20 mg	Each uncoated tablet contains: Tamoxifen Citrate I.P equivalent to Tamoxifen 20 mg	10's	10's X 10	250000
27	177	Albendazole Oral Suspension IP 200 mg per 5ml	Each 5ml contains: Albendazole IP 200mg Suitable base qs.	10ml Bottle	10ml Bottle X 10	1000000
28	186	Domperidone Tablets IP 10 mg	Each film coated tablet contains: Domperidone Maleate IP	10's	10's X 10	1300000

			eq. to Domperidone 10mg			
29	187	Domperidone Suspension IP 5mg per 5ml	Each ml contains: Domperidone IP 5mg in suitable base qs.	30 ml	1's x 10	200000
30	191	Famotidine Tablets IP 20 mg	Each film coated tablet contains: Famotidine IP 20mg	14's	14's X 10	1800000
31	192	Famotidine Tablets IP 40 mg	Each film coated tablet contains: Famotidine IP: 40 mg	14's	14's X 10	3600000
32	196	Lactic Acid Bacillus Tablets 60 Million spores	Each uncoated tablet contains: Lactic Acid Bacillus not less than 60M spores	10's	10's X 10	3100000
33	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	10's X 10	700000
34	202	Metronidazole Tablets IP 400mg	Each film-coated tablet contains: Metronidazole Tablets IP 400mg Excipients q.s.	10's	10's X 10	5100000
35	208	Ondansetron Injection IP 2mg per ml	Each ml contains: Ondansetron Hydrochloride IP eq. to Ondansetron 2 mg	2ml Ampoule	1's x 10	2000000
36	209	Ondansetron Tablets IP 4 mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	10's X 10	2500000
37	212	Pantoprazole Gastro Resistant Tablets IP 40 mg	Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg	10's	10's X 10	100000000
38	216	Ranitidine Injection IP 25 mg per ml	Each ml contains: Ranitidine Hydrochloride IP eq. to Ranitidine 25mg (1.12g of Ranitidine Hydrochloride is eq. to approximately 1g of Ranitidine)	2ml Ampoule	1's x 10	500000
39	223	Pyridoxine Hydrochloride 10mg, Doxylamine 10mg and Folic Acid 2.5mg Tablets	Each enteric coated tablet contains: Pyridoxine Hydrochloride IP 10mg Doxylamine Succinate 10mg Folic Acid IP 2.5mg	30's	30's x 10	350000
40	227	Polyvitamin Tablets NFI (Prophylactic)	Each film-coated tablet contains: Vitamin A 2500 IU Vitamin D3 200IU Vitamin B1 2mg Vitamin B6 0.5mg Vitamin B2 2mg Niacinamide 25mg Calcium Pantothenate 1mg Vitamin C 50mg Folic Acid 0.2mg	10's	10's X 10	800000
41	239	Cetirizine Syrup IP 5 mg per 5 ml	Each 5ml contains: Cetrizine Hydrochloride IP 5mg	60 ml	60ml X 10	800000
42	240	Cetrizine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Cetrizine Hydrochloride IP 10mg	10's	10's X 10	11500000
43	245	Etophylline 77mg and Theophylline 23mg Tablets	Each uncoated tablet contains: Etophylline 77 mg Theophylline (Hydrated) 23 mg	10's	10's X 10	2100000
44	261	Adenosine Injection IP	Each ml contains:	2ml	2ml X 10	150000

		6 mg per 2ml	Adenosine IP 3 mg water for injection IP q.s.	Ampoule		
45	267	Atorvastatin Tablets IP 20mg	Each Film Coated tablets Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 20mg	10's	10's X 10	19000000
46	280	Heparin Sodium Injection IP 1000 IU per ml	Each ml contains: Heparin Sodium IP 1000 IU	5 ml	5 ml Vial X10	100000
47	287	Losartan Potassium 50mg and Hydrochlorothiazide 12.5mg Tabelts IP	Each Film Coated tablet contains: Losartan Potassium IP 50mg Hydrochlorothiazide IP 12.5 mg	10's	10's X 10	6100000
48	300	Telmisartan Tablets IP 40mg	Each uncoated tablet contains: Telmisartan IP 40 mg	10's	10 X 10's	70000000
49	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Ampoules	1's X 10	150000
50	311	Disodium Hydrogen Citrate Syrup (Alkalyser) 1.4 gm per 5 ml	Each 5ml contains: Disodium Hydrogen Citrate 1.4gm	100 ml	100 ml X 6	2000000
51	314	Alprazolam Tablets IP 0.5 mg	Each uncoated tablet contains: Alprazolam IP 0.50mg	10's	10's X 10	5700000
52	317	Carbamazepine Tablets IP 100 mg	Each Uncoated Tablet contains: Carbamazepine IP 100mg	10's	10's X 10	1050000
53	319	Clonazepam Tablets IP 0.5 mg	Each uncoated tablet contains: Clonazepam IP 0.5mg	10's	10's X 10	5000000
54	324	Flunarizine Tablets IP 5 mg	Each uncoated tablet contains: Flunarizine Dihydrochloride equivalent to Flunarizine IP 5mg	10's	10's X 10	500000
55	327	Phenytoin Tablets IP 100 mg	Each film coated tablet contains: Phenytoin Sodium IP 100 mg	100's in Bottle	1's X 10	600000
56	328	Prochlorperazine Tablets IP 5 mg	Each Uncoated tablet contains: Prochlorperazine Maleate IP 5mg	10's	10's X 10	800000
57	336	Allopurinol Tablets IP 100 mg	Each uncoated tablet contains: Allopurinol IP 100 mg	10's	10's X 10	1900000
58	344	Ciprofloxacin Eye Drops IP 0.3% w/v	Composition: Ciprofloxacin Hydrochloride IP eq. To Ciprofloxacin 0.3 % w/v Benzalkonium Chloride Solution IP 0.025% W/V Purified water IP q.s.	5ml	1's X 10	1400000
59	345	Gentamicin Eye Drops IP 0.3% w/v	Composition: Gentamicin Sulphate IP equivalent to Gentamicin 0.3 % w/v Benzalkonium Chloride Solution IP 0.02% w/v (As preservative)	10ml Drops	1's X 10	350000
60	351	Xylometazoline Nasal Drops IP 0.1%w/v	Composition: Xylometazoline Hydrochloride IP 0.1% w/v Benzalkonium Chloride Sodium IP 0.01-0.02%w/v (As preservative)	10ml Drops	1's x 10	5300000
61	352	Bupivacaine Hydrochloride Injection IP 5 mg per ml	Each ml contains: Bupivacaine Hydrochloride IP eq. to Anhydrous Bupivacaine 5 mg	20 ml	1's X 10	200000

62	367	Voglibose Tablets IP 0.3 mg	Each uncoated tablet contains: Voglibose IP 0.3mg	10's	10's X 10	9500000
63	371	Voglibose Tablets IP 0.2 mg	Each uncoated tablet contains: Voglibose IP 0.2mg	10's	10's X 10	5300000
64	372	Metformin Hydrochloride Prolonged release Tablets IP 500 mg	Each film coated Prolonged Release tablet contains: Metformin Hydrochloride IP 500mg	10's	10's X 10	21500000
65	375	Quinine Sulphate Tablets IP 300 mg	Each film coated tablet contains: Quinine Sulphate IP 300mg	10's	10's X 10	150000
66	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg Excipients q.s.	30's	30's x 10	200000
67	393	Aciclovir Dispersible Tablets IP 800 mg	Each dispersible uncoated tablet contains: Aciclovir IP 800mg	5's	5's X 10	350000
68	396	Liposomal Amphotericin B Injection 50 mg per Vial	Each Vial contains: Liposomal Amphotericin B 50 mg	20 ml	1's X 10	150000
69	407	Ivermectin Tablets IP 12 mg	Each uncoated dispersible tablet contains: Ivermectin IP 12mg	10's	10's X 10	300000
70	416	Prazosin Tablets IP 5 mg	Each film coated tablet contains: Prazosin Hydrochloride IP eq. to Prazosin 5mg	15's	15's X 10	1300000
71	421	Nebivolol Tablets IP 5 mg	Each film coated tablet contains: Nebivolol Hydrochloride IP eq. to Nebivolol 5mg	10's	10's X 10	5000000
72	428	Digoxin Tablets IP 0.25 mg	Each uncoated tablet contains: Digoxin IP 0.25 mg	10's	10's X 10	1100000
73	437	Nifedipine sustained release Tablets IP 20mg	Each sustained release film coated tablet contains: Nifedipine IP 20mg	10's	10's X 10	4800000
74	439	Olmesartan Medoxomil 40mg and Hydrochlorothiazide 12.5mg Tablets IP	Each film-coated tablet contains: Olmesartan Medoxomil IP 40mg Hydrochlorothiazide IP 12.5mg	10's	10's X 10	1400000
75	444	Enalapril 10mg and Hydrochlorothiazide 25mg Tablets IP	Each uncoated tablet contains: Enalapril Maleate IP 10 mg Hydrochlorothiazide IP 25 mg	30's	30's x 10	200000
76	455	Verapamil Tablets IP 80 mg	Each Film-Coated Tablet contains: Verapamil Hydrochloride IP 80 mg	10's	10's X 10	1000000
77	456	Atorvastatin Tablets IP 40 mg	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg	10's	10's X 10	15000000
78	473	Pantoprazole 40mg (Enteric Coated) and Levosulpiride 75mg (Sustained Release) Capsules	Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg (As enteric coated pellets) Levosulpride 75mg (As Sustained release pellets)	10's	10's X 10	3400000
79	475	Sucralfate Suspension 500mg per 5ml	Each 5ml contains: Sucralfate IP 500mg	200 ml	1's x 10	900000
80	478	Sodium Picosulphate	Each uncoated tablet contains:	10's	10's X 10	1100000

		Tablets 10 mg	Sodium Picosulphate 10mg			
81	480	Esomeprazole 40mg (Enteric-coated) and Levosulpiride 75mg (Sustained release) Capsules	Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Levosulpiride (as sustained release) 75mg	10's	10's X 10	2800000
82	483	Loperamide Capsules IP 2 mg	Each hard gelatin capsule contains: Loperamide Hydrochloride IP 2mg	10's	10's X 10	1300000
83	486	Pancreatin 170mg and Activated Dimethicone 80mg Tablets	Each enteric-coated tablet contains: Pancreatin 170mg Activated Dimethicone 80mg	10's	10's X 10	250000
84	488	Lansoprazole Capsules IP 15 mg	Each hard gelatin capsule contains: Lansoprazole IP 15 mg (as enteric coated granules)	10's	10's X 10	300000
85	491	Itopride Tablets IP 50 mg	Each Film Coated tablets Contains: Itopride Hydrochloride IP 50 mg	10's	10's X 10	500000
86	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	10's X 10	2700000
87	505	Carbimazole Tablets IP 10 mg	Each uncoated tablet contains: Carbimazole IP 10 mg	100's in Bottle	1's X 10	350000
88	506	Levo-Thyroxine Tablets IP 50 mcg	Each uncoated tablet contains: Levo-thyroxine Sodium IP eq. to Anhydrous Levo-Thyroxine 50mcg	100's in Bottle	100's in bottle X 10	250000
89	507	Carbimazole Tablets IP 5 mg	Each uncoated tablet contains: Carbimazole IP 5 mg	10's	10's X 10	1200000
90	509	Hydroxychloroquine Tablets IP 200 mg	Each film coated tablets Contains: Hydroxychloroquine sulphate IP 200 mg	10's	10's X 10	4400000
91	512	Aceclofenac 100mg, Paracetamol 325mg and Serratiopeptidase 15mg Tablets	Each film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coted form)	10's	10's X 10	15000000
92	528	Paracetamol 325mg, Phenylephrine 10mg and Chlorpheniramine 2mg Tablets	Each uncoated tablet contains: Paracetamol 325 mg Phenylephrine Hydrochloride 10 mg Chlorpheniramine maleate 2 mg	10's	10's X 10	2600000
93	529	Levosalbutamol 1.25mg and Ipratropium 500mcg Respules	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25mcg	2.5ml	2.5ml X 5	9100000
94	530	Formoterol 6mcg and	Each capsule contains:	30's	30's x 10	1500000

		Budesonide 200mcg Rotacaps	Formoterol Fumarate (as Formoterol Fumarate dihydrate IP) 6mcg Budesonide IP 200mcg			
95	532	Salmeterol 50mcg and Fluticasone 250mcg Rotacaps	Each capsule contains: Salmeterol (as Salmeterol Xinofoate) 50mcg Fluticasone Propionate IP 250mcg	30's	30's x 10	700000
96	540	Levosalbutamol 1.25mg and Budesonide 1mg Respules	Each 2ml respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2ml	2ml X 10	400000
97	543	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	10's	10's X 10	300000
98	558	Fluticasone 50mcg and Azelastine 140mcg Nasal Spray	Each Spray delivers: Fluticasone Propionate 50 mcg Azelastine Hydrochloride 140 mcg	70 MDI	1's X 10	300000
99	563	Oxymetazoline Hydrochloride Nasal Drops IP 0.5 mg per ml	Each ml contains: Oxymetazoline Hydrochloride IP 0.5mg in a buffered aqueous solution	10ml	1's X 10	3500000
100	569	Sildenafil Tablets IP 50 mg	Each film coated tablet contains: Sildenafil Citrate IP eq. to Sildenafil 50mg	4's	4's X 10	1300000
101	571	Tamsulosin Hydrochloride (Modified Release) 0.4mg and Dutasteride 0.5mg Tablets	Each film-coated tablet contains: Tamsulosin Hydrochloride 0.4 mg (as modified release tablets) Dutasteride 0.5 mg	15's	15's X 10	16000000
102	583	Cyproheptadine Tablets IP 4 mg	Each uncoated tablet contains: Cyproheptadine Hydrochloride IP 4mg	10's	10's X 10	600000
103	589	Calcium 500mg and Calcitriol 0.25mcg Tablets	Each film coated tablet contains: Calcium Carbonate IP eq. to Calcium 500mg Calcitriol IP 0.25mcg	15's	15's X 10	1300000
104	591	Methylcobalamin Injection 500 mcg	Each ml contains: Methylcobalamin IP 500mcg	1ml Ampoules	1's X 10	900000
105	601	Disulfiram Tablets IP 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	4's x 10	350000
106	608	Betamethasone Dipropionate and Salicylic Acid Ointment	Contains: Betamethasone Dipropionate 0.05% w/w Salicylic acid 3% w/w	20 gm	1's X 20	800000
107	612	Povidone-Iodine Powder 5% W/W	Composition: Povidone-Iodine Powder 5% w/w	10 gm Container	1's X 20	600000
108	627	Etophylline 115mg and Theophylline 35mg Prolonged Release Tablets IP	Each film-coated prolonged release tablet contains: Etophylline 115mg Theophylline IP Anhydrous equivalent to Theophylline IP	10's	10's X 10	4500000

			Hydrate 35mg			
109	632	Etamsylate Tablets 250 mg	Each uncoated tablet contains: Etamsylate 250 mg	10's	10's X 10	350000
110	650	Mefenamic Acid 500mg and Paracetamol 325mg Tablets	Each uncoated tablet contains: Mefenamic Acid 500mg Paracetamol 325mg	10's	10's X 10	500000
111	661	Gama Benzene Hexachloride 1%w/v and Cetrimide 0.1%w/v lotion	Composition: Gama Benzene Hexachloride 1%w/v Cetrimide IP 0.1% w/v in a suitable base qs.	100 ml	100 ml X 6	350000
112	669	Cefuroxime Axetil Oral Suspension 125mg per 5ml	Each 5ml reconstituted suspension contains: Cefuroxime Axetil 125mg In a suitable base qs.	30 ml	1's x 10	200000
113	680	Finasteride Tablets IP 5mg	Each film coated tablet contains: Finasteride IP 5mg	10's	10's X 10	350000
114	690	Timolol Maleate Eye Drops IP 0.5 %	Composition: Timolol Maleate IP eq. to Timolol 0.5% w/v Benzalkonium Chloride IP 0.01% w/v (as preservative)	5ml	1's X 10	600000
115	691	Ofloxacin Eye Drops IP 0.3% w/v	Contains: Ofloxacin IP 0.3% w/v	10 ml	1's X 10	350000
116	705	Levofloxacin Infusion IP 500 mg per100 ml	Each ml contains: Levofloxacin 5 mg	100ml	100ml X 10	200000
117	708	Piroxicam Dispersible Tablets 20 mg	Each uncoated dispersible tablet contains: Piroxicam 20mg	10's	10's X 10	500000
118	718	Escitalopram Oxelate 10mg and Clonazepam 0.5mg Tablets IP	Each uncoated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 10mg Clonazepam 0.5mg	10's	10's X 10	4000000
119	728	Dextrose 5%w/v and Sodium Chloride 0.9%w/v Injection IP	Each 100ml contains: Dextrose Anhydrous IP 5.00g Sodium Chloride IP 0.90 g Water for inj. q.s.	500 ml	500 ml x 10	500000
120	733	Progesterone Sustained Release Tablets 200 mg	Each film-coated sustained release tablet contains: Progesterone 200mg (Natural Micronized)	10's	10's X 10	350000
121	739	Cefuroxime Axetil Tablets IP 125mg	Each film coated tablet contains: Cefuroxime Axetil IP equivalent to Cefuroxime 125mg	6's	6's x 10	200000
122	740	Clarithromycin Tablets IP 250 mg	Each film-coated tablet contains: Clarithromycin IP 250mg	10's	10's X 10	300000
123	747	Glimepiride Tablets IP 3mg	Each uncoated tablet contains: Glimepiride IP 3 mg	10's	10's X 10	1800000
124	762	Nortriptyline Tablets IP 25mg	Each film coated tablet contains: Nortriptyline Hydrochloride IP equivalent to Nortriptylin 25mg	10's	10's X 10	500000
125	788	Anastrozole Tablets IP 1mg	Each film coated tablet contains: Anastrazole IP 1mg	10's	10's X 10	250000
126	791	Atenolol 25mg and Amlodipine 5mg	Each uncoated tablet contains: Amlodipine Besilate IP equivalent	14's	14's X 10	1000000

		Tablets IP	to Amlodipine 5mg Atenolol IP 25mg			
127	796	Aspirin 75mg (Enteric coated) and Atorvastatin 10mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)	10's	10's X 10	31500000
128	806	Bicalutamide Tablets IP 50mg	Each film-coated tablet contains: Bicalutamide IP 50mg	10's	10's X 10	350000
129	809	Bortezomib Injection IP 3.5 mg	Each vial contains: Bortezomib IP 3.5mg	Vial	1's x 10	150000
130	814	Cabergoline Tablets IP 0.5mg	Each uncoated tablet contains: Cabergoline IP 0.5mg	4's	4's x 10	150000
131	817	Calcium Carbonate 1250mg, Vitamin D3 250IU, Magnesium Oxide 40mg, Manganese Sulphate 1.8mg and Zinc 7.5mg Tablets	Each Film Coated tablet contains: 1250 mg Calcium Carbonate from and organic source (Oyster Shell) Eq. to elemental calcium 500mg Vitamin D3 IP (Stabilised) 250 IU Magenesium Hydroxide IP Eq. to elemental Magnesium 40mg Magnesium sulphate USP Eq. to elemental Manganese 1.8 mg Zinc sulphate monohydrateUSP Eq. to elemental zinc 7.5mg Sodium Borate BP Eq. to elemental Boron 250mg Copper sulphate pentahydrate BP Eq. to Elemental cooper 1mg	10's	10's X 10	12000000
132	832	Chlorthalidone Tablets IP 12.5mg	Each uncoated tablet contains: Chlorthalidone IP 12.5mg	10's	10's X 10	2500000
133	835	Glucosamine Sulphate 500mg and Chondroitin 400mg Tablets	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	10's X 10	700000
134	844	Clonazepam Tablets IP 1mg	Each uncoated tablet contains: Clonazepam IP 1mg	10's	10's X 10	1300000
135	850	Cyclosporin capsules IP 50mg	Each soft gelatin capsule contains: Cyclosporine IP 50 mg	5's	5's X 10	200000
136	878	Drotaverine Hydrochloride 80mg and Mefenamic Acid 250mg Tablets	Each film coated tablet contains: Drotaverine Hydrochloride IP 80mg Mefenamic Acid IP 250mg	10's	10's X 10	1200000
137	881	Ebastine Tablets IP 10mg	Each film coated tablet contains: Ebastine IP 10mg	10's	10's X 10	350000
138	882	Efavirenz Tablets IP 600mg	Each film coated tablet contains: Efavirenz IP 600mg	30's	30's x 10	150000
139	885	Ethinylestradiol 0.05mg and Levonorgestrel 0.25mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	21's x 10	200000
140	897	Formoterol 6mcg and Fluticasone Propionate 250mcg Inhaler	Each actuation delivers: Fluticasone Propionate 250 mcg Formoterol Fumarate Dihydrate	120 MDI	1's X 10	300000

			6mcg Suspended in propellant HFA 134a			
141	899	Frusemide 20mg and Spironolactone 50mg Tablets	Each film coated tablet contains: Frusemide IP 20mg Spironolactone IP 50mg	10's	10's X 10	3100000
142	900	Gabapentin 100mg and Methylcobalamin 500mcg Tablets	Each film coated tablet contains: Gabapentin IP 100mg Methylcobalamin IP 500mcg	10's	10's X 10	2200000
143	912	Hydrochlorothiazide Tablets IP 12.5mg	Each uncoated tablet contains: Hydroclorthiazide 12.5mg	10's	10's X 10	2400000
144	916	Imatinib Mesylate Tablets IP 400mg	Each film coated tablet contains: Imatinib mesylate equivalent to imatinib IP 400mg	10's	10's X 10	350000
145	924	Isoxsuprine Hydrochloride Tablets IP 10mg	Each uncoated tablet contains : Isoxsuprine Hydrochloride IP 10mg	50's	50's X 10	150000
146	934	Lenalidomide Capsules 10mg	Each capsule contains: Lenalidomide 10mg	10's in Bottle	1's X 10	150000
147	965	Miconazole 2%w/w and Fluocinolone Acetonide 0.01%w/w Ointment	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15g tubes	1's x 20	350000
148	975	Nebivolol 5mg and Hydrochlorothiazide 12.5mg IP Tablets	Each uncoated tablet contains : Nebivolol Hydrochloride IP equivalent to Nebivolol 5mg Hydrochlorothiazide IP 12.5mg	10's	10's X 10	400000
149	986	Nitrazepam Tablets I.P 10mg	Each uncoated tablet contains: Nitrazepam IP 10 mg	10's	10's X 10	500000
150	994	Oxaliplatin Injection IP 50mg	Each vial contains: Oxaliplatin IP 50mg	Vial with Wfi	1's X 10	150000
151	996	Oxcarbazepine Tablets IP 300mg	Each film coated tablet contains: Oxcarbazepine IP 300mg	10's	10's X 10	2700000
152	1008	Phytomenadione Injection (Vitamin K1) IP 1mg per 0.5ml	Each 0.5ml contains: Phytomenadione 1 mg WFI q.s.	0.5 ml Ampoule	0.5ml Ampoule X 10	300000
153	1026	Propranolol Tablets IP 10mg	Each uncoated tablet contains: Propranolol Hydrochloride IP 10mg	10's	10's X 10	2500000
154	1032	Quetiapine Tablets IP 100mg	Each film coated tablet contains: Quetiapine Fumarate IP equivalent to Quetiapine 100mg	10's	10's X 10	900000
155	1072	Tamsulosin Hydrochloride Prolonged Release Capsules IP 0.4mg	Each hard gelatin capsule contains: Tamsulosin Hydrochloride IP 400mcg (As prolonged release pellets)	10's	10's X 10	16000000
156	1081	Tizanidine Tablets I.P 2mg	Each uncoated tablet contains: Tizanidine Hydrochloride IP equivalent to Tizanidine 2 mg	10's	10's X 10	250000
157	1097	Vitamin A Capsule IP 25000 IU	Each soft gelatin capsule contains: Vitamin A (as concentrate oil) IP 25000 IU	30's	30's x 10	800000
158	1099	Metformin Hydrochloride 500mg and Voglibose 0.3mg	Each uncoated tablet contains: Voglibose 0.3 mg Metformin Hydrochloride 500	10's	10's X 10	3200000

		Tablets	mg			
159	1104	Zoledronic Acid Injection IP 4mg per ml	Each ml contains Zoledronic Acid IP equivalent to Zoledronic Acid (Anhydrous) 4mg Water for Injection IP q.s	5ml Vial with WFI	1's X 10	150000
160	1123	Clomipramine Hydrochloride Sustained release Tablets 75mg	Each film coated sustained release tablet contains: Clomipramine Hydrochloride 75 mg	10's	10's X 10	200000
161	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	10's X 10	800000
162	1149	Lisinopril Tablets IP 10mg	Each uncoated tablet contains: Lisinopril IP equivalent to anhydrous Lisinopril 10 mg	15's	15's X 10	300000
163	1166	Mefenamic Acid Tablets 250 mg	Each uncoated tablet contains: Mefenamic Acid 250 mg	10's	10's X 10	200000
164	1167	Mefenamic Acid Tablets 500 mg	Each uncoated tablet contains: Mefenamic Acid 500 mg	10's	10's X 10	300000
165	1211	Docetaxel Injection IP 80 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with Wfi	1's X 10	150000
166	1212	Docetaxel Injection IP 120 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with Wfi	1's X10	150000
167	1213	Erlotinib Tablets IP 150 mg	Each film coated tablet contains: Erlotinib Hydrochloride IP eq. to Erlotinib 150mg	10's Bottle	1's X 10	150000
168	1215	Pemetrexed Injection IP 100 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 100 mg Water for Injection IP q.s	Vial	1's X 10	150000
169	1216	Pemetrexed Injection IP 500 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 500 mg Water for Injection IP q.s	Vial	1's X 10	150000
170	1217	Temozolomide Capsules IP 100 mg	Each hard gelatin capsule contains Temozolomide IP 100mg	5's in Bottle	1's X 10	150000
171	1218	Temozolomide Capsules IP 250 mg	Each hard gelatin capsule contains Temozolomide IP 250mg	5's in Bottle	1's X 10	150000
172	1220	Oseltamivir Capsules IP 75mg	Each hard gelatin capsule contains: Oseltamivir Phosphate IP 98.5 mg equivalent to Oseltamivir 75mg	10's	10's X 10	200000
173	1223	Iron 50mg, Folic Acid 0.5mg and Zinc 61.8mg Capsules	Each hard gelatin capsule contains: Elemental Iron 50mg Folic Acid IP 0.5mg Zinc Sulphate Monohydrate IP 61.8mg	15's	15's X 10	1500000

174	1225	Orlistat Capsules 120 mg	Each hard gelatin capsule contains: Orlistat 120 mg (as pellets)	10's	10's X 10	300000
175	1246	Fluconazole Tablets IP 150 mg	Each uncoated tablet contains: Fluconazole IP 150mg	1's	1's X 10	11000000
176	1281	Chlordiazepoxide Tablets IP 10 mg	Each Film Coated Tablet contains Chlordiazepoxide IP 10 mg	10's	10's X 10	1000000
177	1307	Ethinylestradiol 0.03mg and Desogestrel 0.15mg Tablets IP	Each uncoated tablet contains Ethinylestradiol IP 0.03 mg Desogestrel IP 0.15 mg	21's	21's X 10	200000
178	1308	Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.03 mg Levonorgestrel IP 0.15 mg	21's	21's X 10	200000
179	1367	Olmesartan 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg Tablets	Each film coated tablet contains: Olmesartan Medoximil 20 mg Amlodipine Besilate equivalent to Amlodipine 5 mg Hydrochlorthiazide 12.5 mg	10's	10's X 10	1100000
180	1368	Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg Tablets	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorthiazide IP 12.5 mg	10's	10's X 10	1200000
181	1375	Phenobarbitone Tablets IP 60 mg	Each uncoated tablet contains: Phenobarbitone IP 60 mg	30's	30's X 10	400000
182	1382	Prasugrel Tablets IP 10 mg	Each film coated tablet contains: Prasugrel Hydrochloride equivalent to Prasugrel IP 10 mg	10's	10's X 10	700000
183	1393	Rosuvastatin 10mg and Clopidogrel 75mg Capsules	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg Clopidogrel IP 75mg	10's	10's X 10	5200000
184	1427	Trypsin 48mg, Bromelain 90mg and Rutoside Trihydrate 100mg Tablets	Each enteric coated tablet contains: Trypsin 48 mg Bromelain 90 mg Rutoside Trihydrate 100 mg	10's	10's X 10	1600000
185	1432	Tobramycin Eye Drops 0.3%w/v	Contains: Tobramycin Sulphate e.q to Tobramycin Anhydrous 0.3%w/v Benzalkonium Chloride Solution 0.02% v/v (as preservative)	5 ml	1's X 10	300000
186	1435	Capecitabine Tablets IP 500mg	Each film cotated tablet cotains: Capecitabine IP 500mg	10's	10's X 10	200000
187	1437	Cefpodoxime Proxetil Oral Suspension IP 50mg	Each 5 ml of the Reconstituted suspension contains: Cefpodoxime Proxetil IP equivalent to equivalent to Cefpodoxime 50mg	30 ml	1's X 10	300000
188	1438	Metformin Hydrochloride 500mg (Sustained Release),	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP	10's	10's X 10	15000000

		Glimepiride 2mg and Voglibose 0.2mg Tablets	500mg (Sustained-release form) Glimepiride IP 2mg Voglibose IP 0.2mg			
189	1441	Nirmal (Nicotine Polacrilex Chewing Gum 2 mg)	Each Gum Contains: Nicotine Polacrilex USP equivalent to Nicotine 2 mg	1 x 9's (mono carton pack)	1's mono carton X 10	3500000
190	1445	Jan Pudina Soft Gel Capsules	Each soft gel capsule contains: Pudina ka Satva (Mentha Sylvestria) 180mg Ajwain Oil (Trachyspermum Ammi) 20mg Anethi Oil (Anthum Graveolens) 5mg Tulsi Oil (Ocimum Sanctum) 5mg Clove Oil (Syzygium Aromaticum) 1mg excipients …. qs	10's	10's X 10	1800000
191	1452	Pyridoxine Hydrochloride Sustained release tablets 100mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	10's X 10	200000
192	1455	L-Arginine Granules 3g	Each sachet contains: L-Arginine IP 3gm	5 gm	1's Sachet X 10	1500000
193	1473	Hand Sanitizer (Ethanol 70% v/v and Chlorhexidine Gluconate 0.5% w/v)	Composition: Chlorhexidine Gluconate Solution IP 0.5%v/v Ethanol IP 70% v/v	100 ml Bottle	100ml Bottle X 10	200000
194	1475	Hand Sanitizer 250 ml (Each pack contains: Ethanol 70% v/v and Chlorhexidine Gluconate 0.5% w/v)	Each pack contains: Ethanol 70% v/v Chlorhexidine Gluconate 0.5% w/v	250 ml	1's X 20	150000
195	1476	Hydroxychloroquine Tablet IP 400 mg	Each film coated tablet contains: Hydroxychloroquine Sulphate IP 400mg	10's	10's X 10	300000
196	1497	Acitretin Capsules IP 25 mg	Each hard gelatin capsule contains: Acitretin IP 25mg	10's	10's X 10	150000
197	1499	Adalimumab Injection 40mg per 0.8 ml (For subcutaneous use only)	Each sterile single-use prefilled pen contains: Adalimumab 40 mg WFI	0.8 ml in 1 prefilled syringe	0.8ml prefilled syringe X 10	150000
198	1502	Amiodarone Tablets IP 100 mg	Each uncoated tablet contains: Amiodarone IP 100 mg	10's	10's X 10	700000
199	1506	Amoxycillin 80mg and Potassium Clavulanate 11.4mg Oral Suspension IP	Each ml contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 80mg Potassium clavulanate diluted IP equivalent to Clavulanic Acid 11.4mg	10 ml	1's X 10	200000
200	1511	Antioxidant Capsules	Each soft gelatin capsule contains: Beta Carotene 30 mg Zinc Sulphate Monohydrate 27.5 mg	30's	30's X 10	600000

			Selenium Dioxide 200 mcg (as Selenious Acid) Manganese 2 mg (as Manganese Sulphate Monohydrate) Copper 1 mg (as Copper Sulphate Pentahydrate)			
201	1515	Atorvastatin 10mg and Aspirin 150mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 150mg (as gastro-resistant)	15's	15's X 10	1000000
202	1523	Beclomethasone 0.025%w/v and Clotrimazole 1%w/v Lotion	Composition: Beclomethasone 0.025%w/v Clotrimazole 1% w/v	30 ml	1's X 10	400000
203	1525	Betahistine Tablets IP 16 mg	Each uncoated tablet contains: Betahistine IP 16mg	15's	15's X 10	2800000
204	1526	Betahistine Tablets IP 24 mg	Each uncoated tablet contains: Betahistine IP 24mg	15's	15's X 10	900000
205	1531	Bisoprolol Fumarate Tablets 2.5 mg	Each film coated tablet contains: Bisoprolol Fumarate 2.5 mg	10's	10's X 10	6300000
206	1538	Calcium Citrate Malate 250mg, Calcitriol 0.25mcg and Vitamin K2-7 50mcg Tablets	Each film coated tablet contains: Calcium citrate Malate equivalent to Elemental Calcium 250 mg Calcitriol 0.25 mcg Vitamin K2-7 50 mcg	10's	10's X 10	1200000
207	1553	Cefpodoxime Oral Suspension IP 100mg	Each 5 ml of reconstituted suspension contains: Cefpodoxime Proxetil IP equivalent to Cefpodoxime 100 mg	30 ml	1's X 10	200000
208	1574	Clobazam Tablets IP 10 mg	Each uncoated tablet contains: Clobazam IP 10 mg	15's	15's X 10	1900000
209	1575	Clobetasol Propionate 0.05%w/w and Gentamicin 0.1%w/w Cream	Contains: Clobetasol Propionate 0.05% w/w Gentamicin 0.1% w/w	25 g	1's X 10	700000
210	1578	Clobetasol Propionate 0.05%w/w and Salicylic Acid 3%w/w Ointment	Contains: Clobetasol Propionate 0.05% w/w Salicylic Acid 3% w/w	20g	1's X 20	1100000
211	1583	Clotrimazole Mouth Paint 1% w/v	Contains: Clotrimazole 1% In Glycerine and Propylene Glycol base q.s	25 ml	25ml X 10	400000
212	1584	Coenzyme Q10 (Ubidecarenone) and L-Carnitine Tablets	Each film coated tablet contains: Ubidocarenone 30 mg L-Carnitine L-Tartrate equivalent to L-carnitine 500 mg	10's	10's X 10	250000

213	1586	Colistin (Colistimethate Sodium) Injection IP 4.5 Million IU	Each vial contains: Colistimethate Sodium IP 45,00,000 IU as sterile powder for reconstitution	Vial (10 ml)	1's X 10	200000
214	1602	Divalproex Tablets IP 500 mg	Each enteric coated tablet contains: Divalproex Sodium equivalent to Valproic Acid 500mg	10's	10's X 10	1100000
215	1607	Drotaverine Hydrochloride Tablets IP 80 mg	Each film coated tablet contains: Drotaverine Hydrochloride IP 80 mg	15's	15's X 10	350000
216	1611	Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg Tablets IP	Each film coated tablet contains: Emtricitabine IP 200mg Tenofovir Disoproxil Fumarate IP 300mg	30's	30's X 10	150000
217	1613	Eplerenone Tablets IP 25 mg	Each film coated tablet contains: Eplerenone IP 25 mg	10's	10's X 10	1700000
218	1627	Formoterol Fumarate 6mcg and Budesonide 400mcg Inhaler	Each actuation delivers: Formoterol Fumarate 6 mcg (as Formoterol Fumarate Dihydrate) Budesonide 400 mcg	120 MD	1's X 10	600000
219	1628	Formoterol Fumarate 12mcg and Budesonide 400mcg Powder for Inhalation IP	Each Capsule Contains: Formoterol Fumarate 12 mcg (as Formoterol Fumarate Dihydrate) Budesonide 400 mcg	30's	30's X 10	600000
220	1645	Gliclazide 60mg (Modified Release) and Metformin 500mg (Extended Release) Tablets	Each uncoated bilayered tablet contains: Gliclazide 60mg (in modified release form) Metformin Hydrochloride 500mg (in extended release form)	10's	10's X 10	3100000
221	1662	Hydroxyzine Tablets IP 25mg	Each Film-coated tablet contains: Hydroxyzine IP 25mg	15's	15's X 10	1100000
222	1664	Ibuprofen 100mg and Paracetamol/Acetaminophen 162.5mg Oral Suspension	Each 5 ml contains: Ibuprofen 100mg Paracetamol/Acetaminophen 162.5mg	100 ml	100ml X 10	600000
223	1668	Carbonyl Iron 100mg, Folic Acid 1.5mg and Vitamin B12 15mcg with Zinc Capsules	Each hard gelatin capsule contains: Carbonyl Iron 100 mg Folic Acid 1.5 mg Cynocobalamine (Vitamin B12) 15 mcg Zinc Sulphate Monohydrate 61.8 mg (eq. to 22.5mg of elemental Zinc)	10's	10's X 10	2600000
224	1671	Ivabradine Tablets 5mg	Each film-coated tablet contains: Ivabradine 5mg	15's	15's X 10	1800000
225	1679	Lecithin Capsules 1000mg	Each soft gelatin capsule contains: Lecithin 1000 mg	10's	10's X 10	200000
226	1683	Levocetirizine Dihydrochloride Tablets IP 10mg	Each film coated tablets contains: Levocetrizine Dihydrochloride IP 10mg	15's	15's X 10	1400000

227	1685	Levodropropizine 30mg and Chlorpheniramine Maleate 2mg Syrup	Each 5 ml contains: Levodropropizine 30mg Chlorpheniramine Maleate 2mg	120 ml	1's X 6	1200000
228	1709	Minoxidil Solution 5%	Composition: Minoxidil IP 5% w/v	60 ml	60ml X 10	400000
229	1720	Nicoumalone/Acenocoumarol Tablets IP 1 mg	Each uncoated tablet contains: Nicoumalone/Acenocoumarol IP 1mg	10's	10's X 10	350000
230	1721	Nicoumalone/Acenocoumarol Tablets IP 3 mg	Each Uncoated Tablet contains: Nicoumalone/Acenocoumar ol IP 3mg	10's	10's X 10	1000000
231	1733	Omeprazole 20mg and Domperidone 30mg (Sustained Release) Capsules	Each hard gelatin Capsule contains: Omeprazole 20 mg (as enteric coated pellets) Domperidone 30 mg (as sustained release pellets)	15's	15's X 10	3400000
232	1739	Pancreatin Capsules 10000	Each hard gelatin capsule contains: Pancreatin Minimicrospheres eq. to Pancreatin IP 150 mg Declared enzymes activity per capsule: Amylase 8000 units Lipase 10,000 units Protease 600 units	10's	10's X 10	1200000
233	1740	Pancreatin Capsules 25000	Each hard gelatin capsule contains: Pancreatin Minimicrospheres eq. to Pancreatin IP 300 mg Declared enzymes activity per capsule: Amylase 18,000 units Lipase 25,000 units Protease 1,000 units	10's	10's X 10	900000
234	1743	Paracetamol Drops 100 mg per ml	Each ml contains: Paracetamol IP 100 mg	15 ml	1's X 10	300000
235	1745	Paracetamol 125 mg, Phenylephrine 5 mg and Chlorpheniramine 1 mg Suspension	Each 5 ml of suspension contains: Paracetamol 125 mg Phenylephrine 5 mg Chlorpheniramine 1 mg	60 ml	60ml X 10	350000
236	1747	Paracetamol 162.5 mg and Tramadol 18.75 mg Tablet	Each Film-coated tablet contains: Paracetamol 162.5 mg Tramadol 18.75 mg	10's	10's X 10	350000
237	1753	Paracetamol 500 mg, Phenylephrine 10 mg and Chlorpheniramine 2 mg Tablet	Each Film-coated tablet contains: Paracetamol 500 mg Phenylephrine 10 mg Chlorpheniramine 2 mg	10's	10's X 10	1000000
238	1755	Paracetamol Suspension IP 120 mg	Each 5 ml contains: Paracetamol IP 120 mg	60 ml	60ml X 10	200000
239	1774	Racecadotril Capsule IP 100 mg	Each Hard Gelatin capsule contains: Racecadotril 100 mg	15's	15's X 10	250000
240	1783	Rosuvastatin IP 20mg and Fenofibrate IP	Each film coated tablets contains: Rosuvastatin Calcium equivalent	10's	10's X 10	1000000

		160mg Tablets	to Rosuvastatin IP 20mg Fenofibrate IP 160mg			
241	1797	Saroglitazar Tablet 4mg	Each Uncoated Tablet contain- Saroglitazar 4mg	10's	10's X 10	240000
242	1814	Telmisartan 40mg, Chlorthalidone 12.5mg and Amlodipine 5mg Tablets	Each film coated tablet contains: Telmisartan 40 mg Chlorthalidone 12.5 mg Amlodipine Besilate equivalent to Amlodipine 5 mg	10's	10's X 10	1000000
243	1824	Tolvaptan Tablets 15mg	Each uncoated tablet contains: Tolvaptan IP 15mg	10's	10's X 10	800000
244	1828	Torsemide Tablets IP 5mg	Each uncoated tablet contains: Torsemide IP 5mg	15's	15's X 10	2600000
245	1833	Ursodeoxycholic Acid Tablets IP 150mg	Each uncoated tablets contains: Ursodeoxycholic Acid IP 150mg	15's	15's X 10	2000000
246	1972	Amoxycillin 500mg, Clavulanic Acid 125mg and Lactic Acid Bacillus 60 Million Spores Tablets	Each film coated tablet contains Amoxycillin Trihydrate IP Equivalant to Amoxyxillin 500 mg Potassium Clavulanate Diluted IP Equivalant to Clavulanic acid 125 mg Lactic Acid Bacillus-60 million spores	10's	10's X 10	1200000
247	1978	Cefdinir Capsule IP 300mg	Each hard gelatin capsule contains: Cefdinir IP 300 mg	10's	10's X 10	150000
248	1982	Cefixime 100Mg and Potassium Clavulanate Acid 62.5 Mg Tablets	Each Film coated tablet contains Cefixime Trihydrate IP Equivalant to Anhydrous Cefixime 100 mg Potassium Clavulanate equivalent to Clavulanic Acid 62.5mg	10's	10's X 10	200000
249	2072	Atorvastatin 10mg, Aspirin 75mg and Clopidogrel 75mg Capsules	Each hard gelatin capsule contais: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (as film coated pellets) Aspirin 75mg (as gestro-resistant pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as film coated pellets)	10's	10's X 10	3500000
250	2076	Atorvastatin Tablets IP 5mg	Each Film Coated tablets Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 5mg	10's	10's X 10	3200000
251	2082	Calcium Dobesilate Monohydrate Capsules 500mg	Each hard gelatin capsule contains: Calcium Dobesilate Monohydrate eq. to Calcium Dobesilate Anhydrous 500mg	10's	10's X 10	400000
252	2088	Carvedilol Phosphate Extended Release Tablets 10mg	Each film coated extended release tablet contains: Carvedilol Phosphate 10mg	10's	10's X 10	400000
253	2089	Carvedilol Phosphate Extended Release Tablets 20mg	Each film coated extended release tablet contains: Carvedilol Phosphate 20mg	10's	10's X 10	350000
254	2090	Carvedilol Tablets IP	Each film coated tablet contains:	10's	10's X 10	900000

		12.5 mg	Carvedilol IP 12.5mg			
255	2091	Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets	Each film coated tablet contains: Cilnidipine 10mg Chlorthalidone 12.5mg	10's	10's X 10	250000
256	2092	Metoprolol Succinate (extended release) 25mg and Cilnidipine 10mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate eq. to Metoprolol Tartarate 25mg (As extended-release form) Cilnidipine 10mg	10's	10's X 10	400000
257	2093	Metoprolol Succinate (extended release) 50mg and Cilnidipine 10mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate eq. to Metoprolol Tartarate 50mg (As extended-release form) Cilnidipine 10mg	10's	10's X 10	700000
258	2104	Divalproex Sodium Extended Release Tablets IP 250 mg	Each film coated prolonged release tablet contains: Divalproex Sodium IP eq. to Valproic Acid 250mg	10's	10's X 10	700000
259	2105	Dosulepin (Dothiepin) Tablets IP 50mg	Each film coated tablet contains: Dosulepin Hydrochloride 50 mg (Formerly Dothiepin Hydrochloride)	10's	10's X 10	300000
260	2106	Doxofylline (Sustained-release) 400mg and Montelukast 10mg Tablets	Each uncoated bilayered tablet contains: Doxofylline IP (As sustained-release form) Montelukast Sodium IP eq to Montelukast 10mg	10's	10's X 10	400000
261	2107	Etizolam 0.5mg and Propranolol Hydrochloride 20mg Tablets	Each film coated tablet contains: Etizolam 0.5mg Propranolol Hydrochloride 20mg	10's	10's X 10	250000
262	2113	Lacosamide Tablets 100mg	Each film coated tablet cotains: Lacosamide 100mg	10's	10's X 10	1100000
263	2116	Methylprednisolone Tablets IP 16mg	Each uncoated tablet contains: Methylprednisolone IP 16mg	10's	10's X 10	600000
264	2119	Miconazole Nitrate Cream IP 2% w/w	Composition: Miconazole Nitrate IP 2% w/w Suitable cream base q.s	15g tubes	1's X 10	400000
265	2120	Mometasone Aqueous Nasal Spray IP 0.05%w/v (nasal suspension in a pressurise container)	Each actuation delivers: Mometasone Furoate 0.05% w/v suitable aqueous base qs.	120 MDI	1's X 10	300000
266	2122	Mycophenolate Sodium Gastro-resistant Tablets 360mg	Each enteric coated tablet cotains: Mycophenolate Sodium eq. to Mycophenolic Acid 360mg	10's	10's X 10	300000
267	2123	Metformin Hydrochloride (sustained-relase) 500mg and Myo-	Each film coated bilayered tablet contains: Metformin Hydrochloride 500mg (as sustained-release form)	10's	10's X 10	200000

		Inositol 600mg Tablets	Myo-Inositol 600mg			
268	2124	Nitroglycerin Controlled Release Tablets 6.4 mg	Each uncoated controlled release tablet contains: Diluted Nitroglycerin IP eq. to Nitroglycerin 6.4mg	30's in Bottle	30's in bottle X 10	600000
269	2125	Nortriptyline Tablets IP 10mg	Each film coated tablet contains: Nortriptyline Hydrochloride IP eq. to Nortriptyline 10mg	10's	10's X 10	400000
270	2127	Oxcarbazepine Tablets IP 150mg	Each film coated tablet contains: Oxcarbazepine IP 150mg	10's	10's X 10	1400000
271	2135	Spironolactone 50mg and Torasemide 20mg Tablets	Each uncoated tablet contains: Torsemide 20mg Spironolactone 50mg	10's	10's X 10	500000
272	2137	Telmisartan 40mg, Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets	Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Chlorthalidone IP 12.5 mg	10's	10's X 10	1200000
273	2138	Torsemide Tablets IP 100mg	Each uncoated tablet contains: Torsemide IP 100mg	10's	10's X 10	300000
274	2139	Valsartan Tablets IP 40 mg	Each film-coated tablet contains: Valsartan IP 40 mg	10's	10's X 10	400000
275	2141	Warfarin Tablets IP 1mg	Each uncoated tablet contains: Warfarin Sodium Clathrate IP equivalent to Warfarin sodium (anhydrous) 1mg	10's	10's X 10	300000
276	2143	Zinc Sulphate Dispersible Tablets IP 20mg	Each uncoated dispersible tablet contains: Zinc Sulphate Monohydrate IP eq. to elemental Zinc 20mg	10's	10's X 10	600000
277	2147	Estradiol Tablets 2mg	Each film coated tablet contains: Estradiol (as hemihydrate) eq. to Anhydrous Estradiol 2mg	28's	28's X 10	150000
278	2162	Eberconazole Cream 1% w/w	Composition: Each gram Contains Eberconazole Nitrate IP equivalent to Eberconazole 10mg In a Cream base q.s.	30 g	1's X 10	250000
279	2204	Tenofovir Alfenamide Tablets 25mg	Each film coted tablet Contain : Tenofovir Alfenamide 25mg	30's in Bottle	30's X 1 X10	200000
280	2221	Alpha Ketoanalouge and Essential Amino Acid Tablets	Each film coated tablet contains: Alpha-Keto, Isoleucine, Calcium Salt 67mg Alpha-Keto, Leucine, Calcium Salt 101mg Alpha-Keto, Phenylalanine, Calcium Salt 68mg Alpha-Keto-Valine, Calcium Salt 86mg Alpha-Hydroxy Methionine, Calcium Salt 59mg Threonine 53mg Tryptophan 23mg Histidine 38mg Tyrosine 30mg Lysine Acetate 105mg Total Nitrogen content 36mg Calcium content per tablet 50mg	10's	10's X 10	3600000

281	2222	Allopurinol Tablets IP 300 mg	Each uncoated tablet contains: Allopurinol IP 300 mg	10's	10's X 10	350000
282	2223	Amisulpride Tablets IP 300mg	Each uncoated tablet contains: Amisulpride IP 300mg	10's	10's X 10	250000
283	2225	Acetylcysteine Effervescent Tablets 600mg	Each effervescent tablet contains: N-Acetylcystein 600mg	10's	10's X 10	800000
284	2283	Abiraterone Acetate Tablets 250mg	Each uncoated Tablet contains Abiraterone Acetate 250Mg	120's Bottle	1 X 10's X 10	500000
285	2319	Ketorolac (0.5% W/V) and Moxifloxacin (0.5% W/V) Eye Drops	Composition; Ketorolac Tromethamine 0.5%w/v Moxifloxacin Hydrochloride equivalent to Moxifloxacin 0.5% w/v	5ml Drop bottle in Mono carton	1 X 1 X 10	250000
286	2320	Lactic Acid 1.2% W/V Intimate Hygiene Wash	Composition Lactic acid 1.2 % w/v Other ingredients Tea Tree oil, Aloe vera gel, Glycerin, Preservative and other required additives like cleansing, humectant and emollient agents Perfume- Tea tree, Mint pH: 3.5 - 4.5	90ml in Mono carton	1 X 1 X 10	250000
287	2326	Lutein, Astaxanthin, Zeaxanthin, Omega 3 Fatty Acid Capsule	Each soft gelatin capsule contains; Omega-3 fatty acid 500 mg Lutein 10 mg Astaxanthin 2 mg Zeaxanthin 2 mg	10's	1 X 10's X 10	500000
288	2327	Omega 3 Fatty Acid 500 mg EPA 150 mg DHA 100 mg Bilberry Extract 50 mg Lutein 20% & Zeaxanthin 4%- 25 mg Beta carotene 4.8 mg Vitamin D3 10 mcg Capsules	Each Soft gelatin capsule contains: Omega 3 Fatty Acid 500 mg EPA 150 mg DHA 100 mg Bilberry Extract 50 mg Lutein 20% & Zeaxanthin 4%- 25 mg Beta carotene 4.8 mg Vitamin D3 10 mcg	30's Bottle	1 X 30's X 10	500000
289	2328	Methylcobalamin 1500 mcg, Vitamin B6 (Pyridoxine) 5mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg Capsule	Each Soft gelatin capsule contains Methylcobalamin 1500 mcg Vitamin B6 (Pyridoxine) 5 mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg	10's	1 X 10's X 10	1100000
290	2330	Modafinil Tablets IP 100mg	Each uncoated tablet contains Modafinil IP 100 mg	10's	10's X 10	250000
291	2332	Nicoumalone (Acenocoumarol) 2mg Tablets	Each Uncoated tablet contains Nicoumalone IP 2 mg (Acenocoumarol)	10's	1 X 10's X 10	250000
292	2335	Obeticholic Acid 10 mg Tablets	Each Film coated tablet contains Obeticholic acid 10 mg	10's	1 X 10's X 10	200000
293	2336	Obeticholic Acid 5 mg Tablets	Each Film coated tablet contains Obeticholic acid 5 mg	10's	1 X 10's X 10	200000
294	2344	Procyclidine Tablets IP	Each Uncoated tablet contains	10's	10's X 10	150000

		5mg	Procyclidine Hydrochloride IP 5 mg			
295	2347	S-Adenosyl L-Methionine 200mg Tablets	Each Film coated Tablet contains S-Adenosyl L-Methionine Disulfate Tosylate equivalent To S-Adenosyl L-Methionine Tablets 200 mg Tablets 200 mg Additive as per Nutraceutical Regulation issued by FSSAI	10's	1 X 10's X 10	300000
296	2349	Sevelamer 800mg Tablets	Each Film coated tablet contains Sevelamer Carbonate 800 mg	10's	1 X 10's X 10	400000
297	2350	Tapentadol 100mg Extended Release Tablet	Each Film coated extended Release tablet contains Tapentadol Hydrochloride IP equivalent To Tapentadol 100 mg	10's	1 X 10's X 10	250000
298	2354	Topiramate IP 50 mg Tablets	Each Film coated tablet contains Topiramate IP 50 mg	10's	1 X 10's X 10	250000
299	2356	Valacyclovir Tablets IP 500 mg	Each Film coated tablet contains Valacyclovir Hydrochloride equivalent To Valacyclovir IP 500 mg	3's in Mono carton	1 X 3's X 10	200000
300	2357	Venlafaxine Prolonged Release Capsule IP 37.5 mg	Each hard Gelatin capsule contains Venlafaxine Hydrochloride equivalent To Venlafaxine IP 37.5 mg (as prolonged release pellets)	10's	1 X 10's X 10	200000
301	2358	Venlafaxine Prolonged Release 75 mg IP Capsule	Each hard Gelatin capsule contains Venlafaxine Hydrochloride equivalent To Venlafaxine IP 75 mg (as prolonged release pellets)	10's	1 X 10's X 10	150000
302	2360	Vildaglipitin 100mg Extended Release Tablet	Each extended release tablet contains Vildagliptin 100 mg	10's	1 X 10's X 10	2000000
303	2365	Ketoconazole 2 % w/v Shampoo pouch, 30 ml	Each pouch contains Ketoconazole 2 % w/v	30ml Pouch	1 X 1 X 10	500000
304	2370	Nebivolol 5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 5mg Cilnidipine IP 10 mg	10's	1 X 10's X 10	250000
305	2371	Nebivolol 2.5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 2.5mg Cilnidipine IP 10 mg	10's	1 X 10's X 10	200000
306	2385	Apixaban Tablets 2.5mg	Each Film Coated tablet contains:Apixaban 2.5mg	10's	10's X 10	1000000
307	2386	Apixaban Tablets 5mg	Each Film Coated tablet contains:Apixaban 5mg	10's	10's X 10	800000
308	2392	Azelnidipine 16 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 16 mg	10's	10's X 10	250000
309	2393	Telmisartan 40 mg and Azelnidipine 8 mg	Each Film coated bi-layered tablet contains:	10's	10's X 10	150000

		Tablets	Telmisartan IP 40 mg Azelnidipine IP 8 mg			
310	2394	Azelnidipine 8 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 8 mg	10's	10's X 10	300000
311	2397	Bethanechol Chloride 25 mg Tablets	Each Uncoated tablet contains: Bethanechol Chloride 25 mg	10's	10's X 10	350000
312	2404	Ciclopirox olamine Cream 1% w/v, 50 gm Lami Tube	Each lami tube contains: Ciclopirox olamine USP 1% w/w Cream Base q.s.	50 gm lami tube in mono carton	1's X 10	200000
313	2414	Diclofenac Diethylamine 1.16% w/w, Sesame Oil 2.50% w/w, Linseed Oil and Menthol Gel	Each lami tube contains:Diclofenac Diethylamine IP 1.16% w/w equivalent to Diclofenac Sodium 1% w/w Sesame Oil IP 2.50% w/w Linseed Oil BP 0.50% w/w, Methylsalicylate IP 10% w/w Menthol 5% w/w Gel Base q.s.	30 g	1's X 10	1100000
314	2416	Eltrombopag Tablets 25mg	Each Film coated tablet contains: Eltrombopag Olamine equivalent to Eltrombopag 25 mg as Eltrombopag free acid	7's	7's X 2	150000
315	2417	Eltrombopag Tablets 50mg	Each Film coated tablet contains: Eltrombopag Olamine equivalent to Eltrombopag 50 mg as Eltrombopag free acid	7's	7's X 2	150000
316	2420	Faropenem 200mg and Clavulanic Acid 125mg Tablets	Each Film coated tablet contains: Faropenem Sodium Hydrate JP equivalent to Faropenem 200mg Potassium Clavulanate equivalent to Clavulanic Acid 125mg	6's	6's X 10	200000
317	2424	Itraconazole (1% w/w) gel, 15 g Lamitube	Each Lamitube contains: Itraconazole 1% w/w Preservative Gel base q.s.	15g tubes	1's X 10	300000
318	2425	Ivermectin Cream 1% w/w	Each gram contains: Ivermectin 1% w/w Cream base q.s.	15g tubes	1's X 10	200000
319	2426	Leflunomide 10 mg Tablets	Each Film coated tablet contains: Leflunomide IP 10 mg	10's	10's X 10	300000
320	2427	Lenalidomide Capsules 25mg	Each Hard Gelatin Capsule contains:Lenalidomide 25mg	30's in PET bottle in monocarton	30's X 10	150000
321	2428	Lenalidomide Capsules 5mg	Each Hard Gelatin Capsule contains:Lenalidomide 5mg	30's in PET bottle in monocarton	30's X 10	150000
322	2431	Lincomycin 250 mg Capsules	Each Hard Gelatin Capsule contains: Lincomycin Hydrochloride IP equivalent to Lincomycin 250 mg	10's	10's X 10	150000
323	2432	Lincomycin 500 mg Capsules	Each Hard Gelatin Capsule contains: Lincomycin Hydrochloride IP equivalent to Lincomycin 500 mg	10's	10's X 10	200000

324	2433	Luliconazole Cream IP 1% w/w, 30 g in Lamitube	Each Lamitube contains: Luliconazole Cream IP 1% w/w Preservative Cream base q.s.	30 g	1's X 10	3700000
325	2440	Metoprolol Extended-Release Tablets IP 100 mg	Each extended-release film coated tablet contains: Metoprolol Succinate IP 95 mg equivalent to Metoprolol Tartarate 100 mg	10's	10's X 10	400000
326	2442	Midodrine Hydrochloride Tablets 10 mg	Each Uncoated tablet contains: Midodrine Hydrochloride USP 10 mg	10's	10's X 10	150000
327	2443	Midodrine Hydrochloride Tablets 2.5 mg	Each Uncoated tablet contains:Midodrine Hydrochloride USP 2.5 mg	10's	10's X 10	200000
328	2444	Midodrine Hydrochloride Tablets 5 mg	Each Uncoated tablet contains:Midodrine Hydrochloride USP 5 mg	10's	10's X 10	250000
329	2448	Olmesartan Medoxomil Tablets IP 10 mg	Each Film coated tablet contains:Olmesartan Medoxomil Tablets IP 10 mg	10's	10's X 10	350000
330	2449	Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, 21g	Each Sachet contains: Sodium Chloride IP 2.6 g+Potassium Chloride IP 1.5 g+Trisodium Citrate 2.9 g+Dextrose (Anhydrous) 13.5 g+Orange Flavour	01's	1's X 10	3600000
331	2450	Ozenoxacin Cream 1% w/w, 10 g Lamitube	Each Lamitube contains: Ozenoxacin 1% w/w Preservative Cream base q.s.	10 g	1's X 10	200000
332	2451	Ozenoxacin Lotion 2% w/v, 10 ml	Each Lamitube contains:Ozenoxacin 2% w/v+PreservativeLotion base q.s.	10 ml PET bottle with pointed nozzle in mono carton	1's X 15	150000
333	2458	Quetiapine Tablets IP 50 mg	Each Film coated tablet contains: Quetiapine Fumarate IP equivalent to Quetiapine 50 mg	10's	10's X 10	800000
334	2463	Repaglinide 0.5mg and Voglibose 0.2mg Tablets	Each Film coated tablet contains: Repaglinide IP 0.5mg Voglibose IP 0.2 mg	10's	10's X 10	250000
335	2464	Repaglinide 0.5mg and Voglibose 0.3mg Tablets	Each Film coated tablet contains: Repaglinide IP 0.5mg Voglibose IP 0.3mg	10's	10's X 10	350000
336	2465	Repaglinide 1mg and Voglibose 0.2mg Tablets	Each Film coated tablet contains: Repaglinide IP 1 mg Voglibose IP 0.2 mg	10's	10's X 10	200000
337	2466	Repaglinide 1mg and Voglibose 0.3mg Tablets	Each Film coated tablet contains: Repaglinide IP 1 mg Voglibose IP 0.3 mg	10's	10's X 10	350000
338	2467	Salmeterol 50mcg and Fluticasone 500mcg Rotacaps	Each Hard Gelatin Capsule contains: Salmeterol 50mcg Fluticasone Propionate IP	30's in PET bottle in monocarton	30's X 10	200000

			500mcg			
339	2477	Thalidomide Capsules 100mg	Each Hard Gelatin Capsule contains: Thalidomide USP 100mg	10's	10's X 10	150000
340	2479	Thalidomide Capsules 50mg	Each Hard Gelatin Capsule contains: Thalidomide USP 50mg	10's	10's X 10	200000
341	2481	Ticagrelor Tablets IP 60 mg	Each film coated tablet contains: Ticagrelor IP 60 mg	10's	10's X 10	500000
342	2482	Topiroxostat Tablets 20mg	Each Uncoated Tablet contains: Topiroxostat Tablets 20mg	10's	10's X 10	200000
343	2483	Topiroxostat Tablets 40mg	Each Uncoated Tablet contains: Topiroxostat Tablets 40mg	10's	10's X 10	150000
344	2484	Topiroxostat Tablets 60mg	Each Uncoated Tablet contains: Topiroxostat Tablets 60mg	10's	10's X 10	150000
345	2485	Torasemide 10 mg and Spironolactone 25 mg Tablets	Each Uncoated Tablet contains: Torasemide IP 10 mg Spironolactone IP 25 mg	10's	10's X 10	1100000
346	2487	Vortioxetine Tablets 10mg	Each Film coated tablet contains: Vortioxetine hydrobromide 12.71 mg equivalent to Vortioxetine 10mg	10's	10's X 10	200000
347	2488	Vortioxetine Tablets 20mg	Each Film coated tablet contains: Vortioxetine hydrobromide 25.42 mg equivalent to Vortioxetine 20mg	10's	10's X 10	150000
348	2489	Vortioxetine Tablets 5mg	Each Film coated tablet contains: Vortioxetine hydrobromide 6.355 mg equivalent to Vortioxetine 05mg	10's	10's X 10	150000
349	2531	Deferiprone Capsules 250mg	Each Hard Gelatin Capsule contains: Deferiprone 250mg	50's	10's X 10	1500000
350	2532	Deferiprone Capsules 500mg	Each Hard Gelatin Capsule contains: Deferiprone 500mg	50's	10's X 10	800000
351	2785	Abiraterone Acetate IP 500mg Tablets	Each Film Coated Tablet contains: Abiraterone Acetate Tablets IP 500mg	60's bottle	60's x 1 x 10	20000
352	2786	Amlodipine 5mg and Enalpril 5mg Tablets	Each Uncoated Tablet contains: Amlodipine 5mg Enalpril 5mg	10's	10's X 10	2000000
353	2787	Amlodipine 5mg and Indapamide 1.5mg Tablets	Each Film Coated Bilayered Tablet contains: Indapamide (Sustained Release) 1.5mg Amlodipine Besilate IP eq. to Amlodipine 5mg	10's	10's X 10	600000
354	2789	Atenolol IP 25mg and Chlorthalidone IP 12.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 25mg Chlorthalidone IP 12.5mg	10's	10's X 10	800000
355	2790	Atenolol IP 50mg and Chlorthalidone IP 12.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 50mg Chlorthalidone IP 12.5mg	10's	10's X 10	1500000
356	2791	Atenolol 50mg and Indapamide 2.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 50mg Indapamide 2.5mg	10's	10's X 10	500000
357	2792	Atenolol 50mg and Losartan 50mg Tablets	Each Film-Coated Tablet contains:	10's	10's X 10	400000

			Atenolol IP 50mg Losartan IP 50mg			
358	2793	Atenolol 50mg and Nifedipine 20mg Tablets	Each Film Coated Tablet contains: Atenolol IP 50mg Nifedipine IP 20mg	10's	10's X 10	2500000
359	2794	Atomoxetine 10mg Tablets	Each Film-Coated Tablet contains: Atomoxetine Hydrochloride IP eq. to Atomoxetine 10mg	10's	10's X 10	600000
360	2795	Azelaic Acid 20% w/w Cream	Composition: Azelaic Acid 20% w/w	15gm	1's X 10	250000
361	2796	Benidipine 4mg and Telmisartan 40mg Tablets	Each Film-Coated Bilayered Tablet contains: Benidipine IP 4mg Telmisartan IP 40mg	15's	15's x 10	500000
362	2797	Benzoyl Peroxide 5% w/w Soap	Composition: Benzoyl Peroxide IP 5% w/w	75gm	1's x 10	300000
363	2798	Benzoyl Peroxide IP 5% w/w Gel	Hydrous Benzoyl Peroxide IP eq. to Anhydrous Benzoyl Peroxide 5.0% w/w	15gm	1's X 10	300000
364	2799	Buspirone IP 10mg Tablets	Each Uncoated Tablet contains: Buspirone 10mg	10's	10's X 10	400000
365	2800	Buspirone IP 5mg Tablets	Each Uncoated Tablet contains: Buspirone 5mg	10's	10's X 10	500000
366	2801	Carbetocin 100mcg Injection	Each ml contains: Carbetocin 100mcg	1ml	1's x 10	150000
367	2802	Clonazepam 0.25mg and Propranolol 10mg Tablets	Each Film-Coated Tablet contains: Clonazepam IP 0.25mg Propranolol Hydrochloride IP 10mg	10's	10's X 10	800000
368	2803	Clonazepam 0.25mg and Propranolol 20mg Tablets	Each Film-Coated Tablet contains: Clonazepam IP 0.25mg Propranolol Hydrochloride IP 20mg	10's	10's X 10	1500000
369	2804	Clonazepam 0.5mg and Propranolol 20mg Tablets	Each Uncoated Tablet contains: Clonazepam IP 0.5mg Propranolol Hydrochloride IP 20mg	10's	10's X 10	800000
370	2805	Combo pack of Vitamin C Injection IP and Vitamin B12, Folic acid and Niacinamide injection	Each 1.5 ml contains:(Part I) Ascorbic Acid IP 150mg Each ml contains (Part II) Cyanocobalamin IP 2500 mcg Folic Acid IP 0.7mg Niacinamide IP 12mg Benzoyl Alcohol IP 1% v/v Water for inj. q.s.	1's	1's X 10	500000
371	2806	Enzalutamide 40mg Tablets	Each Hard Gelatin Capsule contains: Enzalutamide 40 mg	28's in Bottle	28's X 1 x 10	15000
372	2807	Filgrastim Injection IP 300mcg	Each Vial of 1.0 ml contains: Filgrastim concentrated solution IP 30MIU (300mcg)	1ML Vial	1's X 10	100000
373	2808	Flecanide 100mg Tablets	Each Uncoated Tablet contains: Flecanide Acetate 100mg	10's	10's X 10	200000
374	2809	Flecanide 50mg Tablets	Each Uncoated Tablet contains:	10's	10's X 10	300000

			Flecainide Acetate 50mg			
375	2810	Fluoxetine IP 10mg Tablets	Each Film-Coated Tablet contains: Fluoxetine Hydrochloride IP equivalent to Fluoxetine 10mg	10's	10's X 10	400000
376	2811	Fluoxetine 60mg Capsules	Each Hard Gelatin Capsules contains: Fluoxetine Hydrochloride IP 60mg	10's	10's X 10	500000
377	2812	Gliclazide 30mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Uncoated Bilayered Tablet contains: Metformin Hydrochloride IP 500mg (In sustained release form) Gliclazide IP 30mg (In sustained release form) Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg	10's	10's X 10	1000000
378	2813	Gliclazide 60mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Uncoated Bilayered Tablet contains: Metformin Hydrochloride IP 500mg (In Sustained Release form) Gliclazide IP 60mg (In Sustained Release form) Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg	10's	10's X 10	2000000
379	2814	Glycolic Acid 12% w/w Cream	Composition: Glycolic Acid 12%w/w in cream base	30gm	1's X 10	150000
380	2815	Glycolic Acid 6% w/w Cream	Composition: Glycolic Acid 6%w/w in cream base	30gm	1's X 10	200000
381	2816	Glycopyrrolate IP 1mg Tablets	Each Uncoated Tablet contains: Glycopyrrolate IP 1mg	10's	10's X 10	500000
382	2817	Glycopyrrolate IP 2mg Tablets	Each Uncoated Tablet contains: Glycopyrrolate IP 2mg	10's	10's X 10	400000
383	2818	Halobetasol 0.05 % w/w and Fusidic Acid 2% w/w Cream	Composition: Halobetasol Propionate USP 0.05% w/w Fusidic Acid IP 2.0% w/w	10gm	1's X 10	150000
384	2819	Human Papillomavirus Quadrivalent (Types 6, 11, 16, And 18) Vaccine, Recombinant	Each Dose of 0.5ml contains;- Human Papillomavirus type 6 L1 Protein ≥20mcg Human Papillomavirus type 11 L1 Protein ≥ 40mcg Human Papillomavirus type 16 L1 Protein n≥ 40mcg Human Papillomavirus type 18 L1 Protein ≥ 20mcg Aluminium(Al+++) ≤ 1.25mg	0.5 ml in 1 prefilled syringe	0.5ml prefilled syringe X 10	100000
385	2820	Ibrutinib 140mg Capsules	Each Hard Gelatin Capsule contains: Ibrutinib 140mg	30's in Bottle	30's X 1 X10	25000
386	2821	Imipramine 25mg and Diazepam 2mg Tablets	Each Film Coated Tablet contains: Imipramine Hydrochloride IP 25mg	10's	10's X 10	1000000

			Diazepam IP 2mg			
387	2822	Imipramine 25mg and Diazepam 5mg Tablets	Each Film Coated Tablet contains: Imipramine Hydrochloride IP 25mg Diazepam IP 5mg	10's	10's X 10	700000
388	2823	Testosterone Enanthate Injection 250mg	Each ml contains: Testosterone Enanthate 250mg	1 ML	1ml X 10	200000
389	2824	Lenvatinib IP 4mg Capsules	Each Hard Geltain Capsule contains: Lenvatinib Mesylate IP 4.90mg equivalent to Lenvatinib 4mg	10's bottle	10's X 10	150000
390	2825	Levetiracetam IP 500mg Prolonged Release Tablets	Each Film Coated Prolonged Release Tablet contains: Levetiracetam IP 500 mg	10's	10's x 10	3000000
391	2826	Losartan 25mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Tablet contains: Losartan Potassium IP 25mg Chlorthalidone IP 6.25mg	10's	10's X 10	500000
392	2827	Losartan 50mg and S-Amlodipine 2.5mg Tablets	Each Uncoated Tablet contains: Losartan Potassium IP 50mg S-Amlodipine 2.5mg	10's	10's X 10	500000
393	2828	Melatonin 3mg and Zolpidem 10mg Tablets	Each Film Coated Tablet contains: Melatonin 3mg Zolpidem Tartrate IP 10mg	10's	10's X 10	1200000
394	2829	Melatonin 3mg and Zolpidem 5mg Tablets	Each Film Coated Tablet contains: Melatonin 3mg Zolpidem Tartrate IP 5mg	10's	10's X 10	700000
395	2830	Methylphenidate IP 10mg Tablets	Each Film Coated Prolonged Release Tablet contains: Methylphenidate Hydrochloride IP 10mg	10's	10's X 10	400000
396	2831	Methylphenidate IP 18mg Tablets	Each Film Coated Prolonged Release Tablet contains: Methylphenidate Hydrochloride IP 18mg	10's	10's x 10	100000
397	2832	Methylphenidate IP 20mg Tablets	Each Film Coated Prolonged Release Tablet conatins: Methylphenidate Hydrochloride IP 20mg	10's	10's X 10	100000
398	2833	Methylphenidate IP 5mg Tablets	Each Uncoated Tablet contains: Methylphenidate Hydrochloride IP 5mg	10's	10's X 10	150000
399	2834	Metoprolol 25mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 23.75mg equivalent to Metoprolol 25mg Chlorthalidone IP 6.25 mg	10's	10's X 10	600000
400	2835	Metoprolol 50mg and Chlorthalidone 12.5mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol 50mg (as Extended Release Part) Chlorthalidone IP 12.5mg	10's	10's X 10	500000
401	2836	Metoprolol 50mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol 50mg	10's	10's X 10	400000

			Chlorthalidone IP 6.25 mg			
402	2837	Minoxidil IP 5mg Tablets	Each Uncoated Tablet contains: Minoxidil IP 5mg	10's	10's X 10	200000
403	2838	Naltrexone IP 50mg Tablets	Each Uncoated Tablet contains: Naltrexone IP 50mg	10's	10's X 10	200000
404	2839	Nimodipine IP 30mg Tablets	Each Film Coated Tablet contains: Nimodipine 30mg	10's	10's X 10	400000
405	2840	Olmesartan 40mg, Amlodipine 5mg and Chlorthalidone 12.5mg Tablets	Each Film Coated Tablet contains: Olmesartan Medoximil IP 40mg Amlodipine Besylate IP equivalent to Amlodipine 5mg Chlorthalidone IP 12.5mg	10's	10's X 10	600000
406	2841	Olmesartan 20mg and Metoprolol 25mg Tablets	Each Film Coated Bilayer Tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate IP 25mg (as Extended release) Olmesartan Medoxomil IP 20mg	10's	10's X 10	600000
407	2842	Olmesartan 20mg and Metoprolol 50mg Tablets	Each Film Coated Bilayer Tablet contains: Metoprolol Succinate IP 47.5mg eq. to Metoprolol Tartrate IP 50mg (as extended release) Olmesartan Medoxomil IP 20mg	10's	10's X 10	1200000
408	2843	Opipramol Dihydrochloride 50mg Tablets	Each Film Coated Tablet contains: Opipramol Dihydrochloride 50mg	10's	10's X 10	500000
409	2844	Opipramol Dihydrochloride 100mg Tablets	Each Film Coated Tablet contains: Opipramol Dihydrochloride 100mg	10's	10's X 10	500000
410	2845	Orlistat 60mg Capsules	Each Hard Gelatin Capsule contains: Orlistat 60mg	10's	10's X 10	200000
411	2846	Perampanel 2mg Tablets	Each Film Coated Tablet contains: Perampanel 2mg	10's	10's X 10	600000
412	2847	Perampanel 4mg Tablets	Each Film Coated Tablet contains: Perampanel 4mg	10's	10's X 10	600000
413	2848	Pioglitazone 15mg and Glimepiride 2mg Tablets	Each Uncoated Tablet contains: Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg Glimepride IP 2mg	10's	10's X 10	500000
414	2849	Polmacoxib 2mg Capsules	Each Hard Gelatin Capsule contains: Polmacoxib 2 mg	10's	10's X 10	500000
415	2850	Rosuvastatin 10mg and Cholecalciferol 1000IU Tablets	Each Film Coated Tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Vitamin D3 IP (Cholecalciferol) 1000IU	10's	10's X 10	500000
416	2851	Rosuvastatin IP 10mg and Ezetimibe IP 10mg Tablets	Each Film Coated Tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Ezetimibe IP 10mg	10's	10's X 10	600000
417	2852	Rosuvastatin 20mg and Ezetimibe 10mg	Each Film Coated Tablet contains: Rosuvastatin Calcium IP	10's	10's X 10	300000

		Tablets	equivalent to Rosuvastatin 20mg Ezetimibe IP 10mg			
418	2853	Rosuvastatin 20mg And Clopidogrel 75mg Capsules	Each Hard Gelatin Capsule contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 20mg(As Pellets) Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg(As Pellets)	10's	10's X 10	5000000
419	2854	Safinamide 50mg Tablets	Each Film Coated Tablet contains: Safinamide Methane Sulphonate IP equivalent to Safinamide 50mg	10's	10's X 10	500000
420	2855	S-Amlodipine 2.5mg and Hydrochlorothiazide 12.5mg Tablets	Each Uncoated Tablet contains: S-Amlodipine Besylate IP equivalent to S-Amlodipine 2.5mg Hydrochlorthiazide IP 12.5mg	10's	10's X 10	3000000
421	2856	Sitagliptin 100mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Film-Coated Bilayered Tablet contains: Sitagliptin Phosphate IP equivalent to Sitagliptin 100mg Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (As Sustained Release form)	10's	10's X 10	1000000
422	2857	S-Metoprolol 25mg and S-Amlodipine 2.5mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (In Prolonged Release form) S-Amlodipine Besylate IP equivalent to S-Amlodipine 2.5mg	10's	10's X 10	600000
423	2858	S-Metoprolol 25mg and S-Amlodipine 5mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (In Prolonged Release Form) S-Amlodipine Besylate IP equivalent to S-Amlodipine 5mg	10's	10's X 10	400000
424	2859	S-Metoprolol 25mg and Telmisartan 20mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (As Extended Release form) Telmisartan IP 40mg (as Immediate Release)	10's	10's X 10	1000000
425	2860	Telmisartan 40mg and Indapamide 1.5mg Tablets	Each Uncoated Bilayered Tablet contains: Telmisartan IP 40mg	10's	10's X 10	700000

			Indapamide IP 1.5mg (as Sustained Release form)			
426	2861	Telmisartan 40mg and Rosuvastatin 10mg Tablets	Each Film Coated Tablet contains: Telmisartan IP 40mg Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg	10's	10's X 10	1000000
427	2862	Telmisartan 40mg and S- Amlodipine 2.5mg Tablets	Each Uncoated Bilayered Tablet contains: S- Amlodipine Besylate IP equivalent to S- Amlodipine 2.5mg Telmisartan IP 40mg	15's	15's X 10	2000000
428	2863	Telmisartan 40mg and S- Amlodipine 5mg Tablets	Each Uncoated Bilayered Tablet contains: S- Amlodipine Besylate IP equivalent to S- Amlodipine 5mg Telmisartan IP 40mg	15's	15's X 10	5000000
429	2864	Tianeptine 12.5mg Tablets	Each Sugar Coated Tablet contains: Tianeptine Sodium 12.5mg	10's	10's X 10	400000
430	2865	Tofisopam 50mg Tablets	Each Uncoated Tablet contains: Tofisopam IP 50mg	10's	10's X 10	500000
431	2866	Trifluoperazine 2.5mg and Trihexyphenidyl 1mg Tablets	Each Film Coated Tablet contains: Trifluoperazine Hydrochloride IP equivalent to Trifluoperazine 2.5mg Trihexyphenidyl Hydrochloride IP 1mg	10's	10's X 10	2500000
432	2867	Trifluoperazine 5mg and Trihexyphenidyl 2mg Tablets	Each Uncoated Tablet contains: Trifluoperazine Hydrochloride IP equivalent to Trifluoperazine 5 mg Trihexyphenidyl Hydrochloride IP 2mg	10's	10's X 10	2000000
433	2868	Voglibose 0.2mg, Metformin 500mg and Gliclazide 80mg Tablets	Each Uncoated Bilayered Tablet contains: Gliclazide IP 80mg Metformin Hydrochloride IP 500mg (as Sustained Release form) Voglibose IP 0.2mg	10's	10's X 10	1000000
434	2869	Voglibose 0.3mg, Metformin 500mg and Gliclazide 80mg Tablets	Each Uncoated Bilayered Tablet contains: Gliclazide IP 80mg Metformin Hydrochloride IP 500mg (as Sustained Release form) Voglibose IP 0.3mg	15's	15's X 10	1000000
435	2870	Cefepime 250mg Inection	Each Vial contains: Sterile Cefepime Hydrochloride IP eq. to Cefepime 250mg	1.0 Injection in 1 vial	1's x 10	200000
436	2871	Cefepime 1000mg and Tazobactam 125mg Injection	Each Vial contains: Sterile Cefepime Hydrochloride IP eq. to	1.0 Injection in 1 vial	1's x 10	150000

			Cefepime 1000mg Sterile Tazobactum Sodium IP eq. to Tazobactum 125mg			
437	2872	Ciclesonide 200mcg , Formoterol 6mcg and Tiotropium 9mcg Inhaler	Each Actuation Delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium 9mcg Formoterol Fumarate 6mcg (as Formoterol Fumarate Dihydrate IP) Circlesonide IP 200mcg	200 MDI in 1 packet	1's X 10	300000
438	2873	Dolutegravir 50mg, Emtricitabine 200mg and Tenofovir Alafenamide 25mg Tablets	Each Film Coated Tablet contains: Dolutegravir Sodium IP equivalent to Dolutegravir 50mg Emtricitabine IP 200mg Tenofovir Alafenamide fumarate IP equivalent to Tenofovir Alafenamide 25mg	30's in Bottle	1 X 30's X 10	50000
439	2874	Dolutegravir 50mg, Lamivudine 300mg and Tenofovir Disoproxil Fumarate 300mg Tablets	Each Film Coated Tablet contains: Dolutegravir Sodium IP equivalent to Dolutegravir 50mg Lamivudine IP 300mg Tenofovir Disoproxil Fumarate IP 300mg equivalent to Tenofovir Disoproxil Fumarate 245mg	30's in Bottle	1 X 30's X 10	50000
440	2875	Ketoprofen 30mg Patch	Composition: Each Plaster (7cmx10cm) contains: Ketoprofen IP 30mg	7's pack	1 X 7's	150000
441	2876	Lamivudine IP 100mg Tablets	Each Film Coated Tablet contains: Lamivudine IP 100mg	10's	10's X 10	150000
442	2877	Levetiracetam 100mg Injection	Each ml contains: Levetiracetam IP 100mg	5.0 ml in 1 vial	1's x 10	300000
443	2878	Levetiracetam 500mg Injection	Each 5ml contains: Levetiracetam IP 500mg	5.0 ml in 1 vial	1's x 10	200000
444	2879	Magnesium Sulphate Injection 50% w/v	Each ml contains: Magnesium Sulphate IP 50% w/v	2 ml Vial	1's x 10	300000
445	2880	Minocycline 100mg Modified Release Capsules	Each Hard Gelatin Capsule contains: Minocycline Hydrochloride equivalent to Minocycline 100mg	10's	10's X 10	300000
446	2881	Minocycline 45mg Extended Release Tablets	Each Film Coated Extended Release Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 45mg	10's	10's X 10	150000
447	2882	Minocycline 50mg Tablets	Each Film Coated Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 50mg	10's	10's X 10	400000
448	2883	Minocycline 65mg Extended Release Tablets	Each Film Coated Extended Release Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 65mg	10's	10's X 10	200000

449	2884	Minocycline 100mg Tablets	Each Film Coated Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 100mg	10's	10's X 10	300000
450	2885	Mosapride 5mg and Dimethicone 125mg Chewable Tablets	Each Uncoated Chewable Tablet contains: Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 5mg Activated Dimethicone IP 125mg	10's	10's X 10	200000
451	2886	Mosapride Citrate IP 5mg Tablets	Each Film Coated Tablet contains: Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 5mg	10's	10's X 10	400000
452	2887	Nifedipine IP 5mg Capsules	Each Soft Gelatin Capsule contains: Nifedipine 5mg	10's	10's X 10	1000000
453	2888	Olopatadine IP 5mg Tablets	Each Film Coated Tablet contains: Olopatadine Hydrochloride IP 5mg	10's	10's X 10	300000
454	2889	Pantoprazole 40mg and Mosapride 15mg Capsules	Each Hard Gelatin Capsule Contains;- Panoprazole Sodium IP equivalent to Pantoprazole 40mg (as two Pantoprazole Tablet IP 20mg) Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 15mg	10's	10's X 10	200000
455	2890	Phenobarbitone IP 200mg Injection	Each ml contains: Phenobarbitone Sodium IP 200mg	10 ml /vial	1's x 10	250000
456	2891	Phenobarbitone Sodium 20mg Syrup	Each 5ml contains: Phenobarbitone Sodium IP equivalent to Phenobabrbitone 20mg	100 ml	100ml X 6	200000
457	2892	Prednisolone 15mg Syrup	Each 5ml contains: Prednisolone Sodium Phosphate IP equivalent to Prednisolone 15mg	60ml bottle in Monocarton	60ml x 1 x 10	300000
458	2893	Prednisolone Dispersible Tablets 20mg	Each Uncoated Dispersable Tablet contains: Prednisolone IP 20mg	15's	15's X 10	2000000
459	2894	Prednisolone Dispersible Tablets 40mg	Each Uncoated Dispersable Tablet contains: Prednisolone IP 40mg	10's	10's X 10	1200000
460	2895	Rabeprazole 20mg and Mosapride 15mg Tablets	Each Tablet contains: Rabeprazole Sodium IP 20mg Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate Anhydrous 15mg	10's	10's X 10	300000
461	2896	Rupatadine 10mg and Montelukast 10mg Tablets	Each Film Coated Tablet contains: Rupatadine Fumarate IP eq. to Rupatadine 10mg Montelukast Sodium IP eq. to Montelukast 10mg	10's	10's X 10	300000
462	2897	Rupatadine 10mg	Each Uncoated Tablet contains:	10's	10's X 10	250000

		Tablets	Rupatadine Fumarate IP eq. to Rupatadine 10mg			
463	2898	Sumatriptan 50mg Tablets	Each Film Coated Tablet contains: Sumatriptan Succinate IP eq. to Sumatriptan 50mg	10's	10's X 10	150000
464	2899	Terazosin IP 1mg Tablets	Each Uncoated Tablet contains: Terazosin Hydrochloride IP eq. to Terazosin 1mg	10's	10's X 10	300000
465	2900	Terazosin IP 2mg Tablets	Each Uncoated Tablet contains: Terazosin Hydrochloride IP eq. to Terazosin 2mg	10's	10's X 10	400000

Note: *(i) Bidder shall quote their Price bid against quoted drugs as per unit size mentioned under column (e) in above table.*
(ii)Bidder shall note that above mentioned quantity under column (g) is indicative and the actual quantity may vary from zero to the maximum required quantity during the contract as per tender clause 4. D.

Annexure-XIII

Ref. Clause No. 1(ii)(c), 20(B) & 21(A)

Sr. No.	Drug Code	Generic Name of Drug	Detailed Specification	Unit Size	Packing Type	Packing Standard of Blister/Alu-Alu/Ampoules/ Vials/Bottles etc.
1	9	Diclofenac Sodium Prolonged Release Tablets IP 100 mg	Each Prolonged Release film-coated tablet contains: Diclofenac Sodium IP 100 mg	10's	Strip	Strip
2	10	Diclofenac Sodium Injection IP 25mg per ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml Ampoule	Market Standard	Market Standard
3	15	Ibuprofen Tablets IP 200 mg	Each film coated tablet contains: Ibuprofen IP 200 mg	10's	Blister	Transparent
4	26	Tramadol Hydrochloride Injection 100 mg per 2 ml	Each ml contains: Tramadol Hcl 50 mg	2 ml Vial	Market Standard	Market Standard
5	31	Amikacin Injection IP 250 mg per 2 ml	Each ml contains: Amikacin sulphate IP equivalent to Amikacin 125 mg	2 ml Vial	Market Standard	Market Standard
6	35	Amoxycillin 1g and Potassium Clavulanate 200mg Injection IP	Each vial contains: Amoxycillin Sodium IP (Sterile) eq. to Amoxycillin1g Potassium Clavulanate Diluted IP (Sterile) eq. to Clavulanic Acid 200mg	Vial with Wfi	Market Standard	Market Standard
7	42	Amoxycillin Trihydrate Dispersible Tablets IP 125 mg	Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 125mg	10's	Strip	Strip
8	45	Amoxycillin Capsules IP 500mg	Each hard gelatin capsule contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 500mg	10's	Blister	Amber Colored Blister
9	55	Cefixime Tablets IP 200 mg	Each film coated tablet contains: Cefixime Trihydrate IP eq. to Cefixime Anhydrous 200mg	10's	Alu-Alu	Alu-Alu
10	67	Ceftazidime Injection IP 1g	Each vial contains: Ceftazidime Pentahydrate IP eq. to Anhydrous Ceftazidime 1g (As a sterile mixture of sterile Ceftazidime Pentahydrate and Sodium Carbonate IP)	Vial with Wfi	Market Standard	Market Standard
11	68	Ceftazidime Injection IP 250mg	Each vial contains : Sterile Mixture of Ceftazidime Pentahydrate IP eq. to Ceftazidime 250 mg	Vial with Wfi	Market Standard	Market Standard
12	69	Ceftazidime Injection IP 500mg	Each vial contains : Sterile Mixture of Ceftazidime Pentahydrate IP eq. to Ceftazidime 500 mg	Vial with Wfi	Market Standard	Market Standard

13	70	Ceftriaxone 1g and Sulbactam 500mg Injection	Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 1g Sulbactum Sodium IP eq. to Sulbactum 500mg	Vial with Wfi	Market Standard	Market Standard
14	77	Ceftriaxone injection IP 500 mg	Each vial contains: Ceftriaxone Sodium IP (sterile)equivalent to anhydrous Ceftriaxone 500 mg	Vial with Wfi	Market Standard	Market Standard
15	83	Ciprofloxacin 250mg and Tinidazole 300mg Tablets	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Tinidazole IP 300mg	10's	Blister	Blister
16	102	Ofloxacin Tablets IP 400mg	Each film coated Tablet contains: Ofloxacin IP 400mg	10's	Blister	Blister
17	112	Beclomethasone Dipropionate 0.025%w/w, Clotrimazole 1%w/w and Gentamicin Sulphate 0.1%w/w Cream	Contains : Beclomethasone Dipropionate IP 0.025% w/w Clotrimazole 1% w/w Gentamycin Sulphate 0.1% w/w	15g tubes	Lami Tube in Monocarton	Market Standard
18	126	Povidone-Iodine Solution IP 10 % w/v	Composition: Povidone-Iodine IP 10 % w/v	500 ml	Amber Colored Bottle	Amber Colored Bottle
19	133	Glibenclamide Tablets IP 2.5 mg	Each uncoated tablet contains: Glibenclamide IP 2.5 mg	10's	Blister	Amber Colored Blister
20	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	Blister	Transparent
21	145	Metformin Hydrochloride Tablets IP 500mg	Each uncoated tablet contains: Metformin Hydrochloride IP 500mg	10's	Blister	Transparent
22	150	Pioglitazone 15mg and Metformin 500mg Sustained Release Tablets	Each uncoated bilayer tablet contains: Metformin Hydrochloride IP 500mg (As sustained release form) Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg	10's	Blister	Transparent
23	153	Cisplatin Injection IP 10 mg per10ml	Each ml contains: Cisplatin IP 1 mg	Vial	Market Standard	Amber Colored Glass Vial
24	158	Etoposide Injection IP 100 mg per 5 ml	Each ml contains: Etoposide IP 20 mg	Vial	Market Standard	Market Standard
25	163	Tamoxifen Citrate Tablets IP 10 mg	Each uncoated tablet contains: Tamoxifen Citrate I.P equivalent to Tamoxifen 10 mg	10's	Blister	Amber Colored Blister
26	164	Tamoxifen Citrate Tablets IP 20 mg	Each uncoated tablet contains: Tamoxifen Citrate I.P equivalent to Tamoxifen 20 mg	10's	Blister	Amber Colored Blister
27	177	Albendazole Oral	Each 5ml contains:	10ml	Amber	Amber Colored

		Suspension IP 200 mg per 5ml	Albendazole IP 200mg Suitable base qs.	Bottle	Colored Bottle	Bottle
28	186	Domperidone Tablets IP 10 mg	Each film coated tablet contains: Domperidone Maleate IP eq. to Domperidone 10mg	10's	Blister	Transparent
29	187	Domperidone Suspension IP 5mg per 5ml	Each ml contains: Domperidone IP 5mg in suitable base qs.	30 ml	Bottle	Market Standard
30	191	Famotidine Tablets IP 20 mg	Each film coated tablet contains: Famotidine IP 20mg	14's	Blister	Transparent
31	192	Famotidine Tablets IP 40 mg	Each film coated tablet contains: Famotidine IP: 40 mg	14's	Blister	Transparent
32	196	Lactic Acid Bacillus Tablets 60 Million spores	Each uncoated tablet contains: Lactic Acid Bacillus not less than 60M spores	10's	Alu-Alu	Alu-Alu
33	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	Blister	Amber Colored Blister
34	202	Metronidazole Tablets IP 400mg	Each film-coated tablet contains: Metronidazole Tablets IP 400mg Excipients q.s.	10's	Blister	Transparent
35	208	Ondansetron Injection IP 2mg per ml	Each ml contains: Ondansetron Hydrochloride IP eq. to Ondansetron 2 mg	2ml Ampoule	Market Standard	Market Standard
36	209	Ondansetron Tablets IP 4 mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	Blister	Transparent
37	212	Pantoprazole Gastro Resistant Tablets IP 40 mg	Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg	10's	Alu-Alu	Alu-Alu
38	216	Ranitidine Injection IP 25 mg per ml	Each ml contains: Ranitidine Hydrochloride IP eq. to Ranitidine 25mg (1.12g of Ranitidine Hydrochloride is eq. to approximately 1g of Ranitidine)	2ml Ampoule	Market Standard	Amber Colored Ampoules
39	223	Pyridoxine Hydrochloride 10mg, Doxylamine 10mg and Folic Acid 2.5mg Tablets	Each enteric coated tablet contains: Pyridoxine Hydrochloride IP 10mg Doxylamine Succinate 10mg Folic Acid IP 2.5mg	30's	Blister	Blister
40	227	Polyvitamin Tablets NFI (Prophylactic)	Each film-coated tablet contains: Vitamin A 2500 IU Vitamin D3 200IU Vitamin B1 2mg	10's	Blister	Amber Colored Blister

			Vitamin B6 0.5mg Vitamin B2 2mg Niacinamide 25mg Calcium Pantothenate 1mg Vitamin C 50mg Folic Acid 0.2mg			
41	239	Cetirizine Syrup IP 5 mg per 5 ml	Each 5ml contains: Cetrizine Hydrochloride IP 5mg	60 ml	Bottle	Market Standard
42	240	Cetrizine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Cetrizine Hydrochloride IP 10mg	10's	Blister	Transparent
43	245	Etophylline 77mg and Theophylline 23mg Tablets	Each uncoated tablet contains: Etophylline 77 mg Theophylline (Hydrated) 23 mg	10's	Blister	Transparent
44	261	Adenosine Injection IP 6 mg per 2ml	Each ml contains: Adenosine IP 3 mg water for injection IP q.s.	2ml Ampoule	Market Standard	Amber Colored Ampoules
45	267	Atorvastatin Tablets IP 20mg	Each Film Coated tablets Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 20mg	10's	Alu-Alu	Alu-Alu
46	280	Heparin Sodium Injection IP 1000 IU per ml	Each ml contains: Heparin Sodium IP 1000 IU	5 ml	Market Standard	Market Standard
47	287	Losartan Potassium 50mg and Hydrochlorothiazide 12.5mg Tabelts IP	Each Film Coated tablet contains: Losartan Potassium IP 50mg Hydrochlorothiazide IP 12.5 mg	10's	Alu-Alu	Alu-Alu
48	300	Telmisartan Tablets IP 40mg	Each uncoated tablet contains: Telmisartan IP 40 mg	10's	Strip	Alu-Strip
49	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Ampoules	Market Standard	Market Standard
50	311	Disodium Hydrogen Citrate Syrup (Alkalyser) 1.4 gm per 5 ml	Each 5ml contains: Disodium Hydrogen Citrate 1.4gm	100 ml	Market Standard	Amber Colored Bottle
51	314	Alprazolam Tablets IP 0.5 mg	Each uncoated tablet contains: Alprazolam IP 0.50mg	10's	Blister	Transparent
52	317	Carbamazepine Tablets IP 100 mg	Each Uncoated Tablet contains: Carbamazepine IP 100mg	10's	Blister	Amber Colored Blister
53	319	Clonazepam Tablets IP 0.5 mg	Each uncoated tablet contains: Clonazepam IP 0.5mg	10's	Blister	Transparent
54	324	Flunarizine Tablets IP 5 mg	Each uncoated tablet contains: Flunarizine Dihydrochloride equivalent to Flunarizine IP 5mg	10's	Blister	Blister
55	327	Phenytoin Tablets IP 100 mg	Each film coated tablet contains: Phenytoin Sodium IP 100 mg	100's in Bottle	Market Standard	Amber Colored Glass Bottle
56	328	Prochlorperazine Tablets IP 5 mg	Each Uncoated tablet contains: Prochlorperazine Maleate IP 5mg	10's	Strip	Strip
57	336	Allopurinol Tablets IP 100 mg	Each uncoated tablet contains: Allopurinol IP 100 mg	10's	Strip	Strip

58	344	Ciprofloxacin Eye Drops IP 0.3% w/v	Composition: Ciprofloxacin Hydrochloride IP eq. To Ciprofloxacin 0.3 % w/v Benzalkonium Chloride Solution IP 0.025% W/V Purified water IP q.s.	5ml	Market Standard	Market Standard
59	345	Gentamicin Eye Drops IP 0.3% w/v	Composition: Gentamicin Sulphate IP equivalent to Gentamicin 0.3 % w/v Benzalkonium Chloride Solution IP 0.02% w/v (As preservative)	10ml Drops	Market Standard	Market Standard
60	351	Xylometazoline Nasal Drops IP 0.1%w/v	Composition: Xylometazoline Hydrochloride IP 0.1% w/v Benzalkonium Chloride Sodium IP 0.01-0.02%w/v (As preservative)	10ml Drops	Market Standard	Market Standard
61	352	Bupivacaine Hydrochloride Injection IP 5 mg per ml	Each ml contains: Bupivacaine Hydrochloride IP eq. to Anhydrous Bupivacaine 5 mg	20 ml	Market Standard	Amber Colored Glass Vial
62	367	Voglibose Tablets IP 0.3 mg	Each uncoated tablet contains: Voglibose IP 0.3mg	10's	Strip	Strip
63	371	Voglibose Tablets IP 0.2 mg	Each uncoated tablet contains: Voglibose IP 0.2mg	10's	Strip	Strip
64	372	Metformin Hydrochloride Prolonged release Tablets IP 500 mg	Each film coated Prolonged Release tablet contains: Metformin Hydrochloride IP 500mg	10's	Blister	Transparent
65	375	Quinine Sulphate Tablets IP 300 mg	Each film coated tablet contains: Quinine Sulphate IP 300mg	10's	Blister	Transparent
66	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg Excipients q.s.	30's	Blister	Transparent
67	393	Aciclovir Dispersible Tablets IP 800 mg	Each dispersible uncoated tablet contains: Aciclovir IP 800mg	5's	Blister	Transparent
68	396	Liposomal Amphotericin B Injection 50 mg per Vial	Each Vial contains: Liposomal Amphotericin B 50 mg	20 ml	Market Standard	Market Standard
69	407	Ivermectin Tablets IP 12 mg	Each uncoated dispersible tablet contains: Ivermectin IP 12mg	10's	Strip	Alu-Strip
70	416	Prazosin Tablets IP 5 mg	Each film coated tablet contains: Prazosin Hydrochloride IP eq. to Prazosin 5mg	15's	Blister	Transparent
71	421	Nebivolol Tablets IP 5 mg	Each film coated tablet contains: Nebivolol Hydrochloride IP eq. to Nebivolol 5mg	10's	Alu-Alu	Alu-Alu
72	428	Digoxin Tablets IP	Each uncoated tablet contains:	10's	Strip	Strip

		0.25 mg	Digoxin IP 0.25 mg			
73	437	Nifedipine sustained release Tablets IP 20mg	Each sustained release film coated tablet contains: Nifedipine IP 20mg	10's	Blister	Amber Colored Blister
74	439	Olmesartan Medoxomil 40mg and Hydrochlorothiazide 12.5mg Tablets IP	Each film-coated tablet contains: Olmesartan Medoxomil IP 40mg Hydrochlorothiazide IP 12.5mg	10's	Strip	Strip
75	444	Enalapril 10mg and Hydrochlorothiazide 25mg Tablets IP	Each uncoated tablet contains: Enalapril Maleate IP 10 mg Hydrochlorothiazide IP 25 mg	30's	Strip	Strip
76	455	Verapamil Tablets IP 80 mg	Each Film-Coated Tablet contains: Verapamil Hydrochloride IP 80 mg	10's	Blister	Amber Colored Blister
77	456	Atorvastatin Tablets IP 40 mg	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg	10's	Alu-Alu	Alu-Alu
78	473	Pantoprazole 40mg (Enteric Coated) and Levosulpiride 75mg (Sustained Release) Capsules	Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg (As enteric coated pellets) Levosulpride 75mg (As Sustained release pellets)	10's		Alu-Alu
79	475	Sucralfate Suspension 500mg per 5ml	Each 5ml contains: Sucralfate IP 500mg	200 ml	Amber Colored Bottle	Amber Colored Bottle
80	478	Sodium Picosulphate Tablets 10 mg	Each uncoated tablet contains: Sodium Picosulphate 10mg	10's	Blister	Blister
81	480	Esomeprazole 40mg (Enteric-coated) and Levosulpiride 75mg (Sustained release) Capsules	Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Levosulpiride (as sustained release) 75mg	10's	Alu-Alu	Alu-Alu
82	483	Loperamide Capsules IP 2 mg	Each hard gelatin capsule contains: Loperamide Hydrochloride IP 2mg	10's	Blister	Blister
83	486	Pancreatin 170mg and Activated Dimethicone 80mg Tablets	Each enteric-coated tablet contains: Pancreatin 170mg Activated Dimethicone 80mg	10's	Strip	Strip
84	488	Lansoprazole Capsules IP 15 mg	Each hard gelatin capsule contains: Lansoprazole IP 15 mg (as enteric coated granules)	10's	Alu-Alu	Alu-Alu
85	491	Itopride Tablets IP 50 mg	Each Film Coated tablets Contains: Itopride Hydrochloride IP 50 mg	10's	Blister	Blister

86	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	Alu-Alu	Alu-Alu
87	505	Carbimazole Tablets IP 10 mg	Each uncoated tablet contains: Carbimazole IP 10 mg	100's in Bottle	Market Standard	Market Standard
88	506	Levo-Thyroxine Tablets IP 50 mcg	Each uncoated tablet contains: Levo-thyroxine Sodium IP eq. to Anhydrous Levo-Thyroxine 50mcg	100's in Bottle	Amber Colored Bottle	Amber Colored Bottle
89	507	Carbimazole Tablets IP 5 mg	Each uncoated tablet contains: Carbimazole IP 5 mg	10's	Blister	Transparent
90	509	Hydroxychloroquine Tablets IP 200 mg	Each film coated tablets Contains: Hydroxychloroquine sulphate IP 200 mg	10's	Blister	Transparent
91	512	Aceclofenac 100mg, Paracetamol 325mg and Serratiopeptidase 15mg Tablets	Each film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coted form)	10's	Alu-Alu	Alu-Alu
92	528	Paracetamol 325mg, Phenylephrine 10mg and Chlorpheniramine 2mg Tablets	Each uncoated tablet contains: Paracetamol 325 mg Phenylephrine Hydrochloride 10 mg Chlorpheniramine maleate 2 mg	10's	Blister	Transparent
93	529	Levosalbutamol 1.25mg and Ipratropium 500mcg Respules	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25mcg	2.5ml	Market Standard	Market Standard
94	530	Formoterol 6mcg and Budesonide 200mcg Rotacaps	Each capsule contains: Formoterol Fumarate (as Formoterol Fumarate dihydrate IP) 6mcg Budesonide IP 200mcg	30's	Market Standard	Market Standard
95	532	Salmeterol 50mcg and Fluticasone 250mcg Rotacaps	Each capsule contains: Salmeterol (as Salmeterol Xinofoate) 50mcg Fluticasone Propionate IP 250mcg	30's	Market Standard	Market Standard
96	540	Levosalbutamol 1.25mg and Budesonide 1mg Respules	Each 2ml respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2ml	Market Standard	Market Standard
97	543	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	10's	Blister	Transparent
98	558	Fluticasone 50mcg and Azelastine 140mcg Nasal Spray	Each Spray delivers: Fluticasone Propionate 50 mcg Azelastine Hydrochloride 140	70 MDI	Market Standard	Market Standard

			mcg			
99	563	Oxymetazoline Hydrochloride Nasal Drops IP 0.5 mg per ml	Each ml contains: Oxymetazoline Hydrochloride IP 0.5mg in a buffered aqueous solution	10ml	Market Standard	Market Standard
100	569	Sildenafil Tablets IP 50 mg	Each film coated tablet contains: Sildenafil Citrate IP eq. to Sildenafil 50mg	4's	Blister	Amber Colored Blister
101	571	Tamsulosin Hydrochloride (Modified Release) 0.4mg and Dutasteride 0.5mg Tablets	Each film-coated tablet contains: Tamsulosin Hydrochloride 0.4 mg (as modified release tablets) Dutasteride 0.5 mg	15's	Alu-Alu	Alu-Alu
102	583	Cyproheptadine Tablets IP 4 mg	Each uncoated tablet contains: Cyproheptadine Hydrochloride IP 4mg	10's	Blister	Transparent
103	589	Calcium 500mg and Calcitriol 0.25mcg Tablets	Each film coated tablet contains: Calcium Carbonate IP eq. to Calcium 500mg Calcitriol IP 0.25mcg	15's	Blister	Transparent
104	591	Methylcobalamin Injection 500 mcg	Each ml contains: Methylcobalamin IP 500mcg	1ml Ampoules	Market Standard	Amber Colored Ampoules
105	601	Disulfiram Tablets IP 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	Blister	Blister
106	608	Betamethasone Dipropionate and Salicylic Acid Ointment	Contains: Betamethasone Dipropionate 0.05% w/w Salicylic acid 3% w/w	20 gm	Lami Tube	Lami Tube
107	612	Povidone-Iodine Powder 5% W/W	Composition: Povidone-Iodine Powder 5% w/w	10 gm Container	Market Standard	Market Standard
108	627	Etophylline 115mg and Theophylline 35mg Prolonged Release Tablets IP	Each film-coated prolonged release tablet contains: Etophylline 115mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 35mg	10's	Blister	Transparent
109	632	Etamsylate Tablets 250 mg	Each uncoated tablet contains: Etamsylate 250 mg	10's	Strip	Strip
110	650	Mefenamic Acid 500mg and Paracetamol 325mg Tablets	Each uncoated tablet contains: Mefenamic Acid 500mg Paracetamol 325mg	10's	Blister	Transparent
111	661	Gama Benzene Hexachloride 1%w/v and Cetrimide 0.1%w/v lotion	Composition: Gama Benzene Hexachloride 1%w/v Cetrimide IP 0.1% w/v in a suitable base qs.	100 ml	Bottle	Market Standard
112	669	Cefuroxime Axetil Oral Suspension 125mg per 5ml	Each 5ml reconstituted suspension contains: Cefuroxime Axetil 125mg In a suitable base qs.	30 ml	Bottle	Market Standard
113	680	Finasteride Tablets IP	Each film coated tablet	10's	Strip	Strip

		5mg	contains: Finasteride IP 5mg			
114	690	Timolol Maleate Eye Drops IP 0.5 %	Composition: Timolol Maleate IP eq. to Timolol 0.5% w/v Benzalkonium Chloride IP 0.01% w/v (as preservative)	5ml	Market Standard	Market Standard
115	691	Ofloxacin Eye Drops IP 0.3% w/v	Contains: Ofloxacin IP 0.3% w/v	10 ml	Market Standard	Market Standard
116	705	Levofloxacin Infusion IP 500 mg per100 ml	Each ml contains: Levofloxacin 5 mg	100ml	Bottle	Market Standard
117	708	Piroxicam Dispersible Tablets 20 mg	Each uncoated dispersible tablet contains: Piroxicam 20mg	10's	Blister	Amber Colored Blister
118	718	Escitalopram Oxelate 10mg and Clonazepam 0.5mg Tablets IP	Each uncoated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 10mg Clonazepam 0.5mg	10's	Alu-Alu	Alu-Alu
119	728	Dextrose 5%w/v and Sodium Chloride 0.9%w/v Injection IP	Each 100ml contains: Dextrose Anhydrous IP 5.00g Sodium Chloride IP 0.90 g Water for inj. q.s.	500 ml	Market Standard	Transparent
120	733	Progesterone Sustained Release Tablets 200 mg	Each film-coated sustained release tablet contains: Progesterone 200mg (Natural Micronized)	10's	Blister	Transparent
121	739	Cefuroxime Axetil Tablets IP 125mg	Each film coated tablet contains: Cefuroxime Axetil IP equivalent to Cefuroxime 125mg	6's	Alu-Alu	Alu-Alu
122	740	Clarithromycin Tablets IP 250 mg	Each film-coated tablet contains: Clarithromycin IP 250mg	10's	Blister	Transparent
123	747	Glimepiride Tablets IP 3mg	Each uncoated tablet contains: Glimepiride IP 3 mg	10's	Blister	Blister
124	762	Nortriptyline Tablets IP 25mg	Each film coated tablet contains: Nortriptyline Hydrochloride IP equivalent to Nortriptylin 25mg	10's	Blister	Transparent
125	788	Anastrozole Tablets IP 1mg	Each film coated tablet contains: Anastrazole IP 1mg	10's	Blister in Monocarton	Transparent
126	791	Atenolol 25mg and Amlodipine 5mg Tablets IP	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Atenolol IP 25mg	14's	Alu-Alu	Alu-Alu
127	796	Aspirin 75mg (Enteric coated) and Atorvastatin 10mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)	10's	Strip	Strip

128	806	Bicalutamide Tablets IP 50mg	Each film-coated tablet contains: Bicalutamide IP 50mg	10's	Blister	Blister
129	809	Bortezomib Injection IP 3.5 mg	Each vial contains: Bortezomib IP 3.5mg	Vial	Market Standard	Glass Vial
130	814	Cabergoline Tablets IP 0.5mg	Each uncoated tablet contains: Cabergoline IP 0.5mg	4's	Strip	Strip
131	817	Calcium Carbonate 1250mg, Vitamin D3 250IU, Magnesium Oxide 40mg, Manganese Sulphate 1.8mg and Zinc 7.5mg Tablets	Each Film Coated tablet contains: 1250 mg Calcium Carbonate from and organic source (Oyster Shell) Eq. to elemental calcium 500mg Vitamin D3 IP (Stabilised) 250 IU Magenesium Hydroxide IP Eq. to elemental Magnesium 40mg Magnesium sulphate USP Eq. to elemental Manganese 1.8 mg Zinc sulphate monohydrateUSP Eq. to elemental zinc 7.5mg Sodium Borate BP Eq. to elemental Boron 250mg Copper sulphate pentahydrate BP Eq. to Elemental cooper 1mg	10's	Blister	Transparent
132	832	Chlorthalidone Tablets IP 12.5mg	Each uncoated tablet contains: Chlorthalidone IP 12.5mg	10's	Alu-Alu	Alu-Alu
133	835	Glucosamine Sulphate 500mg and Chondroitin 400mg Tablets	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	Alu-Alu	Alu-Alu
134	844	Clonazepam Tablets IP 1mg	Each uncoated tablet contains: Clonazepam IP 1mg	10's	Blister	Blister
135	850	Cyclosporin capsules IP 50mg	Each soft gelatin capsule contains: Cyclosporine IP 50 mg	5's	Alu-Alu	Alu-Alu
136	878	Drotaverine Hydrochloride 80mg and Mefenamic Acid 250mg Tablets	Each film coated tablet contains: Drotaverine Hydrochloride IP 80mg Mefenamic Acid IP 250mg	10's	Blister	Transparent
137	881	Ebastine Tablets IP 10mg	Each film coated tablet contains: Ebastine IP 10mg	10's	Blister	Blister
138	882	Efavirenz Tablets IP 600mg	Each film coated tablet contains: Efavirenz IP 600mg	30's	Bottle	Market Standard
139	885	Ethinylestradiol 0.05mg and Levonorgestrel 0.25mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	Blister	Blister
140	897	Formoterol 6mcg and Fluticasone	Each actuation delivers: Fluticasone Propionate 250	120 MDI	Market Standard	Market Standard

		Propionate 250mcg Inhaler	mcg Formoterol Fumarate Dihydrate 6mcg Suspended in propellant HFA 134a			
141	899	Frusemide 20mg and Spironolactone 50mg Tablets	Each film coated tablet contains: Frusemide IP 20mg Spironolactone IP 50mg	10's	Blister	Blister
142	900	Gabapentin 100mg and Methylcobalamin 500mcg Tablets	Each film coated tablet contains: Gabapentin IP 100mg Methylcobalamin IP 500mcg	10's	Alu-Alu	Alu-Alu
143	912	Hydrochlorothiazide Tablets IP 12.5mg	Each uncoated tablet contains: Hydroclorthiazide 12.5mg	10's	Blister	Transparent
144	916	Imatinib Mesylate Tablets IP 400mg	Each film coated tablet contains: Imatinib mesylate equivalent to imatinib IP 400mg	10's	Alu-Alu	Alu-Alu
145	924	Isoxsuprine Hydrochloride Tablets IP 10mg	Each uncoated tablet contains : Isoxsuprine Hydrochloride IP 10mg	50's	Blister	Amber Colored Blister
146	934	Lenalidomide Capsules 10mg	Each capsule contains: Lenalidomide 10mg	10's in Bottle	Market Standard	Market Standard
147	965	Miconazole 2%w/w and Fluocinolone Acetonide 0.01%w/w Ointment	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15g tubes	Lami Tube in Monocarton	Market Standard
148	975	Nebivolol 5mg and Hydrochlorothiazide 12.5mg IP Tablets	Each uncoated tablet contains : Nebivolol Hydrochloride IP equivalent to Nebivolol 5mg Hydrochlorothiazide IP 12.5mg	10's	Blister	Transparent
149	986	Nitrazepam Tablets I.P 10mg	Each uncoated tablet contains: Nitrazepam IP 10 mg	10's	Blister	Amber Colored Blister
150	994	Oxaliplatin Injection IP 50mg	Each vial contains: Oxaliplatin IP 50mg	Vial with Wfi	Market Standard	Market Standard
151	996	Oxcarbazepine Tablets IP 300mg	Each film coated tablet contains: Oxcarbazepine IP 300mg	10's	Blister	Transparent
152	1008	Phytomenadione Injection (Vitamin K1) IP 1mg per 0.5ml	Each 0.5ml contains: Phytomenadione 1 mg WFI q.s.	0.5 ml Ampoule	Market Standard	Market Standard
153	1026	Propranolol Tablets IP 10mg	Each uncoated tablet contains: Propranolol Hydrochloride IP 10mg	10's	Blister	Amber Colored Blister
154	1032	Quetiapine Tablets IP 100mg	Each film coated tablet contains: Quetiapine Fumarate IP equivalent to Quetiapine 100mg	10's	Blister	Amber Colored Blister
155	1072	Tamsulosin Hydrochloride Prolonged Release Capsules IP 0.4mg	Each hard gelatin capsule contains: Tamsulosin Hydrochloride IP 400mcg (As prolonged release pellets)	10's	Blister	Blister
156	1081	Tizanidine Tablets I.P	Each uncoated tablet contains:	10's	Blister	Transparent

		2mg	Tizanidine Hydrochloride IP equivalent to Tizanidine 2 mg			
157	1097	Vitamin A Capsule IP 25000 IU	Each soft gelatin capsule contains: Vitamin A (as concentrate oil) IP 25000 IU	30's	Blister	Blister
158	1099	Metformin Hydrochloride 500mg and Voglibose 0.3mg Tablets	Each uncoated tablet contains: Voglibose 0.3 mg Metformin Hydrochloride 500 mg	10's	Blister	Transparent
159	1104	Zoledronic Acid Injection IP 4mg per ml	Each ml contains Zoledronic Acid IP equivalent to Zoledronic Acid (Anhydrous) 4mg Water for Injection IP q.s	5ml Vial with WFI	Market Standard	Market Standard
160	1123	Clomipramine Hydrochloride Sustained release Tablets 75mg	Each film coated sustained release tablet contains: Clomipramine Hydrochloride 75 mg	10's	Blister	Transparent
161	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	Blister	Transparent
162	1149	Lisinopril Tablets IP 10mg	Each uncoated tablet contains: Lisinopril IP equivalent to anhydrous Lisinopril 10 mg	15's	Blister	Blister
163	1166	Mefenamic Acid Tablets 250 mg	Each uncoated tablet contains: Mefenamic Acid 250 mg	10's	Blister	Blister
164	1167	Mefenamic Acid Tablets 500 mg	Each uncoated tablet contains: Mefenamic Acid 500 mg	10's	Blister	Blister
165	1211	Docetaxel Injection IP 80 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with Wfi	Market Standard	Market Standard
166	1212	Docetaxel Injection IP 120 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with Wfi	Market Standard	Market Standard
167	1213	Erlotinib Tablets IP 150 mg	Each film coated tablet contains: Erlotinib Hydrochloride IP eq. to Erlotinib 150mg	10's Bottle	Bottle	White Plastic Bottle
168	1215	Pemetrexed Injection IP 100 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 100 mg Water for Injection IP q.s	Vial	Market Standard	Transparent Glass Vial
169	1216	Pemetrexed Injection IP 500 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 500 mg Water for Injection IP q.s	Vial	Market Standard	Glass vial
170	1217	Temozolomide Capsules IP 100 mg	Each hard gelatin capsule contains Temozolomide IP 100mg	5's in Bottle	Market Standard	White Plastic Bottle
171	1218	Temozolomide Capsules IP 250 mg	Each hard gelatin capsule contains	5's in Bottle	Market Standard	Market Standard

			Temozolomide IP 250mg			
172	1220	Oseltamivir Capsules IP 75mg	Each hard gelatin capsule contains: Oseltamivir Phosphate IP 98.5 mg equivalent to Oseltamivir 75mg	10's	Alu-Alu	Alu-Alu
173	1223	Iron 50mg, Folic Acid 0.5mg and Zinc 61.8mg Capsules	Each hard gelatin capsule contains: Elemental Iron 50mg Folic Acid IP 0.5mg Zinc Sulphate Monohydrate IP 61.8mg	15's	Blister	Transparent
174	1225	Orlistat Capsules 120 mg	Each hard gelatin capsule contains: Orlistat 120 mg (as pellets)	10's	Alu-Alu	Alu-Alu
175	1246	Fluconazole Tablets IP 150 mg	Each uncoated tablet contains: Fluconazole IP 150mg	1's	Blister	Blister
176	1281	Chlordiazepoxide Tablets IP 10 mg	Each Film Coated Tablet contains Chlordiazepoxide IP 10 mg	10's	Blister	Amber Colored Blister
177	1307	Ethinylestradiol 0.03mg and Desogestrel 0.15mg Tablets IP	Each uncoated tablet contains Ethinylestradiol IP 0.03 mg Desogestrel IP 0.15 mg	21's	Blister in Monocarton	Transparent
178	1308	Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.03 mg Levonorgestrel IP 0.15 mg	21's	Blister in Monocarton	Transparent
179	1367	Olmesartan 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg Tablets	Each film coated tablet contains: Olmesartan Medoximil 20 mg Amlodipine Besilate equivalent to Amlodipine 5 mg Hydrochlorthiazide 12.5 mg	10's	Alu-Alu	Alu-Alu
180	1368	Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg Tablets	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorthiazide IP 12.5 mg	10's	Strip	Alu-Strip
181	1375	Phenobarbitone Tablets IP 60 mg	Each uncoated tablet contains: Phenobarbitone IP 60 mg	30's	Strip	Alu-Strip
182	1382	Prasugrel Tablets IP 10 mg	Each film coated tablet contains: Prasugrel Hydrochloride equivalent to Prasugrel IP 10 mg	10's	Alu-Alu	Alu-Alu
183	1393	Rosuvastatin 10mg and Clopidogrel 75mg Capsules	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg Clopidogrel IP 75mg	10's	Alu-Alu	Alu-Alu
184	1427	Trypsin 48mg, Bromelain 90mg and	Each enteric coated tablet contains:	10's	Alu-Alu	Alu-Alu

		Rutoside Trihydrate 100mg Tablets	Trypsin 48 mg Bromelain 90 mg Rutoside Trihydrate 100 mg			
185	1432	Tobramycin Eye Drops 0.3%w/v	Contains: Tobramycin Sulphate e.q to Tobramycin Anhydrous 0.3%w/v Benzalkonium Chloride Solution 0.02% v/v (as preservative)	5 ml	Market Standard	Market Standard
186	1435	Capecitabine Tablets IP 500mg	Each film cotated tablet cotains: Capecitabine IP 500mg	10's	Strip	Strip
187	1437	Cefpodoxime Proxetil Oral Suspension IP 50mg	Each 5 ml of the Reconstituted suspension contains: Cefpodoxime Proxetil IP equivalent to equivalent to Cefpodoxime 50mg	30 ml	Market Standard	Market Standard
188	1438	Metformin Hydrochloride 500mg (Sustained Release), Glimepiride 2mg and Voglibose 0.2mg Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (Sustained-release form) Glimepiride IP 2mg Voglibose IP 0.2mg	10's	Blister	Transparent
189	1441	Nirmal (Nicotine Polacrilex Chewing Gum 2 mg)	Each Gum Contains: Nicotine Polacrilex USP equivalent to Nicotine 2 mg	1 x 9's (mono carton pack)	Blister	Transparent
190	1445	Jan Pudina Soft Gel Capsules	Each soft gel capsule contains: Pudina ka Satva (Mentha Sylvestria) 180mg Ajwain Oil (Trachyspermum Ammi) 20mg Anethi Oil (Anthum Graveolens) 5mg Tulsi Oil (Ocimum Sanctum) 5mg Clove Oil (Syzygium Aromaticum) 1mg excipients …. qs	10's	Blister	Transparent
191	1452	Pyridoxine Hydrochloride Sustained release tablets 100mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	Blister	Amber Colored Blister
192	1455	L-Arginine Granules 3g	Each sachet contains: L-Arginine IP 3gm	5 gm	Market Standard	Market Standard
193	1473	Hand Sanitizer (Ethanol 70% v/v and Chlorhexidine Gluconate 0.5% w/v)	Composition: Chlorhexidine Gluconate Solution IP 0.5%v/v Ethanol IP 70% v/v	100 ml Bottle	Plastic Transparent Bottle	Plastic Transparent Bottle
194	1475	Hand Sanitizer 250 ml (Each pack contains: Ethanol 70% v/v and Chlorhexidine	Each pack contains: Ethanol 70% v/v Chlorhexidine Gluconate 0.5% w/v	250 ml	Bottle	Market Standard

		Gluconate 0.5% w/v)				
195	1476	Hydroxychloroquine Tablet IP 400 mg	Each film coated tablet contains: Hydroxychloroquine Sulphate IP 400mg	10's	Blister	Blister
196	1497	Acitretin Capsules IP 25 mg	Each hard gelatin capsule contains: Acitretin IP 25mg	10's	Blister	Transparent
197	1499	Adalimumab Injection 40mg per 0.8 ml (For subcutaneous use only)	Each sterile single-use prefilled pen contains: Adalimumab 40 mg WFI	0.8 ml in 1 prefilled syringe	Market Standard	Market Standard
198	1502	Amiodarone Tablets IP 100 mg	Each uncoated tablet contains: Amiodarone IP 100 mg	10's	Blister	Transparent
199	1506	Amoxycillin 80mg and Potassium Clavulanate 11.4mg Oral Suspension IP	Each ml contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 80mg Potassium clavulanate diluted IP equivalent to Clavulanic Acid 11.4mg	10 ml	Market Standard	Market Standard
200	1511	Antioxidant Capsules	Each soft gelatin capsule contains: Beta Carotene 30 mg Zinc Sulphate Monohydrate 27.5 mg Selenium Dioxide 200 mcg (as Selenious Acid) Manganese 2 mg (as Manganese Sulphate Monohydrate) Copper 1 mg (as Copper Sulphate Pentahydrate)	30's	Blister	Amber Colored Blister
201	1515	Atorvastatin 10mg and Aspirin 150mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 150mg (as gastro-resistant)	15's	Strip	Strip
202	1523	Beclomethasone 0.025%w/v and Clotrimazole 1%w/v Lotion	Composition: Beclomethasone 0.025%w/v Clotrimazole 1% w/v	30 ml	Lami Tube in Monocarton	Bottle
203	1525	Betahistine Tablets IP 16 mg	Each uncoated tablet contains: Betahistine IP 16mg	15's	Alu-Alu	Alu-Alu
204	1526	Betahistine Tablets IP 24 mg	Each uncoated tablet contains: Betahistine IP 24mg	15's	Strip	Strip
205	1531	Bisoprolol Fumarate Tablets 2.5 mg	Each film coated tablet contains: Bisoprolol Fumarate 2.5 mg	10's	Blister	Transparent
206	1538	Calcium Citrate Malate 250mg, Calcitriol 0.25mcg and Vitamin K2-7	Each film coated tablet contains: Calcium citrate Malate equivalent to Elemental	10's	Strip	Strip

		50mcg Tablets	Calcium 250 mg Calcitriol 0.25 mcg Vitamin K2-7 50 mcg			
207	1553	Cefpodoxime Oral Suspension IP 100mg	Each 5 ml of reconstituted suspension contains: Cefpodoxime Proxetil IP equivalent to Cefpodoxime 100 mg	30 ml	Market Standard	Market Standard
208	1574	Clobazam Tablets IP 10 mg	Each uncoated tablet contains: Clobazam IP 10 mg	15's	Blister	Blister
209	1575	Clobetasol Propionate 0.05%w/w and Gentamicin 0.1%w/w Cream	Contains: Clobetasol Propionate 0.05% w/w Gentamicin 0.1% w/w	25 g	Lami Tube in Monocarton	Market Standard
210	1578	Clobetasol Propionate 0.05%w/w and Salicylic Acid 3%w/w Ointment	Contains: Clobetasol Propionate 0.05% w/w Salicylic Acid 3% w/w	20g	Lami Tube in Monocarton	Lami Tube
211	1583	Clotrimazole Mouth Paint 1% w/v	Contains: Clotrimazole 1% In Glycerine and Propylene Glycol base q.s	25 ml	Bottle	Market Standard
212	1584	Coenzyme Q10 (Ubidecarenone) and L-Carnitine Tablets	Each film coated tablet contains: Ubidocarenone 30 mg L-Carnitine L-Tartrate equivalent to L-carnitine 500 mg	10's	Alu-Alu	Alu-Alu
213	1586	Colistin (Colistimethate Sodium) Injection IP 4.5 Million IU	Each vial contains: Colistimethate Sodium IP 45,00,000 IU as sterile powder for reconstitution	Vial (10 ml)	Market Standard	Transparent Glass Vial
214	1602	Divalproex Tablets IP 500 mg	Each enteric coated tablet contains: Divalproex Sodium equivalent to Valproic Acid 500mg	10's	Strip	Alu-Strip
215	1607	Drotaverine Hydrochloride Tablets IP 80 mg	Each film coated tablet contains: Drotaverine Hydrochloride IP 80 mg	15's	Blister	Transparent
216	1611	Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg Tablets IP	Each film coated tablet contains: Emtricitabine IP 200mg Tenofovir Disoproxil Fumarate IP 300mg	30's	Bottle	White Plastic Bottle
217	1613	Eplerenone Tablets IP 25 mg	Each film coated tablet contains: Eplerenone IP 25 mg	10's	Blister	Transparent
218	1627	Formoterol Fumarate 6mcg and Budesonide 400mcg	Each actuation delivers: Formoterol Fumarate 6 mcg (as Formoterol Fumarate	120 MD	Market Standard	Market Standard

		Inhaler	Dihydrate) Budesonide 400 mcg			
219	1628	Formoterol Fumarate 12mcg and Budesonide 400mcg Powder for Inhalation IP	Each Capsule Contains: Formoterol Fumarate 12 mcg (as Formoterol Fumarate Dihydrate) Budesonide 400 mcg	30's	Market Standard	Market Standard
220	1645	Gliclazide 60mg (Modified Release) and Metformin 500mg (Extended Release) Tablets	Each uncoated bilayered tablet contains: Gliclazide 60mg (in modified release form) Metformin Hydrochloride 500mg (in extended release form)	10's	Blister	Blister
221	1662	Hydroxyzine Tablets IP 25mg	Each Film-coated tablet contains: Hydroxyzine IP 25mg	15's	Blister	Blister
222	1664	Ibuprofen 100mg and Paracetamol/Acetaminophen 162.5mg Oral Suspension	Each 5 ml contains: Ibuprofen 100mg Paracetamol/Acetaminophen 162.5mg	100 ml	Bottle	Market Standard
223	1668	Carbonyl Iron 100mg, Folic Acid 1.5mg and Vitamin B12 15mcg with Zinc Capsules	Each hard gelatin capsule contains: Carbonyl Iron 100 mg Folic Acid 1.5 mg Cynocobalamine (Vitamin B12) 15 mcg Zinc Sulphate Monohydrate 61.8 mg (eq. to 22.5mg of elemental Zinc)	10's	Blister	Blister
224	1671	Ivabradine Tablets 5mg	Each film-coated tablet contains: Ivabradine 5mg	15's	Blister	Transparent
225	1679	Lecithin Capsules 1000mg	Each soft gelatin capsule contains: Lecithin 1000 mg	10's	Blister	Transparent
226	1683	Levocetirizine Dihydrochloride Tablets IP 10mg	Each film coated tablets contains: Levocetrizine Dihydrochloride IP 10mg	15's	Alu-Alu	Alu-Alu
227	1685	Levodropropizine 30mg and Chlorpheniramine Maleate 2mg Syrup	Each 5 ml contains: Levodropropizine 30mg Chlorpheniramine Maleate 2mg	120 ml	Amber Colored Bottle	Amber Colored Bottle
228	1709	Minoxidil Solution 5%	Composition: Minoxidil IP 5% w/v	60 ml	Market Standard	Amber Colored Bottle
229	1720	Nicoumalone/Acenocoumarol Tablets IP 1 mg	Each uncoated tablet contains: Nicoumalone/Acenocoumarol IP 1mg	10's	Strip	Strip
230	1721	Nicoumalone/Acenocoumarol Tablets IP 3 mg	Each Uncoated Tablet contains: Nicoumalone/Acenocoumar ol IP 3mg	10's	Strip	Strip
231	1733	Omeprazole 20mg and Domperidone 30mg (Sustained Release) Capsules	Each hard gelatin Capsule contains: Omeprazole 20 mg (as enteric coated pellets)	15's	Strip	Alu-Strip

			Domperidone 30 mg (as sustained release pellets)			
232	1739	Pancreatin Capsules 10000	Each hard gelatin capsule contains: Pancreatin Minimicrospheres eq. to Pancreatin IP 150 mg Declared enzymes activity per capsule: Amylase 8000 units Lipase 10,000 units Protease 600 units	10's	Strip	Alu-Strip
233	1740	Pancreatin Capsules 25000	Each hard gelatin capsule contains: Pancreatin Minimicrospheres eq. to Pancreatin IP 300 mg Declared enzymes activity per capsule: Amylase 18,000 units Lipase 25,000 units Protease 1,000 units	10's	Strip	Alu-Strip
234	1743	Paracetamol Drops 100 mg per ml	Each ml contains: Paracetamol IP 100 mg	15 ml	Market Standard	Market Standard
235	1745	Paracetamol 125 mg, Phenylephrine 5 mg and Chlorpheniramine 1 mg Suspension	Each 5 ml of suspension contains: Paracetamol 125 mg Phenylephrine 5 mg Chlorpheniramine 1 mg	60 ml	Bottle	Market Standard
236	1747	Paracetamol 162.5 mg and Tramadol 18.75 mg Tablet	Each Film-coated tablet contains: Paracetamol 162.5 mg Tramadol 18.75 mg	10's	Blister	Blister
237	1753	Paracetamol 500 mg, Phenylephrine 10 mg and Chlorpheniramine 2 mg Tablet	Each Film-coated tablet contains: Paracetamol 500 mg Phenylephrine 10 mg Chlorpheniramine 2 mg	10's	Blister	Blister
238	1755	Paracetamol Suspension IP 120 mg	Each 5 ml contains: Paracetamol IP 120 mg	60 ml	Market Standard	Amber Colored Bottle
239	1774	Racecadotril Capsule IP 100 mg	Each Hard Gelatin capsule contains: Racecadotril 100 mg	15's	Blister	Transparent
240	1783	Rosuvastatin IP 20mg and Fenofibrate IP 160mg Tablets	Each film coated tablets contains: Rosuvastatin Calcium equivalent to Rosuvastatin IP 20mg Fenofibrate IP 160mg	10's	Strip	Strip
241	1797	Saroglitazar Tablet 4mg	Each Uncoated Tablet contain- Saroglitazar 4mg	10's	Alu-Alu	Alu-Alu Blister
242	1814	Telmisartan 40mg, Chlorthalidone 12.5mg and Amlodipine 5mg Tablets	Each film coated tablet contains: Telmisartan 40 mg Chlorthalidone 12.5 mg Amlodipine Besilate equivalent to	10's	Strip	Strip

			Amlodipine 5 mg			
243	1824	Tolvaptan Tablets 15mg	Each uncoated tablet contains: Tolvaptan IP 15mg	10's	Alu-Alu	Alu-Alu
244	1828	Torsemide Tablets IP 5mg	Each uncoated tablet contains: Torsemide IP 5mg	15's	Blister	Transparent
245	1833	Ursodeoxycholic Acid Tablets IP 150mg	Each uncoated tablets contains: Ursodeoxycholic Acid IP 150mg	15's	Blister	Amber Colored Blister
246	1972	Amoxycillin 500mg, Clavulanic Acid 125mg and Lactic Acid Bacillus 60 Million Spores Tablets	Each film coated tablet contains Amoxycillin Trihydrate IP Equivalant to Amoxyxillin 500 mg Potassium Clavulanate Diluted IP Equivalant to Clavulanic acid 125 mg Lactic Acid Bacillus-60 million spores	10's	Alu-Alu	Alu-Alu
247	1978	Cefdinir Capsule IP 300mg	Each hard gelatin capsule contains: Cefdinir IP 300 mg	10's	Alu-Alu	Alu-Alu
248	1982	Cefixime 100Mg and Potassium Clavulanate Acid 62.5 Mg Tablets	Each Film coated tablet contains Cefixime Trihydrate IP Equivalant to Anhydrous Cefixime 100 mg Potassium Clavulanate equivalent to Clavulanic Acid 62.5mg	10's	Alu-Alu	Alu-Alu
249	2072	Atorvastatin 10mg, Aspirin 75mg and Clopidogrel 75mg Capsules	Each hard gelatin capsule contais: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (as film coated pellets) Aspirin 75mg (as gestro-resistant pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as film coated pellets)	10's	Alu-Alu	Alu-Alu
250	2076	Atorvastatin Tablets IP 5mg	Each Film Coated tablets Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 5mg	10's	Blister	Transparent
251	2082	Calcium Dobesilate Monohydrate Capsules 500mg	Each hard gelatin capsule contains: Calcium Dobesilate Monohydrate eq. to Calcium Dobesilate Anhydrous 500mg	10's	Alu-Alu	Alu-Alu
252	2088	Carvedilol Phosphate Extended Release Tablets 10mg	Each film coated extended release tablet contains: Carvedilol Phosphate 10mg	10's	Blister	Blister
253	2089	Carvedilol Phosphate Extended Release Tablets 20mg	Each film coated extended release tablet contains: Carvedilol Phosphate 20mg	10's	Blister	Blister
254	2090	Carvedilol Tablets IP 12.5 mg	Each film coated tablet contains: Carvedilol IP 12.5mg	10's	Blister	Blister

255	2091	Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets	Each film coated tablet contains: Cilnidipine 10mg Chlorthalidone 12.5mg	10's	Blister	Transparent
256	2092	Metoprolol Succinate (extended release) 25mg and Cilnidipine 10mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate eq. to Metoprolol Tartarate 25mg (As extended-release form) Cilnidipine 10mg	10's	Blister	Amber Colored Blister
257	2093	Metoprolol Succinate (extended release) 50mg and Cilnidipine 10mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate eq. to Metoprolol Tartarate 50mg (As extended-release form) Cilnidipine 10mg	10's	Blister	Transparent
258	2104	Divalproex Sodium Extended Release Tablets IP 250 mg	Each film coated prolonged release tablet contains: Divalproex Sodium IP eq. to Valproic Acid 250mg	10's	Alu-Alu	Alu-Alu
259	2105	Dosulepin (Dothiepin) Tablets IP 50mg	Each film coated tablet contains: Dosulepin Hydrochloride 50 mg (Formerly Dothiepin Hydrochloride)	10's	Blister	Transparent
260	2106	Doxofylline (Sustained-release) 400mg and Montelukast 10mg Tablets	Each uncoated bilayered tablet contains: Doxofylline IP (As sustained-release form) Montelukast Sodium IP eq to Montelukast 10mg	10's	Alu-Alu	Alu-Alu
261	2107	Etizolam 0.5mg and Propranolol Hydrochloride 20mg Tablets	Each film coated tablet contains: Etizolam 0.5mg Propranolol Hydrochloride 20mg	10's	Blister	Transparent
262	2113	Lacosamide Tablets 100mg	Each film coated tablet cotains: Lacosamide 100mg	10's	Blister	Blister
263	2116	Methylprednisolone Tablets IP 16mg	Each uncoated tablet contains: Methylprednisolone IP 16mg	10's	Blister	Transparent
264	2119	Miconazole Nitrate Cream IP 2% w/w	Composition: Miconazole Nitrate IP 2% w/w Suitable cream base q.s	15g tubes	Lami Tube in Monocarton	Market Standard
265	2120	Mometasone Aqueous Nasal Spray IP 0.05%w/v (nasal suspension in a pressurise container)	Each actuation delivers: Mometasone Furoate 0.05% w/v suitable aqueous base qs.	120 MDI	Market Standard	Market Standard
266	2122	Mycophenolate Sodium Gastro-resistant Tablets	Each enteric coated tablet cotains: Mycophenolate Sodium	10's	Alu-Alu	Alu-Alu

		360mg	eq. to Mycophenolic Acid 360mg			
267	2123	Metformin Hydrochloride (sustained-relase) 500mg and Myo-Inositol 600mg Tablets	Each film coated bilayered tablet contains: Metformin Hydrochloride 500mg (as sustained-release form) Myo-Inositol 600mg	10's	Alu-Alu	Alu-Alu
268	2124	Nitroglycerin Controlled Release Tablets 6.4 mg	Each uncoated controlled release tablet contains: Diluted Nitroglycerin IP eq. to Nitroglycerin 6.4mg	30's in Bottle	Bottle	Market Standard
269	2125	Nortriptyline Tablets IP 10mg	Each film coated tablet contains: Nortriptyline Hydrochloride IP eq. to Nortriptyline 10mg	10's	Blister	Blister
270	2127	Oxcarbazepine Tablets IP 150mg	Each film coated tablet contains: Oxcarbazepine IP 150mg	10's	Blister	Blister
271	2135	Spironolactone 50mg and Torasemide 20mg Tablets	Each uncoated tablet contains: Torsemide 20mg Spironolactone 50mg	10's	Blister	Blister
272	2137	Telmisartan 40mg, Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets	Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Chlorthalidone IP 12.5 mg	10's	Alu-Alu	Alu-Alu
273	2138	Torsemide Tablets IP 100mg	Each uncoated tablet contains: Torsemide IP 100mg	10's	Blister	Blister
274	2139	Valsartan Tablets IP 40 mg	Each film-coated tablet contains: Valsartan IP 40 mg	10's	Blister	Blister
275	2141	Warfarin Tablets IP 1mg	Each uncoated tablet contains: Warfarin Sodium Clathrate IP equivalent to Warfarin sodium (anhydrous) 1mg	10's	Blister	Blister
276	2143	Zinc Sulphate Dispersible Tablets IP 20mg	Each uncoated dispersible tablet contains: Zinc Sulphate Monohydrate IP eq. to elemental Zinc 20mg	10's	Blister	Blister
277	2147	Estradiol Tablets 2mg	Each film coated tablet contains: Estradiol (as hemihydrate) eq. to Anhydrous Estradiol 2mg	28's	Blister	Blister
278	2162	Eberconazole Cream 1% w/w	Composition: Each gram Contains Eberconazole Nitrate IP equivalent to Eberconazole 10mg In a Cream base q.s.	30 g	30gm Lami tube	Market Standard
279	2204	Tenofovir Alfenamide Tablets 25mg	Each film coted tablet Contain : Tenofovir Alfenamide 25mg	30's in Bottle	Bottle in Monocarton	Market Standard
280	2221	Alpha Ketoanalouge and Essential Amino Acid Tablets	Each film coated tablet contains: Alpha-Keto, Isoleucine, Calcium Salt 67mg	10's	Alu-Alu	Alu-Alu

			Alpha-Keto, Leucine, Calcium Salt 101mg Alpha-Keto, Phenylalanine, Calcium Salt 68mg Alpha-Keto-Valine, Calcium Salt 86mg Alpha-Hydroxy Methionine, Calcium Salt 59mg Threonine 53mg Tryptophan 23mg Histidine 38mg Tyrosine 30mg Lysine Acetate 105mg Total Nitrogen content 36mg Calcium content per tablet 50mg			
281	2222	Allopurinol Tablets IP 300 mg	Each uncoated tablet contains: Allopurinol IP 300 mg	10's	Alu-Alu	Alu-Alu
282	2223	Amisulpride Tablets IP 300mg	Each uncoated tablet contains: Amisulpride IP 300mg	10's	Blister	Transparent
283	2225	Acetylcysteine Effervescent Tablets 600mg	Each effervescent tablet contains: N-Acetylcystein 600mg	10's	Alu-Alu	Alu-Alu
284	2283	Abiraterone Acetate Tablets 250mg	Each uncoated Tablet contains Abiraterone Acetate 250Mg	120's Bottle	Bottle in Monocarton	Market Standard
285	2319	Ketorolac (0.5% W/V) and Moxifloxacin (0.5% W/V) Eye Drops	Composition; Ketorolac Tromethamine 0.5%w/v Moxifloxacin Hydrochloride equivalent to Moxifloxacin 0.5% w/v	5ml Drop bottle in Mono carton	Mono Carton containing Screw cap dropper bottle for Ophthalmic Solution	Market Standard
286	2320	Lactic Acid 1.2% W/V Intimate Hygiene Wash	Composition Lactic acid 1.2 % w/v Other ingredients Tea Tree oil, Aloe vera gel, Glycerin, Preservative and other required additives like cleansing, humectant and emollient agents Perfume- Tea tree, Mint pH: 3.5 - 4.5	90ml in Mono carton	Flip top cap HDPE bottle	Market Standard
287	2326	Lutein, Astaxanthin, Zeaxanthin, Omega 3 Fatty Acid Capsule	Each soft gelatin capsule contains; Omega-3 fatty acid 500 mg Lutein 10 mg Astaxanthin 2 mg Zeaxanthin 2 mg	10's	Blister	Transparent
288	2327	Omega 3 Fatty Acid 500 mg EPA 150 mg DHA 100 mg Bilberry Extract 50	Each Soft gelatin capsule contains: Omega 3 Fatty Acid 500 mg EPA 150 mg DHA 100 mg	30's Bottle	Bottle in Monocarton	Market Standard

		mg Lutein 20% & Zeaxanthin 4%- 25 mg Beta carotene 4.8 mg Vitamin D3 10 mcg Capsules	Bilberry Extract 50 mg Lutein 20% & Zeaxanthin 4%- 25 mg Beta carotene 4.8 mg Vitamin D3 10 mcg			
289	2328	Methylcobalamin 1500 mcg, Vitamin B6 (Pyridoxine) 5mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg Capsule	Each Soft gelatin capsule contains Methylcobalamin 1500 mcg Vitamin B6 (Pyridoxine) 5 mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg	10's	Alu-Alu	Market Standard
290	2330	Modafinil Tablets IP 100mg	Each uncoated tablet contains Modafinil IP 100 mg	10's	Alu-Alu	Alu-Alu
291	2332	Nicoumalone (Acenocoumarol) 2mg Tablets	Each Uncoated tablet contains Nicoumalone IP 2 mg (Acenocoumarol)	10's	Alu-Alu	Market Standard
292	2335	Obeticholic Acid 10 mg Tablets	Each Film coated tablet contains Obeticholic acid 10 mg	10's	Alu-Alu	Market Standard
293	2336	Obeticholic Acid 5 mg Tablets	Each Film coated tablet contains Obeticholic acid 5 mg	10's	Alu-Alu	Market Standard
294	2344	Procyclidine Tablets IP 5mg	Each Uncoated tablet contains Procyclidine Hydrochloride IP 5 mg	10's	Blister	Blister
295	2347	S-Adenosyl L-Methionine 200mg Tablets	Each Film coated Tablet contains S-Adenosyl L-Methionine Disulfate Tosylate equivalent To S-Adenosyl L-Methionine Tablets 200 mg Tablets 200 mg Additive as per Nutraceutical Regulation issued by FSSAI	10's	Alu-Alu	Market Standard
296	2349	Sevelamer 800mg Tablets	Each Film coated tablet contains Sevelamer Carbonate 800 mg	10's	Alu-Alu	Market Standard
297	2350	Tapentadol 100mg Extended Release Tablet	Each Film coated extended Release tablet contains Tapentadol Hydrochloride IP equivalent To Tapentadol 100 mg	10's	Alu-Alu	Market Standard
298	2354	Topiramate IP 50 mg Tablets	Each Film coated tablet contains Topiramate IP 50 mg	10's	Alu-Alu	Market Standard
299	2356	Valacyclovir Tablets IP 500 mg	Each Film coated tablet contains Valacyclovir Hydrochloride equivalent To Valacyclovir IP 500 mg	3's in Mono carton	Alu-Alu	Market Standard
300	2357	Venlafaxine Prolonged Release Capsule IP 37.5 mg	Each hard Gelatin capsule contains Venlafaxine Hydrochloride	10's	Blister	Transparent

			equivalent To Venlafaxine IP 37.5 mg (as prolonged release pellets)			
301	2358	Venlafaxine Prolonged Release 75 mg IP Capsule	Each hard Gelatin capsule contains Venlafaxine Hydrochloride equivalent To Venlafaxine IP 75 mg (as prolonged release pellets)	10's	Blister	Transparent
302	2360	Vildaglipitin 100mg Extended Release Tablet	Each extended release tablet contains Vildagliptin 100 mg	10's	Alu-Alu	Market Standard
303	2365	Ketoconazole 2 % w/v Shampoo pouch, 30 ml	Each pouch contains Ketoconazole 2 % w/v	30ml Pouch	Mono carton containing 30 shampoo pouch	Market Standard
304	2370	Nebivolol 5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 5mg Cilnidipine IP 10 mg	10's	Alu-Alu	Market Standard
305	2371	Nebivolol 2.5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 2.5mg Cilnidipine IP 10 mg	10's	Alu-Alu	Market Standard
306	2385	Apixaban Tablets 2.5mg	Each Film Coated tablet contains:Apixaban 2.5mg	10's	Alu-Alu	Market Standard
307	2386	Apixaban Tablets 5mg	Each Film Coated tablet contains:Apixaban 5mg	10's	Alu-Alu	Market Standard
308	2392	Azelnidipine 16 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 16 mg	10's	Blister	Market Standard
309	2393	Telmisartan 40 mg and Azelnidipine 8 mg Tablets	Each Film coated bi-layered tablet contains: Telmisartan IP 40 mg Azelnidipine IP 8 mg	10's	Composite Blister	Market Standard
310	2394	Azelnidipine 8 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 8 mg	10's	Blister	Market Standard
311	2397	Bethanechol Chloride 25 mg Tablets	Each Uncoated tablet contains: Bethanechol Chloride 25 mg	10's	Composite Blister	Market Standard
312	2404	Ciclopirox olamine Cream 1% w/v, 50 gm Lami Tube	Each lami tube contains: Ciclopirox olamine USP 1% w/w Cream Base q.s.	50 gm lami tube in mono carton	Lami Tube in Monocarton	Market Standard
313	2414	Diclofenac Diethylamine 1.16% w/w, Sesame Oil 2.50% w/w, Linseed Oil and Menthol Gel	Each lami tube contains:Diclofenac Diethylamine IP 1.16% w/w equivalent to Diclofenac Sodium 1% w/w Sesame Oil IP 2.50% w/w Linseed Oil BP 0.50% w/w, Methylsalicylate IP 10% w/w Menthol 5% w/w Gel Base q.s.	30 g	Lami Tube in Monocarton	Market Standard
314	2416	Eltrombopag Tablets	Each Film coated tablet	7's	Composit	Market

		25mg	contains: Eltrombopag Olamine equivalent to Eltrombopag 25 mg as Eltrombopag free acid		e Blister in mono carton	Standard
315	2417	Eltrombopag Tablets 50mg	Each Film coated tablet contains: Eltrombopag Olamine equivalent to Eltrombopag 50 mg as Eltrombopag free acid	7's	Composit e Blister in mono carton	Market Standard
316	2420	Faropenem 200mg and Clavulanic Acid 125mg Tablets	Each Film coated tablet contains: Faropenem Sodium Hydrate JP equivalent to Faropenem 200mg Potassium Clavulanate equivalent to Clavulanic Acid 125mg	6's	Alu-Alu	Market Standard
317	2424	Itraconazole (1% w/w) gel, 15 g Lamitube	Each Lamitube contains: Itraconazole 1% w/w Preservative Gel base q.s.	15g tubes	Lami Tube in Monocar ton	Market Standard
318	2425	Ivermectin Cream 1% w/w	Each gram contains: Ivermectin 1% w/w Cream base q.s.	15g tubes	Lami Tube in Monocar ton	Market Standard
319	2426	Leflunomide 10 mg Tablets	Each Film coated tablet contains: Leflunomide IP 10 mg	10's	Alu-Alu	Market Standard
320	2427	Lenalidomide Capsules 25mg	Each Hard Gelatin Capsule contains:Lenalidomide 25mg	30's in PET bottle in monocart on	PET Bottle in Monocar ton	Market Standard
321	2428	Lenalidomide Capsules 5mg	Each Hard Gelatin Capsule contains:Lenalidomide 5mg	30's in PET bottle in monocart on	PET Bottle in Monocar ton	Market Standard
322	2431	Lincomycin 250 mg Capsules	Each Hard Gelatin Capsule contains: Lincomycin Hydrochloride IP equivalent to Lincomycin 250 mg	10's	Composit e Blister	Market Standard
323	2432	Lincomycin 500 mg Capsules	Each Hard Gelatin Capsule contains: Lincomycin Hydrochloride IP equivalent to Lincomycin 500 mg	10's	Composit e Blister	Market Standard
324	2433	Luliconazole Cream IP 1% w/w, 30 g in Lamitube	Each Lamitube contains: Luliconazole Cream IP 1% w/w Preservative Cream base q.s.	30 g	Lami Tube in Monocar ton	Market Standard
325	2440	Metoprolol Extended-Release Tablets IP 100 mg	Each extended-release film coated tablet contains: Metoprolol Succinate IP 95 mg equivalent to Metoprolol Tartarate 100 mg	10's	Alu-Alu	Market Standard
326	2442	Midodrine Hydrochloride	Each Uncoated tablet contains: Midodrine Hydrochloride USP	10's	Alu-Alu	Market Standard

		Tablets 10 mg	10 mg			
327	2443	Midodrine Hydrochloride Tablets 2.5 mg	Each Uncoated tablet contains:Midodrine Hydrochloride USP 2.5 mg	10's	Alu-Alu	Market Standard
328	2444	Midodrine Hydrochloride Tablets 5 mg	Each Uncoated tablet contains:Midodrine Hydrochloride USP 5 mg	10's	Alu-Alu	Market Standard
329	2448	Olmesartan Medoxomil Tablets IP 10 mg	Each Film coated tablet contains:Olmesartan Medoxomil Tablets IP 10 mg	10's	Composite Blister	Market Standard
330	2449	Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, 21g	Each Sachet contains: Sodium Chloride IP 2.6 g+Potassium Chloride IP 1.5 g+Trisodium Citrate 2.9 g+Dextrose (Anhydrous) 13.5 g+Orange Flavour	01's	Triple layer laminated Hermetically sealed sachet	Market Standard
331	2450	Ozenoxacin Cream 1% w/w, 10 g Lamitube	Each Lamitube contains: Ozenoxacin 1% w/w Preservative Cream base q.s.	10 g	Lami Tube in Monocarton	Market Standard
332	2451	Ozenoxacin Lotion 2% w/v, 10 ml	Each Lamitube contains:Ozenoxacin 2% w/v+PreservativeLotion base q.s.	10 ml PET bottle with pointed nozzle in mono carton	PET Bottle with pointed nozzle in Monocarton	Market Standard
333	2458	Quetiapine Tablets IP 50 mg	Each Film coated tablet contains: Quetiapine Fumarate IP equivalent to Quetiapine 50 mg	10's	Alu-Alu	Market Standard
334	2463	Repaglinide 0.5mg and Voglibose 0.2mg Tablets	Each Film coated tablet contains: Repaglinide IP 0.5mg Voglibose IP 0.2 mg	10's	Composite Blister	Market Standard
335	2464	Repaglinide 0.5mg and Voglibose 0.3mg Tablets	Each Film coated tablet contains: Repaglinide IP 0.5mg Voglibose IP 0.3mg	10's	Composite Blister	Market Standard
336	2465	Repaglinide 1mg and Voglibose 0.2mg Tablets	Each Film coated tablet contains: Repaglinide IP 1 mg Voglibose IP 0.2 mg	10's	Composite Blister	Market Standard
337	2466	Repaglinide 1mg and Voglibose 0.3mg Tablets	Each Film coated tablet contains: Repaglinide IP 1 mg Voglibose IP 0.3 mg	10's	Composite Blister	Market Standard
338	2467	Salmeterol 50mcg and Fluticasone 500mcg Rotacaps	Each Hard Gelatin Capsule contains: Salmeterol 50mcg Fluticasone Propionate IP 500mcg	30's in PET bottle in monocarton	PET Bottle in Monocarton	Market Standard
339	2477	Thalidomide Capsules 100mg	Each Hard Gelatin Capsule contains:	10's	Blister	Market Standard

			Thalidomide USP 100mg			
340	2479	Thalidomide Capsules 50mg	Each Hard Gelatin Capsule contains: Thalidomide USP 50mg	10's	Blister	Market Standard
341	2481	Ticagrelor Tablets IP 60 mg	Each film coated tablet contains: Ticagrelor IP 60 mg	10's	Composite Blister	Market Standard
342	2482	Topiroxostat Tablets 20mg	Each Uncoated Tablet contains: Topiroxostat Tablets 20mg	10's	Blister	Market Standard
343	2483	Topiroxostat Tablets 40mg	Each Uncoated Tablet contains: Topiroxostat Tablets 40mg	10's	Blister	Market Standard
344	2484	Topiroxostat Tablets 60mg	Each Uncoated Tablet contains: Topiroxostat Tablets 60mg	10's	Blister	Market Standard
345	2485	Torasemide 10 mg and Spironolactone 25 mg Tablets	Each Uncoated Tablet contains: Torasemide IP 10 mg Spironolactone IP 25 mg	10's	Composite Blister	Market Standard
346	2487	Vortioxetine Tablets 10mg	Each Film coated tablet contains: Vortioxetine hydrobromide 12.71 mg equivalent to Vortioxetine 10mg	10's	Blister	Market Standard
347	2488	Vortioxetine Tablets 20mg	Each Film coated tablet contains: Vortioxetine hydrobromide 25.42 mg equivalent to Vortioxetine 20mg	10's	Blister	Market Standard
348	2489	Vortioxetine Tablets 5mg	Each Film coated tablet contains: Vortioxetine hydrobromide 6.355 mg equivalent to Vortioxetine 05mg	10's	Blister	Market Standard
349	2531	Deferiprone Capsules 250mg	Each Hard Gelatin Capsule contains: Deferiprone 250mg	50's	Alu-Alu	Alu-Alu
350	2532	Deferiprone Capsules 500mg	Each Hard Gelatin Capsule contains: Deferiprone 500mg	50's	Alu-Alu	Alu-Alu
351	2785	Abiraterone Acetate IP 500mg Tablets	Each Film Coated Tablet contains: Abiraterone Acetate Tablets IP 500mg	60's bottle	HDPE BOTTLE	HDPE BOTTLE
352	2786	Amlodipine 5mg and Enalpril 5mg Tablets	Each Uncoated Tablet contains: Amlodipine 5mg Enalpril 5mg	10's	Blister	Transparent
353	2787	Amlodipine 5mg and Indapamide 1.5mg Tablets	Each Film Coated Bilayered Tablet contains: Indapamide (Sustained Release) 1.5mg Amlodipine Besilate IP eq. to Amlodipine 5mg	10's	Alu-Alu	Alu-Alu
354	2789	Atenolol IP 25mg and Chlorthalidone IP 12.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 25mg Chlorthalidone IP 12.5mg	10's	Blister	Amber Colored Blister
355	2790	Atenolol IP 50mg and Chlorthalidone IP 12.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 50mg Chlorthalidone IP 12.5mg	10's	Blister	Amber Colored Blister
356	2791	Atenolol 50mg and Indapamide 2.5mg Tablets	Each Uncoated Tablet contains: Atenolol IP 50mg Indapamide 2.5mg	10's	Strip	Alu-Strip

357	2792	Atenolol 50mg and Losartan 50mg Tablets	Each Film-Coated Tablet contains: Atenolol IP 50mg Losartan IP 50mg	10's	Blister	Alu-Alu
358	2793	Atenolol 50mg and Nifedipine 20mg Tablets	Each Film Coated Tablet contains: Atenolol IP 50mg Nifedipine IP 20mg	10's	Blister	Amber Colored Blister
359	2794	Atomoxetine 10mg Tablets	Each Film-Coated Tablet contains: Atomoxetine Hydrochloride IP eq. to Atomoxetine 10mg	10's	Alu-Alu	Alu-Alu
360	2795	Azelaic Acid 20% w/w Cream	Composition: Azelaic Acid 20% w/w	15gm	Lami Tube in Monocarton	Market Standard
361	2796	Benidipine 4mg and Telmisartan 40mg Tablets	Each Film-Coated Bilayered Tablet contains: Benidipine IP 4mg Telmisartan IP 40mg	15's	Alu-Alu	Alu-Alu
362	2797	Benzoyl Peroxide 5% w/w Soap	Composition: Benzoyl Peroxide IP 5% w/w	75gm	Market Standard	Market Standard
363	2798	Benzoyl Peroxide IP 5% w/w Gel	Hydrous Benzoyl Peroxide IP eq. to Anhydrous Benzoyl Peroxide 5.0% w/w	15gm	Lami Tube in Monocarton	Market Standard
364	2799	Buspirone IP 10mg Tablets	Each Uncoated Tablet contains: Buspirone 10mg	10's	Blister	Transparent
365	2800	Buspirone IP 5mg Tablets	Each Uncoated Tablet contains: Buspirone 5mg	10's	Blister	Transparent
366	2801	Carbetocin 100mcg Injection	Each ml contains: Carbetocin 100mcg	1ml	Glass Vial	Market Standard
367	2802	Clonazepam 0.25mg and Propranolol 10mg Tablets	Each Film-Coated Tablet contains: Clonazepam IP 0.25mg Propranolol Hydrochloride IP 10mg	10's	Blister	Alu-Alu
368	2803	Clonazepam 0.25mg and Propranolol 20mg Tablets	Each Film-Coated Tablet contains: Clonazepam IP 0.25mg Propranolol Hydrochloride IP 20mg	10's	Blister	Alu-Alu
369	2804	Clonazepam 0.5mg and Propranolol 20mg Tablets	Each Uncoated Tablet contains: Clonazepam IP 0.5mg Propranolol Hydrochloride IP 20mg	10's	Blister	Transparent
370	2805	Combo pack of Vitamin C Injection IP and Vitamin B12, Folic acid and Niacinamide injection	Each 1.5 ml contains:(Part I) Ascorbic Acid IP 150mg Each ml contains (Part II) Cyanocobalamin IP 2500 mcg Folic Acid IP 0.7mg Niacinamide IP 12mg Benzoyl Alcohol IP 1% v/v Water for inj. q.s.	1's	1ml Ampoule	Ampoule in Blister Pack
371	2806	Enzalutamide 40mg Tablets	Each Hard Gelatin Capsule contains: Enzalutamide 40 mg	28's in Bottle	Bottle in Monocarton	Market Standard

372	2807	Filgrastim Injection IP 300mcg	Each Vial of 1.0 ml contains: Filgrastim concentrated solution IP 30MIU (300mcg)	1ML Vial	Glass Vial	Market Standard
373	2808	Flecanide 100mg Tablets	Each Uncoated Tablet contains: Flecanide Acetate 100mg	10's	Alu-Alu	Alu-Alu
374	2809	Flecanide 50mg Tablets	Each Uncoated Tablet contains: Flecainide Acetate 50mg	10's	Alu-Alu	Alu-Alu
375	2810	Fluoxetine IP 10mg Tablets	Each Film-Coated Tablet contains: Fluoxetine Hydrochloride IP equivalent to Fluoxetine 10mg	10's	Blister	Transparent
376	2811	Fluoxetine 60mg Capsules	Each Hard Gelatin Capsules contains: Fluoxetine Hydrochloride IP 60mg	10's	Blister	Transparent
377	2812	Gliclazide 30mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Uncoated Bilayered Tablet contains: Metformin Hydrochloride IP 500mg (In sustained release form) Gliclazide IP 30mg (In sustained release form) Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg	10's	Blister	Transparent
378	2813	Gliclazide 60mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Uncoated Bilayered Tablet contains: Metformin Hydrochloride IP 500mg (In Sustained Release form) Gliclazide IP 60mg (In Sustained Release form) Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg	10's	Blister	Transparent
379	2814	Glycolic Acid 12% w/w Cream	Composition: Glycolic Acid 12%w/w in cream base	30gm	Lami Tube in Monocarton	Market Standard
380	2815	Glycolic Acid 6% w/w Cream	Composition: Glycolic Acid 6%w/w in cream base	30gm	Lami Tube in Monocarton	Market Standard
381	2816	Glycopyrrolate IP 1mg Tablets	Each Uncoated Tablet contains: Glycopyrrolate IP 1mg	10's	Blister	Amber Colored Blister
382	2817	Glycopyrrolate IP 2mg Tablets	Each Uncoated Tablet contains: Glycopyrrolate IP 2mg	10's	Blister	Amber Colored Blister
383	2818	Halobetasol 0.05 % w/w and Fusidic Acid 2% w/w Cream	Composition: Halobetasol Propionate USP 0.05% w/w Fusidic Acid IP 2.0% w/w	10gm	Lami Tube in Monocarton	Market Standard
384	2819	Human Papillomavirus Quadrivalent (Types 6, 11, 16, And 18) Vaccine,	Each Dose of 0.5ml contains;- Human Papillomavirus type 6 L1 Protein ≥20mcg Human Papillomavirus type 11 L1 Protein ≥ 40mcg	0.5 ml in 1 prefilled syringe	Pre-Filled Syringe	Market Standard

		Recombinant	Human Papillomavirus type 16 L1 Protein n≥ 40mcg Human Papillomavirus type 18 L1 Protein ≥ 20mcg Aluminium(Al+++) ≤ 1.25mg			
385	2820	Ibrutinib 140mg Capsules	Each Hard Gelatin Capsule contains: Ibrutinib 140mg	30's in Bottle	HDPE BOTTLE	HDPE BOTTLE
386	2821	Imipramine 25mg and Diazepam 2mg Tablets	Each Film Coated Tablet contains: Imipramine Hydrochloride IP 25mg Diazepam IP 2mg	10's	Blister	Transparent
387	2822	Imipramine 25mg and Diazepam 5mg Tablets	Each Film Coated Tablet contains: Imipramine Hydrochloride IP 25mg Diazepam IP 5mg	10's	Blister	Transparent
388	2823	Testosterone Enanthate Injection 250mg	Each ml contains: Testosterone Enanthate 250mg	1 ML	1ml AMPOULE	Market Standard
389	2824	Lenvatinib IP 4mg Capsules	Each Hard Geltain Capsule contains: Lenvatinib Mesylate IP 4.90mg equivalent to Lenvatinib 4mg	10's bottle	HDPE BOTTLE	HDPE BOTTLE
390	2825	Levetiracetam IP 500mg Prolonged Release Tablets	Each Film Coated Prolonged Release Tablet contains: Levetiracetam IP 500 mg	10's	Blister	Alu-Alu
391	2826	Losartan 25mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Tablet contains: Losartan Potassium IP 25mg Chlorthalidone IP 6.25mg	10's	Blister	Transparent
392	2827	Losartan 50mg and S-Amlodipine 2.5mg Tablets	Each Uncoated Tablet contains: Losartan Potassium IP 50mg S-Amlodipine 2.5mg	10's	Alu-Alu	Alu-Alu
393	2828	Melatonin 3mg and Zolpidem 10mg Tablets	Each Film Coated Tablet contains: Melatonin 3mg Zolpidem Tartrate IP 10mg	10's	Blister	Transparent
394	2829	Melatonin 3mg and Zolpidem 5mg Tablets	Each Film Coated Tablet contains: Melatonin 3mg Zolpidem Tartrate IP 5mg	10's	Blister	Transparent
395	2830	Methylphenidate IP 10mg Tablets	Each Film Coated Prolonged Release Tablet contains: Methylphenidate Hydrochloride IP 10mg	10's	Alu-Alu	Alu-Alu
396	2831	Methylphenidate IP 18mg Tablets	Each Film Coated Prolonged Release Tablet contains: Methylphenidate Hydrochloride IP 18mg	10's	Alu-Alu	Alu-Alu
397	2832	Methylphenidate IP 20mg Tablets	Each Film Coated Prolonged Release Tablet conatins: Methylphenidate Hydrochloride IP 20mg	10's	Alu-Alu	Alu-Alu

398	2833	Methylphenidate IP 5mg Tablets	Each Uncoated Tablet contains: Methylphenidate Hydrochloride IP 5mg	10's	Alu-Alu	Alu-Alu
399	2834	Metoprolol 25mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 23.75mg equivalent to Metoprolol 25mg Chlorthalidone IP 6.25 mg	10's	Alu-Alu	Alu-Alu
400	2835	Metoprolol 50mg and Chlorthalidone 12.5mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol 50mg (as Extended Release Part) Chlorthalidone IP 12.5mg	10's	Alu-Alu	Alu-Alu
401	2836	Metoprolol 50mg and Chlorthalidone 6.25mg Tablets	Each Film Coated Bilayered Tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol 50mg Chlorthalidone IP 6.25 mg	10's	Alu-Alu	Alu-Alu
402	2837	Minoxidil IP 5mg Tablets	Each Uncoated Tablet contains: Minoxidil IP 5mg	10's	Alu-Alu	Alu-Alu
403	2838	Naltrexone IP 50mg Tablets	Each Uncoated Tablet contains: Naltrexone IP 50mg	10's	Alu-Alu	Alu-Alu
404	2839	Nimodipine IP 30mg Tablets	Each Film Coated Tablet contains: Nimodipine 30mg	10's	Strip	Alu-Strip
405	2840	Olmesartan 40mg, Amlodipine 5mg and Chlorthalidone 12.5mg Tablets	Each Film Coated Tablet contains: Olmesartan Medoximil IP 40mg Amlodipine Besylate IP equivalent to Amlodipine 5mg Chlorthalidone IP 12.5mg	10's	Alu-Alu	Alu-Alu
406	2841	Olmesartan 20mg and Metoprolol 25mg Tablets	Each Film Coated Bilayer Tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate IP 25mg (as Extended release) Olmesartan Medoxomil IP 20mg	10's	Alu-Alu	Alu-Alu
407	2842	Olmesartan 20mg and Metoprolol 50mg Tablets	Each Film Coated Bilayer Tablet contains: Metoprolol Succinate IP 47.5mg eq. to Metoprolol Tartrate IP 50mg (as extended release) Olmesartan Medoxomil IP 20mg	10's	Alu-Alu	Alu-Alu
408	2843	Opipramol Dihydrochloride 50mg Tablets	Each Film Coated Tablet contains: Opipramol Dihydrochloride	10's	Blister	Amber Colored Blister

			50mg			
409	2844	Opipramol Dihydrochloride 100mg Tablets	Each Film Coated Tablet contains: Opipramol Dihydrochloride 100mg	10's	Blister	Amber Colored Blister
410	2845	Orlistat 60mg Capsules	Each Hard Gelatin Capsule contains: Orlistat 60mg	10's	Alu-Alu	Alu-Alu
411	2846	Perampanel 2mg Tablets	Each Film Coated Tablet contains: Perampanel 2mg	10's	Blister	Transparent
412	2847	Perampanel 4mg Tablets	Each Film Coated Tablet contains: Perampanel 4mg	10's	Blister	Transparent
413	2848	Pioglitazone 15mg and Glimepiride 2mg Tablets	Each Uncoated Tablet contains: Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg Glimepride IP 2mg	10's	Blister	Transparent
414	2849	Polmacoxib 2mg Capsules	Each Hard Gelatin Capsule contains: Polmacoxib 2 mg	10's	Alu-Alu	Alu-Alu
415	2850	Rosuvastatin 10mg and Cholecalciferol 1000IU Tablets	Each Film Coated Tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Vitamin D3 IP (Cholecalciferol) 1000IU	10's	Alu-Alu	Alu-Alu
416	2851	Rosuvastatin IP 10mg and Ezetimibe IP 10mg Tablets	Each Film Coated Tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Ezetimibe IP 10mg	10's	Alu-Alu	Alu-Alu
417	2852	Rosuvastatin 20mg and Ezetimibe 10mg Tablets	Each Film Coated Tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 20mg Ezetimibe IP 10mg	10's	Alu-Alu	Alu-Alu
418	2853	Rosuvastatin 20mg And Clopidogrel 75mg Capsules	Each Hard Gelatin Capsule contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 20mg(As Pellets) Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg(As Pellets)	10's	Alu-Alu	Alu-Alu
419	2854	Safinamide 50mg Tablets	Each Film Coated Tablet contains: Safinamide Methane Sulphonate IP equivalent to Safinamide 50mg	10's	Blister	Transparent
420	2855	S-Amlodipine 2.5mg and Hydrochlorothiazide	Each Uncoated Tablet contains: S-Amlodipine Besylate IP equivalent to S-Amlodipine	10's	Blister	Alu-Alu

		12.5mg Tablets	2.5mg Hydrochlorthiazide IP 12.5mg			
421	2856	Sitagliptin 100mg, Pioglitazone 15mg and Metformin 500mg Tablets	Each Film-Coated Bilayered Tablet contains: Sitagliptin Phosphate IP equivalent to Sitagliptin 100mg Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (As Sustained Release form)	10's	Alu-Alu	Alu-Alu
422	2857	S-Metoprolol 25mg and S-Amlodipine 2.5mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (In Prolonged Release form) S-Amlodipine Besylate IP equivalent to S-Amlodipine 2.5mg	10's	Alu-Alu	Alu-Alu
423	2858	S-Metoprolol 25mg and S-Amlodipine 5mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (In Prolonged Release Form) S-Amlodipine Besylate IP equivalent to S-Amlodipine 5mg	10's	Alu-Alu	Alu-Alu
424	2859	S-Metoprolol 25mg and Telmisartan 20mg Tablets	Each Modified Release Uncoated Bilayered Tablet contains: S-Metoprolol Succinate 23.75mg equivalent to S-Metoprolol 25mg (As Extended Release form) Telmisartan IP 40mg (as Immediate Release)	10's	Alu-Alu	Alu-Alu
425	2860	Telmisartan 40mg and Indapamide 1.5mg Tablets	Each Uncoated Bilayered Tablet contains: Telmisartan IP 40mg Indapamide IP 1.5mg (as Sustained Release form)	10's	Alu-Alu	Alu-Alu
426	2861	Telmisartan 40mg and Rosuvastatin 10mg Tablets	Each Film Coated Tablet contains: Telmisartan IP 40mg Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg	10's	Alu-Alu	Alu-Alu
427	2862	Telmisartan 40mg	Each Uncoated Bilayered Tablet	15's	Alu-Alu	Alu-Alu

		and S- Amlodipine 2.5mg Tablets	contains: S- Amlodipine Besylate IP equivalent to S- Amlodipine 2.5mg Telmisartan IP 40mg			
428	2863	Telmisartan 40mg and S- Amlodipine 5mg Tablets	Each Uncoated Bilayered Tablet contains: S- Amlodipine Besylate IP equivalent to S- Amlodipine 5mg Telmisartan IP 40mg	15's	Alu-Alu	Alu-Alu
429	2864	Tianeptine 12.5mg Tablets	Each Sugar Coated Tablet contains: Tianeptine Sodium 12.5mg	10's	Strip	Strip
430	2865	Tofisopam 50mg Tablets	Each Uncoated Tablet contains: Tofisopam IP 50mg	10's	Blister	Transparent
431	2866	Trifluoperazine 2.5mg and Trihexyphenidyl 1mg Tablets	Each Film Coated Tablet contains: Trifluoperazine Hydrochloride IP equivalent to Trifluoperazine 2.5mg Trihexyphenidyl Hydrochloride IP 1mg	10's	Blister	Transparent
432	2867	Trifluoperazine 5mg and Trihexyphenidyl 2mg Tablets	Each Uncoated Tablet contains: Trifluoperazine Hydrochloride IP equivalent to Trifluoperazine 5 mg Trihexyphenidyl Hydrochloride IP 2mg	10's	Blister	Transparent
433	2868	Voglibose 0.2mg, Metformin 500mg and Gliclazide 80mg Tablets	Each Uncoated Bilayered Tablet contains: Gliclazide IP 80mg Metformin Hydrochloride IP 500mg (as Sustained Release form) Voglibose IP 0.2mg	10's	Blister	Transparent
434	2869	Voglibose 0.3mg, Metformin 500mg and Gliclazide 80mg Tablets	Each Uncoated Bilayered Tablet contains: Gliclazide IP 80mg Metformin Hydrochloride IP 500mg (as Sustained Release form) Voglibose IP 0.3mg	15's	Blister	Transparent
435	2870	Cefepime 250mg Inection	Each Vial contains: Sterile Cefepime Hydrochloride IP eq. to Cefepime 250mg	1.0 Injection in 1 vial	Glass Vial	Market Standard
436	2871	Cefepime 1000mg and Tazobactam 125mg Injection	Each Vial contains: Sterile Cefepime Hydrochloride IP eq. to Cefepime 1000mg Sterile Tazobactum Sodium IP eq. to Tazobactum 125mg	1.0 Injection in 1 vial	Glass Vial	Market Standard
437	2872	Ciclesonide 200mcg , Formoterol 6mcg and Tiotropium 9mcg	Each Actuation Delivers: Tiotropium Bromide Monohydrate IP equivalent to	200 MDI in 1 packet	Market Standard	Market Standard

		Inhaler	Tiotropium 9mcg Formoterol Fumarate 6mcg (as Formoterol Fumarate Dihydrate IP) Circlesonide IP 200mcg			
438	2873	Dolutegravir 50mg, Emtricitabine 200mg and Tenofovir Alafenamide 25mg Tablets	Each Film Coated Tablet contains: Dolutegravir Sodium IP equivalent to Dolutegravir 50mg Emtricitabine IP 200mg Tenofovir Alafenamide fumarate IP equivalent to Tenofovir Alafenamide 25mg	30's in Bottle	HDPE BOTTLE	HDPE BOTTLE
439	2874	Dolutegravir 50mg, Lamivudine 300mg and Tenofovir Disoproxil Fumarate 300mg Tablets	Each Film Coated Tablet contains: Dolutegravir Sodium IP equivalent to Dolutegravir 50mg Lamivudine IP 300mg Tenofovir Disoproxil Fumarate IP 300mg equivalent to Tenofovir Disoproxil Fumarate 245mg	30's in Bottle	HDPE BOTTLE	HDPE BOTTLE
440	2875	Ketoprofen 30mg Patch	Composition: Each Plaster (7cmx10cm) contains: Ketoprofen IP 30mg	7's pack	Market Standard	Market Standard
441	2876	Lamivudine IP 100mg Tablets	Each Film Coated Tablet contains: Lamivudine IP 100mg	10's	Blister	Transparent
442	2877	Levetiracetam 100mg Injection	Each ml contains: Levetiracetam IP 100mg	5.0 ml in 1 vial	Glass Vial	Market Standard
443	2878	Levetiracetam 500mg Injection	Each 5ml contains: Levetiracetam IP 500mg	5.0 ml in 1 vial	Glass Vial	Market Standard
444	2879	Magnesium Sulphate Injection 50% w/v	Each ml contains: Magnesium Sulphate IP 50% w/v	2 ml Vial	2ml Vial	Market Standard
445	2880	Minocycline 100mg Modified Release Capsules	Each Hard Gelatin Capsule contains: Minocycline Hydrochloride equivalent to Minocycline 100mg	10's	Alu-Alu	Alu-Alu
446	2881	Minocycline 45mg Extended Release Tablets	Each Film Coated Extended Release Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 45mg	10's	Alu-Alu	Alu-Alu
447	2882	Minocycline 50mg Tablets	Each Film Coated Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 50mg	10's	Alu-Alu	Alu-Alu
448	2883	Minocycline 65mg Extended Release Tablets	Each Film Coated Extended Release Tablet contains: Minocycline Hydrochloride	10's	Alu-Alu	Alu-Alu

			equivalent to Minocycline 65mg			
449	2884	Minocycline 100mg Tablets	Each Film Coated Tablet contains: Minocycline Hydrochloride equivalent to Minocycline 100mg	10's	Alu-Alu	Alu-Alu
450	2885	Mosapride 5mg and Dimethicone 125mg Chewable Tablets	Each Uncoated Chewable Tablet contains: Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 5mg Activated Dimethicone IP 125mg	10's	Blister	Transparent
451	2886	Mosapride Citrate IP 5mg Tablets	Each Film Coated Tablet contains: Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 5mg	10's	Blister	Amber Colored Blister
452	2887	Nifedipine IP 5mg Capsules	Each Soft Gelatin Capsule contains: Nifedipine 5mg	10's	Blister	Amber Colored Blister
453	2888	Olopatadine IP 5mg Tablets	Each Film Coated Tablet contains: Olopatadine Hydrochloride IP 5mg	10's	Blister	Transparent
454	2889	Pantoprazole 40mg and Mosapride 15mg Capsules	Each Hard Gelatin Capsule Contains;- Panoprazole Sodium IP equivalent to Pantoprazole 40mg (as two Pantoprazole Tablet IP 20mg) Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate 15mg	10's	Alu-Alu	Alu-Alu
455	2890	Phenobarbitone IP 200mg Injection	Each ml contains: Phenobarbitone Sodium IP 200mg	10 ml /vial	1ml AMPOULE	Market Standard
456	2891	Phenobarbitone Sodium 20mg Syrup	Each 5ml contains: Phenobarbitone Sodium IP equivalent to Phenobabrbitone 20mg	100 ml	Amber Colored Bottle	Amber Colored Bottle
457	2892	Prednisolone 15mg Syrup	Each 5ml contains: Prednisolone Sodium Phosphate IP equivalent to Prednisolone 15mg	60ml bottle in Monocarton	Amber Colored Bottle	Amber Colored Bottle
458	2893	Prednisolone Dispersible Tablets 20mg	Each Uncoated Dispersable Tablet contains: Prednisolone IP 20mg	15's	Blister	Amber Colored Blister
459	2894	Prednisolone Dispersible Tablets 40mg	Each Uncoated Dispersable Tablet contains: Prednisolone IP 40mg	10's	Blister	Amber Colored Blister
460	2895	Rabeprazole 20mg and Mosapride 15mg Tablets	Each Tablet contains: Rabeprazole Sodium IP 20mg Mosapride Citrate Dihydrate IP equivalent to Mosapride Citrate Anhydrous 15mg	10's	Strip	Strip

461	2896	Rupatadine 10mg and Montelukast 10mg Tablets	Each Film Coated Tablet contains: Rupatadine Fumarate IP eq. to Rupatadine 10mg Montelukast Sodium IP eq. to Montelukast 10mg	10's	Alu-Alu	Alu-Alu
462	2897	Rupatadine 10mg Tablets	Each Uncoated Tablet contains: Rupatadine Fumarate IP eq. to Rupatadine 10mg	10's	Blister	Transparent
463	2898	Sumatriptan 50mg Tablets	Each Film Coated Tablet contains: Sumatriptan Succinate IP eq. to Sumatriptan 50mg	10's	Blister	Transparent
464	2899	Terazosin IP 1mg Tablets	Each Uncoated Tablet contains: Terazosin Hydrochloride IP eq. to Terazosin 1mg	10's	Blister	Transparent
465	2900	Terazosin IP 2mg Tablets	Each Uncoated Tablet contains: Terazosin Hydrochloride IP eq. to Terazosin 2mg	10's	Blister	Transparent

Note:

- ***Light sensitive drugs shall be provided in an "Amber color PVC" in case of Blister packing.***
- ***Vials of eye drops, ear drops, and nasal drops should be packed in an individual mono carton with a dispensing device.***
- ***PMBI may ask the awarded bidder for necessary modification on design/artwork in case if product is decided to be launched at wider platform.***
- ***Cap on bottle/jar type of packing shall contain printed design as per specimen design provided under clause 3. (h) of Enclosure - 2 to Annexure – VII, Ref. Clause No. 3(M) & 20***
- ***Drugs / Medicines meant for external uses or external preparations shall not be packed in PET bottle. Awarded bidder / supplier shall supply them in specified bottle as per market standard.***
- ***Wherever syrup/suspension/solution/drops etc. are mentioned in the specification, measuring cap/ hermetically sealed dropper shall be provided inside the mono-carton.***

Annexure – XIV

{Ref: - clause 19(J), Para VI of Annexure II}

(For declaration of shelf-life under Annexure-II)

For all the tendered drugs, bidder must comply the shelf life of each quoted drugs in accordance with the "Schedule - P" of Drugs and Cosmetics Rules, 1945. In case drug/medicine not covered in Schedule P of Drugs and Cosmetics Rules, 1945, the bidder must supply the drug/medicine with minimum 24 months shelf life.

Note:

I. Bidders have to declare the required shelf-life detail in Para VI of Annexure II.

II. In case bidder(s) has not complied to either "Schedule P of Drugs and Cosmetics Rules, 1945" or as per market standard (not less than 24 months for drugs not covered under Schedule P of Drugs and Cosmetics Rules, 1945) while declaring the shelf life on Annexure II.

III. Bids shall be rejected if bidder(s) fails to declare shelf life.

IV. Bidder(s) must have supporting stability data (long term stability studies and accelerated stability studies) for all quoted/awarded drugs for producing to PMBI on requirement. For New drugs, complete stability data of 6 months' period shall be acceptable as mentioned in clause 4. F.

…….

ANNEXURE- XV

(Ref. Clause no.3.1)

DECLARATION BY AUTHORISED SIGNATORY OF THE FIRM

(On Non-Judicial Paper duly notarized)

(Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020& 24 Jul 2020 on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017.)

I, the undersigned,…… (full names), do hereby declare, in my capacity as……..……..……of M/s ……., that:

1) The facts contained herein are within my own personal knowledge.

2) I have read the Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020 & 24 Jul 2020 on the subject of Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 regarding restrictions on procurement from a bidder of a country which shares a land border with India and comply to all the provisions of the Order.

3) I certify that M/s ……..(name of bidder/entity) is not from such a country / is from such a country and has been registered with the Competent Authority as per Department of Expenditure Order No. 6/18/2019-PPD dated 23.07.2020 **(strike out whichever is not applicable)**, I hereby certify that this SUPPLIER fulfils all requirements in this regard and is eligible to be considered. [Where applicable, evidence of valid registration by the Competent Authority is attached].

4) I understand that the submission of incorrect data and / or if certificate / declaration given by M/s……..(name of bidder entity) is found to be false, this would be a ground for immediate termination and further legal action in accordance with law as per Clause 12 of the Public Order on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017.

Authorized Signature:

Signature with date…….

Name: …….

Designation/ capacity ……..…

(Seal / Stamp of Bidder)

ANNEXURE- XVI

(Ref. Clause no. 3.G)

DECLARATION OF SOURCE OF ACTIVE PHARMACEUTICAL INGREDIENT (API)

I……S/o, D/o, W/o……Resident at ……..…….. in the capacity of Proprietor / Managing Partner /Managing Director / Authorized Signatory in M/s…… having its registered office at……..……and factory premises at……..……..……..……..……..……..……..……do hereby solemnly affirms and declare the source of Active Pharmaceutical Ingredient (API) for the quoted drug(s) as under:

Sl. No.	Drug Code (As per Annexure XII nd Annexure XIII)	Name of Active Pharmaceutical Ingredient (API)	Source of API (Supplier / Manufacturer Name)	Address of Source of API (Supplier / Manufacturer / importer Name)	Invoice No.	Invoice Date	Batch No. (Two Batch)	Date of Manufacturing	Date of Expiry
1									
2									
3									

That I……..abide by the terms and conditions laid down in guidelines issued or provision under this tender document or the clause(s) on behalf of M/s…… I further declare that all the Active Pharmaceutical Ingredients (API) polymorphic form used in formulation for all quoted drugs are internationally accepted active polymorphs.

That the information furnished hereinafter is correct to the best of my knowledge and belief and on behalf of M/s…… I hereby undertake to produce relevant records before the procuring entity, or any authority so nominated by the Tender inviting Authority/ Department/ Any assigned by the Tender inviting Authority for the purpose of assessing the local content and verification.

Signature.....

Name: ……..

Designation……

(Company Seal/Stamp)

(To be furnished by person in capacity as per para 1)

ANNEXURE - XVII

Reference Clause No. 16.E

AGREEMENT

THIS AGREEMENT is executed on ……. Between Pharmaceuticals and Medical Devices Bureau of India, B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029 (hereinafter called as "PMBI")

AND

..……..……..……...(Name of Supplier)……..……..…(City and Country of Supplier) …… (hereinafter called "SECOND PARTY"):

Party under this agreement means individual party to this however Parties mean all parties or more than one party to this agreement collectively.

WHEREAS **"Pharmaceuticals & Medical Devices Bureau of India"** hereinafter referred to as "**PMBI**" is a Society registered under the Societies registration act XXI of 1860, having its Registered Office at B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029 is under the aegis of Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India. PMBI is the implementing agency of Pradhan Mantri Bhartiya Janaushadhi Pariyojna (PMBJP), scheme of Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. PMBI deals in the distribution of Janaushadhi Medicines and fulfil the needs of medicines of Janaushadhi Kendras throughout India".

AND WHEREAS, PMBI has floated a Tender reference No. PMBI/DRUG-…… for the supply of Drugs/ Goods mentioned in the said tender.

AND WHEREAS (Name of Second Party) has submitted the tender and has been declared as successful bidder for the tender Reference No. PMBI/DRUG-…… and bid has been accepted by PMBI for supply of those goods and services for the sum of ……. (Contract Price in Words and figure) (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSES AS FOLLOWS:

1. The words and expressions mentioned in this Agreement shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement. The Tender Document shall also be treated as part of this agreement.
2. The Second Party is not blacklisted/debarred/de-registered/banned by any State Government/ Central Government or Drug procurement agencies due to quality failure of the drugs or any other reasons at the time of entering this agreement.
3. If any information/ declaration made by the Second Party is found false at any stage before or after award of contract or deliberately defraud with PMBI, the Second Party shall be blacklisted for a period of 2 years. Apart from blacklisting, the Earnest Money / Security Deposit submitted by the Second Party shall be

forfeited and all its existing contracts would also be cancelled and security deposits in other contracts shall also be forfeited.

4. In case of NSQ or spurious or adulterated or misbranded drugs/products are supplied such batch(s) will be deemed to be rejected and the second party shall be liable for such losses and debit note shall be issued against the same.
5. In case of NSQ, the drug/product shall be tested by empanelled laboratory of PMBI and the full amount debit note may be issued against second party for the invoices/purchase order and product may be returned to the second party at the second party cost if asked.
6. If NSQ by way of Market complaint during shelf life is observed, then the control sample may be tested through empanelled laboratory of PMBI and if the control sample is also found NSQ then full amount debit note shall be issued against the second party and remaining stock may be given back to the second party on demand and logic.
7. In case of DI failure, the first party (PMBI) will put the batch on hold and the batch may be re-called and detailed information shall be sent to the concerned Government authority and as per defined policy, the necessary protocol may be followed.
8. Non-supply shall be considered as serious violation of tender/contract condition. In this case the first party shall use alternate/Risk purchase option to mitigate public demand In lieu of violation of contract condition or as defined in the tender.
9. In consideration of the payments to be made by PMBI to the Second Party as hereinafter mentioned, the Second Party hereby covenants with the PMBI to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract.
10. The PMBI hereby covenants to pay the Second Party in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.
11. **Signing Authority/ Testifying witness:** The Second party / Signing Authority shall be in capacity of Proprietor/Managing Partner /Managing Director/Authorised Signatory of the concerned awarded company/entity as declared in the tender. The Competent Testifying Witness shall be the regular employee of the concerned awarded company/entity.
12. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz
    a. The Letter of Acceptance issued by the First Party.
    b. The Notice Inviting Tender
    c. The supplier's bid including enclosures, annexures, etc.
    d. The Terms and Condition of the Contract.
    e. The Schedule of Requirement.
    f. The Technical Specification
    g. Any other document required and listed in the bid and replies to queries clarifications issued by the First Party, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.

13. Brief particulars of the goods and services which shall be supplied / provided by the Second Party are mentioned under:

Sl. No.	Drug Code	Name of Product	Unit Size	Unit Price Exclusive GST	GST	Unit Price inclusive GST
				Total Contract Value (Appx.)		

Total awarded value in words in Rs._____

Tender quantity indicated in the tender is for the tender purpose only and it represent the basis of unit for ease of pricing. The actual quantity may vary from zero to maximum required during the contract period. The quantity shall be drawn from time to time during the contract period subjected to various terms and conditions of the tender.

14. PERFORMANCE SECURITY DEPOSIT:

A) On being informed about the acceptance of the tender for Rate Contract, the Performance Security Deposit @ 3% or as defined by the Government through notifications, will be deducted from each running bills and accumulated security deposit will be refunded without any interest by PMBI to the second party within 60 days following the date of completion of second party performance obligations under the contract including the shelf-life obligation.

B) The Security deposit of second party will be returned by PMBI only after the second party has given undertaking to replace such medicines and indemnify PMBI against any losses on account of quality parameters duly notarized.

15. DELIVERY SCHEDULE

Supply shall be completed by the second party within stipulated date/days for all first/subsequent purchase order(s) as per tender clause 19.C.

16. DISPUTE RESOLUTION

This agreement shall be deemed to have been made/executed at Delhi for all purposes.

Normally, there should not be any scope of dispute between the PMBI and the Second Party after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement between PMBI and the Second Party, then parties shall first try to resolve the same amicably by mutual Consultation and negotiation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then either the PMBI or the Second Party shall give notice to the other party of its intention to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator appointed by the CEO of PMBI. The venue of Arbitration shall be at New Delhi. The award published by

the Arbitrator shall be full and final which shall be binding on both the parties. The second party do hereby consent that the arbitrator appointed by CEO, PMBI shall be paid fees for each hearing/proceeding of arbitration. The fees of the arbitrator shall be such as decided by PMBI. The fees of the arbitrator for each hearing/proceeding shall be borne by both the parties in equal-half-proportion.

17. GOVERNING LAW/JURISDICTION

The applicable law governing this agreement shall be the laws of India and the courts of Delhi shall have the exclusive jurisdiction to try any dispute arising out of this agreement.

IN WITNESS where of the parties here to have executed this Agreement in accordance with the laws on the date and year as mentioned above.

Signed, Sealed and Delivered by the

FIRST PARTY – PMBI

In the presence of witnesses

1. Witness 1 ……

Signature and stamp

2. Witness 2 …….

Signature and stamp

NAME- (SECOND PARTY)

Address-

Designation-

In the presence of witnesses

1. Witness 1 ……

Signature and stamp

2. Witness 2 . …….

Signature and stamp

Sd/-
DGM (Procurement & Quality)
For & on behalf of PMBI
Ph: 011-49431800 (811)